{"7861354ea88a70e273f405155fddada9e54f7473": [["This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.", [["this version", "TREATMENT", 136, 148]]], ["Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Title pageHuman patient simulation: educational issues and practical implications in COVID-19 times", [["patient", "ORGANISM", 182, 189], ["patient", "SPECIES", 182, 189]]]], "60ce0c41a11d5edd9d96b12a32a8a2f85b931956": [["This approach inherits from statistical physics and variational procedures in Bayesian modelling and machine learning (Dauwels, 2007; Feynman, 1972; Friston et al., 2007; MacKay, 1995; MacKay, 2003; Winn and Bishop, 2005) .", [["variational procedures", "TREATMENT", 52, 74]]], ["The validity of this approach has been partly established in a series of reports looking at the role of population immunity within an outbreak in a single region (Friston et al., 2020a) , the effect of population fluxes between multiple regions (in the United States of America) (Friston et al., 2020b) and the genesis of rebounds following lockdown, in relation to a second wave of infections (Friston et al., 2020c) .", [["infections", "DISEASE", 383, 393], ["this approach", "TREATMENT", 16, 29], ["population fluxes between multiple regions", "PROBLEM", 202, 244], ["infections", "PROBLEM", 383, 393], ["population fluxes", "OBSERVATION", 202, 219], ["multiple", "OBSERVATION_MODIFIER", 228, 236], ["regions", "OBSERVATION_MODIFIER", 237, 244], ["infections", "OBSERVATION", 383, 393]]], ["In brief, the conclusions of this kind of modelling are: (i) population immunity-inherited from the initial phases of the pandemic-plays a key role in nuancing its subsequent progression (ii) in the context of population exchange between regional outbreaks, social distancing and lockdown strategies based upon the local prevalence of infection reduce morbidity and mortality.", [["infection", "DISEASE", 335, 344], ["lockdown strategies", "TREATMENT", 280, 299], ["infection", "PROBLEM", 335, 344], ["population", "OBSERVATION", 210, 220], ["infection", "OBSERVATION", 335, 344]]], ["This affords a window of opportunity within which track and trace protocols may delay or defer any second wave until it can be rendered innocuous through vaccination or clinical advances (Aleta A et al., 2020; Chinazzi et al., 2020; Hellewell et al., 2020; Keeling et al., 2020; Kissler et al., 2020; Kucharski et al., 2020; Simonsen et al., 2018; Streeck et al., 2020; .", [["trace protocols", "TREATMENT", 60, 75]]], ["In this report, we consider a key question: how long is this window-or, equivalently, what is the period of effective immunity inherited at the population level from the first wave (Kissler et al., 2020) .IntroductionDynamic causal modelling 1 can be characterised as a generalisation of state-space modelling based upon differential equations.", [["differential equations", "TEST", 321, 343]]], ["This contrasts with advanced descriptive approaches that fit curves to timeseries data, without any explicit reference to the underlying dynamics: e.g., (Tsallis and Tirnakli, 2020) .", [["timeseries data", "TEST", 71, 86]]], ["Dynamic causal modelling differs from conventional epidemiological modelling in that it uses mean field approximations and variational procedures to model the evolution of probability densities-in a way that is similar to quantum mechanics and statistical physics (Greenland, 2006) .", [["mean field approximations", "TREATMENT", 93, 118], ["variational procedures", "TREATMENT", 123, 145], ["probability densities", "PROBLEM", 172, 193], ["probability", "OBSERVATION_MODIFIER", 172, 183], ["densities", "OBSERVATION", 184, 193]]], ["One advantage of variational procedures is that they are orders of magnitude more efficient; enabling model inversion or fitting within minutes (on a laptop) as opposed to hours or days on a supercomputer (Rhodes and Hollingsworth, 2009 ).", [["variational procedures", "TREATMENT", 17, 39]]], ["More importantly, variational procedures provide an efficient way of assessing the quality of one model relative to another, in terms of model evidence (a.k.a., marginal likelihood) (Penny, 2012) .", [["variational procedures", "TREATMENT", 18, 40]]], ["This enables one to compare different models using Bayesian model comparison (a.k.a. structure learning) and use the best model for nowcasting, forecasting or, indeed, test competing hypotheses about viral transmission.IntroductionWe have used this technology to build epidemiological models of how data are generated-in terms of latent causes like the prevalence of infection-that embed conventional epidemiological models (e.g., SEIR models: susceptible, exposed, infected, recovered) in an extended state space.", [["infection", "DISEASE", 367, 376], ["this technology", "TREATMENT", 244, 259], ["infection", "PROBLEM", 367, 376], ["infection", "OBSERVATION", 367, 376]]], ["A key example of this is to model a joint distribution over states of infection and clinical manifestation.", [["infection", "DISEASE", 70, 79], ["infection", "PROBLEM", 70, 79], ["joint", "ANATOMY", 36, 41], ["infection", "OBSERVATION", 70, 79]]], ["In other words, instead of assuming that there is a difference between being infected (I) and having recovered (R), one can accommodate the fact that it is possible to express symptoms without being infected: e.g., a secondary bacterial infection following interstitial pneumonia (Huang et al., 2020) .", [["interstitial", "ANATOMY", 257, 269], ["bacterial infection", "DISEASE", 227, 246], ["interstitial pneumonia", "DISEASE", 257, 279], ["symptoms", "PROBLEM", 176, 184], ["a secondary bacterial infection", "PROBLEM", 215, 246], ["interstitial pneumonia", "PROBLEM", 257, 279], ["infected", "OBSERVATION", 77, 85], ["bacterial", "OBSERVATION_MODIFIER", 227, 236], ["infection", "OBSERVATION", 237, 246], ["interstitial", "ANATOMY_MODIFIER", 257, 269], ["pneumonia", "OBSERVATION", 270, 279]]], ["Conversely, one can be infected without showing symptoms.", [["symptoms", "PROBLEM", 48, 56], ["infected", "OBSERVATION", 23, 31]]], ["Crucially, dynamic causal models can be extended to generate any kind of data at hand: for example, the number of positive tests.", [["hand", "ORGANISM_SUBDIVISION", 81, 85], ["positive tests", "TEST", 114, 128]]], ["This requires careful consideration of how positive tests are generated, by modelling latent variables such as the bias towards testing people with or without infection or, indeed, the capacity for testing, which may itself be time-dependent.", [["infection", "DISEASE", 159, 168], ["people", "ORGANISM", 136, 142], ["people", "SPECIES", 136, 142], ["how positive tests", "TEST", 39, 57], ["infection", "PROBLEM", 159, 168], ["testing", "TEST", 198, 205]]], ["In short, everything that might matter-in terms of the latent (hidden) causes of the data-can be installed in the model, including social distancing, self-isolation and other processes that underwrite transmission.", [["self-isolation", "TREATMENT", 150, 164]]], ["Here, we leverage the efficiency of dynamic causal modelling to evaluate the evidence for a series of models that are distinguished by the rate at which effective immunity to SARS-CoV-2 is lost.", [["SARS", "DISEASE", 175, 179], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 175, 185], ["SARS-CoV", "SPECIES", 175, 183], ["CoV", "TEST", 180, 183]]], ["In what follows, effective population immunity refers to the proportion of people who cannot contract or transmit the virus.", [["people", "ORGANISM", 75, 81], ["people", "SPECIES", 75, 81], ["the virus", "PROBLEM", 114, 123]]], ["This means that the loss of effective immunity can be mediated in several ways, e.g., through viral mutation or increasing the size of the susceptible population, through population fluxes or spread of the virus into new regions.IntroductionDetails about the dynamic causal model can be found in the above technical reports (Friston et al., 2020a; Friston et al., 2020b; Friston et al., 2020c) .", [["the loss of effective immunity", "PROBLEM", 16, 46], ["viral mutation", "PROBLEM", 94, 108], ["the susceptible population", "PROBLEM", 135, 161], ["population fluxes", "PROBLEM", 171, 188], ["the virus into new regions", "PROBLEM", 202, 228], ["size", "OBSERVATION_MODIFIER", 127, 131], ["susceptible", "OBSERVATION_MODIFIER", 139, 150], ["population", "OBSERVATION", 151, 161], ["virus", "OBSERVATION", 206, 211], ["new", "OBSERVATION_MODIFIER", 217, 220]]], ["The model was fitted to new cases and deaths using data available from Johns Hopkins University 2 .", [["deaths", "DISEASE", 38, 44]]], ["The inversion and subsequent model comparison used standard variational (Laplace) procedures (Friston et al., 2007; Marreiros et al., 2009) , as implemented in academic (open source) software 3 .", [["standard variational (Laplace) procedures", "TREATMENT", 51, 92]]], ["The particular model used here has a degree of face validity.", [["face validity", "PROBLEM", 47, 60], ["face", "ANATOMY", 47, 51], ["validity", "OBSERVATION", 52, 60]]], ["For example, it predicted death rates would peak on 10 April in the United Kingdom, with an initial relaxation of lockdown on 8 May 2020.", [["death", "DISEASE", 26, 31], ["an initial relaxation of lockdown", "TREATMENT", 89, 122]]], ["In what follows, we use dynamic causal modelling to ask a simple but crucial question: how quickly will immunity to SARS-CoV-2 be lost at a population level?IntroductionBefore addressing this question, we reiterate that this paper is a technical report illustrating how questions of this sort can be answered using variational Bayes and dynamic causal modelling.", [["SARS", "DISEASE", 116, 120], ["SARS-CoV-2", "ORGANISM", 116, 126]]], ["Although these inferences are described definitively, they are entirely conditional upon the model used in this analysis, and the data available at the time of writing (8 June 2020).FIGURE 1The LIST model: This schematic summarises the LIST (location, infection, symptom, and testing) generative model used for the following analyses.", [["infection", "DISEASE", 252, 261], ["this analysis", "TEST", 107, 120], ["the data", "TEST", 126, 134], ["infection", "PROBLEM", 252, 261], ["symptom", "PROBLEM", 263, 270]]], ["It includes a state (isolation) to model people who are self-isolating because they think they may be infectious (within their home or elsewhere).", [["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["infectious", "PROBLEM", 102, 112], ["may be", "UNCERTAINTY", 95, 101], ["infectious", "OBSERVATION", 102, 112]]], ["This absorbing state also plays the role of the recovered or removed states of SEIR models, namely, once entered, people stay in the state for the duration of the outbreak.", [["people", "ORGANISM", 114, 120], ["people", "SPECIES", 114, 120]]], ["This ensures that the total population is conserved, e.g., deaths are offset by births into the susceptible state.", [["deaths", "DISEASE", 59, 65]]], ["The blue discs represent the four factors of the model, and the segments of these discs correspond to their states (i.e., compartments).", [["discs", "ANATOMY", 82, 87], ["The blue discs", "TREATMENT", 0, 14], ["blue discs", "OBSERVATION", 4, 14], ["segments", "ANATOMY_MODIFIER", 64, 72], ["discs", "ANATOMY", 82, 87]]], ["The states within any factor are mutually exclusive, whereas the factors embody the factorial form of the compartmental model.", [["compartmental model", "OBSERVATION", 106, 125]]], ["The orange boxes represent the observable outputs that are generated by this dynamic causal model, in this instance, daily reports of positive tests and deaths.", [["deaths", "DISEASE", 153, 159], ["orange boxes", "DNA", 4, 16], ["positive tests", "TEST", 134, 148]]], ["The rate of transition between states-or the dwell time within any state-rests upon the model parameters that, in many instances, can be specified with fairly precise prior densities.", [["densities", "OBSERVATION", 173, 182]]], ["For example, a six-day period of contagion is shorter than the period that someone might be infectious (W\u00f6lfel et al., 2020) 4 , on the (prior) assumption that they will self-isolate, when they realise they could be contagious.", [["infectious", "PROBLEM", 92, 102], ["might be", "UNCERTAINTY", 83, 91], ["infectious", "OBSERVATION", 92, 102]]], ["The priors for the non-susceptible and non-contagious proportion of the population are based upon clinical and serological studies reported over the past few weeks; e.g., (Ing et al., 2020; Stringhini et al., 2020) .", [["serological studies", "TEST", 111, 130]]], ["Although the (scale) parameters are implemented as probabilities or rates, they are estimated as log parameters, denoted by lnResultsThe dynamic causal model above was fitted (i.e., inverted) using timeseries data from Johns Hopkins University 5 covering reported new cases and deaths from countries showing the highest cumulative number of deaths.", [["deaths", "DISEASE", 278, 284], ["deaths", "DISEASE", 341, 347]]], ["Crucially, this model inversion was repeated with different rates at which effective immunity is lost (i.e., the expected period of immunity following infection).", [["infection", "DISEASE", 151, 160], ["this model inversion", "PROBLEM", 11, 31], ["infection", "PROBLEM", 151, 160]]], ["The worst-case scenario would correspond to a short-term period of immunity, less than that associated with the betacoronaviruses that cause the common cold: SARS-CoV-2 belongs to the betacoronavirus genus, which includes the SARS, MERS, and two other human coronaviruses, HCoV-OC43 and HCoV-HKU1 that cause the common cold (Kissler et al., 2020; Su et al., 2016) .", [["SARS", "DISEASE", 158, 162], ["SARS", "DISEASE", 226, 230], ["SARS-CoV-2", "ORGANISM", 158, 168], ["betacoronavirus genus", "ORGANISM", 184, 205], ["human", "ORGANISM", 252, 257], ["coronaviruses", "ORGANISM", 258, 271], ["HCoV-OC43", "ORGANISM", 273, 282], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 287, 296], ["human", "SPECIES", 252, 257], ["SARS-CoV", "SPECIES", 158, 166], ["human coronaviruses", "SPECIES", 252, 271], ["the betacoronaviruses", "PROBLEM", 108, 129], ["SARS", "PROBLEM", 158, 162], ["the SARS", "PROBLEM", 222, 230], ["HCoV", "TEST", 273, 277], ["short-term", "OBSERVATION_MODIFIER", 46, 56], ["common cold", "ANATOMY", 312, 323]]], ["Immunity to HCoV-OC43 and HCoV-HKU1 appears to be lost over a few months.", [["HCoV-OC43", "ORGANISM", 12, 21], ["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 26, 35], ["HCoV", "DNA", 26, 30], ["HKU1", "DNA", 31, 35], ["HCoV", "SPECIES", 26, 30], ["HCoV", "TEST", 12, 16], ["HCoV", "TEST", 26, 30]]], ["However, betacoronaviruses might induce immune responses against each another.", [["betacoronaviruses", "CHEMICAL", 9, 26], ["betacoronaviruses", "SIMPLE_CHEMICAL", 9, 26], ["betacoronaviruses", "PROBLEM", 9, 26]]], ["For example, SARS can generate neutralizing antibodies against HCoV-OC43 that can endure for years, while HCoV-OC43 infection can generate cross-reactive antibodies against SARS (Chan et al., 2013) .", [["SARS", "DISEASE", 13, 17], ["infection", "DISEASE", 116, 125], ["SARS", "DISEASE", 173, 177], ["HCoV-OC43", "ORGANISM", 63, 72], ["HCoV-OC43", "ORGANISM", 106, 115], ["neutralizing antibodies", "PROTEIN", 31, 54], ["HCoV", "PROTEIN", 63, 67], ["cross-reactive antibodies", "PROTEIN", 139, 164], ["HCoV", "SPECIES", 63, 67], ["HCoV", "SPECIES", 106, 110], ["OC43", "SPECIES", 111, 115], ["SARS", "PROBLEM", 13, 17], ["neutralizing antibodies", "TEST", 31, 54], ["HCoV", "PROBLEM", 63, 67], ["OC43", "PROBLEM", 68, 72], ["HCoV", "TEST", 106, 110], ["OC43 infection", "PROBLEM", 111, 125], ["SARS", "PROBLEM", 173, 177], ["OC43", "ANATOMY", 111, 115], ["infection", "OBSERVATION", 116, 125]]], ["A period of 32 months corresponds to a level of effective immunity for close to three years, comparable to SARS-CoV-1.ResultsThe dynamic causal model used in this analysis accommodates heterogeneity of susceptibility and transmission at three levels, including a non-contagious proportion of the population that stands in for people who cannot transmit the virus.", [["SARS", "DISEASE", 107, 111], ["SARS-CoV-1", "GENE_OR_GENE_PRODUCT", 107, 117], ["people", "ORGANISM", 326, 332], ["people", "SPECIES", 326, 332], ["SARS-CoV-1", "SPECIES", 107, 117], ["this analysis", "TEST", 158, 171], ["susceptibility and transmission at three levels", "PROBLEM", 202, 249]]], ["This inclusion speaks to the increasing appreciation of how heterogeneity in the population can have a fundamental effect on the epidemiological dynamics.", [["fundamental effect", "OBSERVATION", 103, 121]]], ["In the current model, such heterogeneity was modelled in terms of three successive bipartitions (see Figure 2 ):Heterogeneity in exposure:This was implicitly modelled in terms of an effective population size that is a subset of the total (census) population.", [["effective", "OBSERVATION_MODIFIER", 182, 191], ["population", "OBSERVATION", 192, 202], ["size", "OBSERVATION_MODIFIER", 203, 207]]], ["The effective population is constituted by individuals who are in contact with contagious individuals.", [["effective", "OBSERVATION_MODIFIER", 4, 13], ["population", "OBSERVATION", 14, 24]]], ["The remainder of the population are assumed to be geographically sequestered from a regional outbreak or are shielded from it.", [["a regional outbreak", "PROBLEM", 82, 101], ["remainder", "OBSERVATION_MODIFIER", 4, 13], ["assumed to be", "UNCERTAINTY", 36, 49], ["geographically", "OBSERVATION_MODIFIER", 50, 64], ["sequestered", "OBSERVATION", 65, 76], ["regional", "OBSERVATION_MODIFIER", 84, 92], ["outbreak", "OBSERVATION", 93, 101]]], ["For example, if the population of the UK was 68 million, and the effective population was 39 million, then only 57% are considered to participate in the outbreak 6 .", [["UK", "GENE_OR_GENE_PRODUCT", 38, 40]]], ["Of this effective population, a certain proportion are susceptible to infection:Heterogeneity in susceptibility:This was modelled in terms of a portion of the effective population that are not susceptible to infection.", [["infection", "DISEASE", 70, 79], ["infection", "DISEASE", 208, 217], ["this effective population", "PROBLEM", 3, 28], ["infection", "PROBLEM", 70, 79], ["the effective population", "PROBLEM", 155, 179], ["infection", "PROBLEM", 208, 217], ["effective", "OBSERVATION_MODIFIER", 8, 17], ["population", "OBSERVATION", 18, 28], ["infection", "OBSERVATION", 70, 79], ["Heterogeneity", "OBSERVATION", 80, 93], ["effective", "OBSERVATION_MODIFIER", 159, 168], ["population", "OBSERVATION", 169, 179], ["not susceptible to", "UNCERTAINTY", 189, 207], ["infection", "OBSERVATION", 208, 217]]], ["For example, they may have pre-existing immunity, e.g., via cross-reactivity (Grifoni et al., 2020; Ng et al., 2020) or particular host factors (Bunyavanich et al., 2020; Zheng et al., 2020) such as mucosal immunity (Seo et al., 2020) .", [["mucosal", "ANATOMY", 199, 206], ["mucosal", "MULTI-TISSUE_STRUCTURE", 199, 206], ["mucosal", "ANATOMY", 199, 206]]], ["Of the susceptible proportion of the effective population, a certain proportion can transmit the virus to others:Heterogeneity in transmission:We modelled heterogeneity in transmission with a free parameter (with a prior of one half and a prior standard deviation of 1/16).", [["susceptible", "OBSERVATION_MODIFIER", 7, 18], ["proportion", "OBSERVATION_MODIFIER", 19, 29], ["effective", "OBSERVATION_MODIFIER", 37, 46], ["population", "OBSERVATION", 47, 57], ["heterogeneity", "OBSERVATION", 155, 168]]], ["This parameter corresponds to the proportion of susceptible people that cannot transmit the virus, i.e., those who move directly from a state of being exposed to a state of resistance, as opposed to moving from a state of being infectious to subsequent immunity.", [["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66]]], ["We associated this with a potentially mild illness-e.g., (Chau et al., 2020 )-that does not entail seroconversion, e.g., recovery in terms of T-cell mediated responses (Grifoni et al., 2020; Zheng et al., 2020) .", [["T-cell", "ANATOMY", 142, 148], ["T-cell", "CELL", 142, 148], ["a potentially mild illness", "PROBLEM", 24, 50], ["mild", "OBSERVATION_MODIFIER", 38, 42], ["illness", "OBSERVATION", 43, 50]]], ["Note that this construction conflates transmission with the probability of developing symptoms, in that being infectious means you can transmit the virus but also increases the period during which you could move from a healthy state to a symptomatic state.FIGURE 2Heterogeneity of exposure, susceptibility, and transmission: Schematic illustrating the composition of a population in terms of people who are not exposed to contagious contact, not susceptible to contagion, susceptible but not contagious and, finally susceptible and contagious.FIGURE 2The resistant state therefore plays the role of an immune state for people who never become contagious, either because they are not susceptible to infection or become resistant after a mild illness.", [["infection", "DISEASE", 698, 707], ["people", "ORGANISM", 392, 398], ["people", "ORGANISM", 619, 625], ["people", "SPECIES", 392, 398], ["people", "SPECIES", 619, 625], ["developing symptoms", "PROBLEM", 75, 94], ["the virus", "PROBLEM", 144, 153], ["infection", "PROBLEM", 698, 707], ["a mild illness", "PROBLEM", 734, 748], ["infection", "OBSERVATION", 698, 707], ["mild", "OBSERVATION_MODIFIER", 736, 740], ["illness", "OBSERVATION", 741, 748]]], ["This model reconciles the apparent disparity between the relatively high morbidity/mortality rates and the relatively low seroprevalence observed empirically e.g., (Stringhini et al., 2020) 7 .", [["the relatively high morbidity/mortality rates", "PROBLEM", 53, 98], ["relatively", "OBSERVATION_MODIFIER", 57, 67], ["high", "OBSERVATION_MODIFIER", 68, 72], ["morbidity", "OBSERVATION", 73, 82]]], ["Bayesian model comparison confirmed that there was very strong evidence (Kass and Raftery, 1995) for all three types of heterogeneity (portrayed as 'immunological dark matter' in the media); namely, an effective population that is a subset of the census population, a susceptible population that is a subset of the effective population and a contagious population that is a subset of the susceptible population (c.f., a super spreaders).", [["a susceptible population", "PROBLEM", 266, 290], ["a contagious population", "PROBLEM", 340, 363], ["effective", "OBSERVATION_MODIFIER", 202, 211], ["population", "OBSERVATION", 212, 222], ["contagious", "OBSERVATION_MODIFIER", 342, 352]]], ["In this model, only susceptible individuals who become contagious develop antibodies to SARS-CoV-2, typically around 8% of the total population.FIGURE 2Crucially, we did not impose any prior constraints on the effective population size 8 .", [["SARS", "DISEASE", 88, 92], ["individuals", "ORGANISM", 32, 43], ["SARS-CoV-2", "ORGANISM", 88, 98], ["antibodies", "PROTEIN", 74, 84], ["SARS-CoV", "SPECIES", 88, 96], ["SARS", "TEST", 88, 92], ["CoV", "TEST", 93, 96], ["size", "OBSERVATION_MODIFIER", 231, 235]]], ["In other words, we treated the data from each country as reflecting an outbreak in a population of unknown size that comprised a mixture of susceptible and non-susceptible individuals, where susceptible individuals comprised a mixture contagious and non-contagious individuals.", [["susceptible and non-susceptible individuals", "PROBLEM", 140, 183], ["susceptible individuals", "PROBLEM", 191, 214], ["outbreak", "OBSERVATION_MODIFIER", 71, 79], ["size", "OBSERVATION_MODIFIER", 107, 111]]], ["In this way, we were able to model the self-evident dissociation between the total size of a population and the number of people affected in each country.FIGURE 2We specified a total of 32 models, each differing in their assumption about how long immunity would last, from 1 month to 32 months, in monthly increments.", [["people", "ORGANISM", 122, 128], ["people", "SPECIES", 122, 128], ["dissociation", "OBSERVATION", 52, 64], ["total", "OBSERVATION_MODIFIER", 77, 82], ["size", "OBSERVATION_MODIFIER", 83, 87]]], ["The log evidence for each of these 32 models was pooled over the 10 countries with the highest reported deaths (listed in Table 2 ).", [["deaths", "DISEASE", 104, 110]]], ["This evidence accumulation furnishes the marginal likelihood of each period of immunity (i.e., model) that-under uninformative priors over the period of immunity-corresponds to a posterior distribution, having marginalised out conditional uncertainty about all other parameters.", [["marginal", "OBSERVATION_MODIFIER", 41, 49], ["likelihood", "OBSERVATION_MODIFIER", 50, 60], ["posterior", "ANATOMY_MODIFIER", 179, 188]]], ["Model inversion itself maximises the marginal likelihood that implicitly penalises overfitting, with respect to model complexity 9 .", [["Model inversion itself", "PROBLEM", 0, 22], ["marginal", "OBSERVATION_MODIFIER", 37, 45]]], ["The resulting accuracy of the data fits are shown in Figure 3 , in terms of cumulative death rates and new cases for the countries considered.", [["death", "DISEASE", 87, 92], ["the data", "TEST", 26, 34], ["cumulative death rates", "PROBLEM", 76, 98]]], ["The accompanying distribution over the period of immunity is shown in Figure 4 , suggesting that the expected period of immunity is about three months, with fairly precise 90% Bayesian credible intervals (less than the one month resolution of the model search).", [["distribution", "OBSERVATION_MODIFIER", 17, 29]]], ["There are many mechanisms that could contribute to this loss; for example, population fluxes could slowly increase the proportion of susceptible individuals (e.g., by relaxing lockdown); thereby diluting immunity acquired by the contagious proportion.", [["this loss", "PROBLEM", 51, 60], ["population fluxes", "PROBLEM", 75, 92], ["susceptible individuals", "PROBLEM", 133, 156], ["susceptible", "OBSERVATION_MODIFIER", 133, 144]]], ["Other viral and host factors (Beutler et al., 2007; Su et al., 2016 ) may clearly play a role (e.g., viral mutation or loss of antibodies)FIGURE 4Loss of immunity: the left-hand panel reports the posterior distribution over the period of immunity based upon the marginal likelihood of a series of models that assume a particular prior expectation (with a precise prior covariance of 1/512).", [["left-hand", "ANATOMY", 168, 177], ["antibodies", "PROTEIN", 127, 137], ["viral mutation", "PROBLEM", 101, 115], ["loss of antibodies)", "PROBLEM", 119, 138], ["the left-hand panel", "TEST", 164, 183], ["left", "ANATOMY_MODIFIER", 168, 172], ["posterior", "ANATOMY_MODIFIER", 196, 205]]], ["The form of the posterior over this key parameter reflects the fact that the trajectory of new cases and deaths contains sufficient information to make fairly precise inferences about the rate at which immunity is lost.", [["deaths", "DISEASE", 105, 111], ["posterior", "ANATOMY_MODIFIER", 16, 25]]], ["The right-hand panel shows the same results in terms of a cumulative distribution.", [["right-hand", "ANATOMY", 4, 14], ["The right-hand panel", "TEST", 0, 20], ["right", "ANATOMY_MODIFIER", 4, 9], ["hand", "ANATOMY", 10, 14], ["cumulative distribution", "OBSERVATION", 58, 81]]], ["The broken lines correspond to 90% Bayesian credible intervals.FIGURE 4The rate at which immunity is lost is important because it constrains the onset of any putative second wave.", [["lines", "CELL", 11, 16], ["broken lines", "CELL_LINE", 4, 16], ["The broken lines", "TREATMENT", 0, 16], ["broken lines", "OBSERVATION", 4, 16]]], ["Figure 5 illustrates this in terms of three scenarios for the effective population in the United Kingdom: first, a worst-case scenario with rapid loss of immunity (over a period of one month): a most likely scenario based upon the posterior expectation from Figure 4 (left panel) and, finally, a best-case scenario with a period of immunity lasting for years (32 months) 10 .", [["loss of immunity", "DISEASE", 146, 162], ["rapid loss of immunity", "PROBLEM", 140, 162], ["posterior", "ANATOMY_MODIFIER", 231, 240]]], ["We see that a very short period of immunity effectively merges the second wave into the first to produce a protracted time course of fatality rates.", [["protracted", "OBSERVATION_MODIFIER", 107, 117]]], ["In effect, (a quasi) endemic equilibrium is obtained quickly as people lose immunity and become re-infected.", [["people", "ORGANISM", 64, 70], ["people", "SPECIES", 64, 70]]], ["With enduring immunity (here of 32 months) any second wave will be deferred for a year or more.FIGURE 4Interestingly, cumulative death rates appear to be higher with a three-month period of immunity, relative to a one-month period.", [["death", "DISEASE", 129, 134], ["cumulative death rates", "PROBLEM", 118, 140]]], ["This is because the predictions are posterior predictive densities, which are the most likely outcomes under the two periods of immunity.", [["posterior predictive densities", "PROBLEM", 36, 66], ["posterior", "OBSERVATION_MODIFIER", 36, 45], ["predictive densities", "OBSERVATION", 46, 66]]], ["One would be hoping to see death rates fall to negligible levels by October.", [["death", "DISEASE", 27, 32]]], ["If they persist at 20 deaths per day, then one might anticipate a second wave in January.FIGURE 5Second waves: This figure reports the expected death rates as a function of time for the effective United Kingdom population.", [["deaths", "DISEASE", 22, 28], ["death", "DISEASE", 144, 149], ["the expected death rates", "PROBLEM", 131, 155]]], ["The three trajectories (blue lines) and accompanying 90% Bayesian credible intervals (shaded areas) correspond to posterior predictions with a loss of immunity over 1, 3 and 32 months.", [["blue lines", "CELL", 24, 34], ["accompanying 90% Bayesian credible intervals (shaded areas)", "PROBLEM", 40, 99], ["posterior predictions", "PROBLEM", 114, 135], ["blue lines", "OBSERVATION", 24, 34], ["posterior", "ANATOMY_MODIFIER", 114, 123]]], ["These represent the smallest, most likely and longest period of immunity considered in the Bayesian model comparison (summarised in the previous figure) .", [["smallest", "OBSERVATION_MODIFIER", 20, 28], ["most likely", "UNCERTAINTY", 30, 41]]], ["The black dots correspond to empirical data, after smoothing with a four-day Gaussian kernel.", [["The black dots", "PROBLEM", 0, 14], ["empirical data", "TEST", 29, 43], ["black dots", "OBSERVATION", 4, 14]]], ["The right panel reproduces the data in the left panel with a focus on the second wave peaking in January of next year.FIGURE 5A common metric of viral spread is the effective reproduction ratio (Rt).", [["The right panel", "TEST", 0, 15], ["viral spread", "PROBLEM", 145, 157], ["right", "ANATOMY_MODIFIER", 4, 9], ["left", "ANATOMY_MODIFIER", 43, 47], ["focus", "OBSERVATION", 61, 66], ["viral spread", "OBSERVATION", 145, 157]]], ["This can be evaluated directly from 10 Note that the best and worst scenarios are not determined by the credible intervals of the posterior distribution, but are the limits of the scenarios considered a priori.FIGURE 5the posterior expectations of latent states as a function of time.", [["posterior", "ANATOMY_MODIFIER", 130, 139], ["posterior", "OBSERVATION_MODIFIER", 222, 231], ["latent", "OBSERVATION", 248, 254]]], ["The initial fall in the effective reproduction ratio is subtended by lockdown in the first instance, followed by an acquisition of population immunity in the effective population.", [["The initial fall", "PROBLEM", 0, 16], ["population immunity", "TREATMENT", 131, 150], ["fall", "OBSERVATION", 12, 16]]], ["After reaching a minimum of about 0.7, the effective reproduction ratio slowly increases with loss of population immunity to peak in the late autumn, portending a second wave infections in January.", [["infections", "DISEASE", 175, 185], ["the effective reproduction ratio", "PROBLEM", 39, 71], ["loss of population immunity", "PROBLEM", 94, 121], ["a second wave infections", "PROBLEM", 161, 185], ["wave", "OBSERVATION_MODIFIER", 170, 174], ["infections", "OBSERVATION", 175, 185]]], ["Following this, the reproduction ratio remains largely below one and slowly drifts back to one after a year.FIGURE 6Reproduction ratios: this figure uses the same format as the previous figure; here, showing the predictions of the effective reproduction ratio for the United Kingdom.", [["the reproduction ratio", "TEST", 16, 38]]], ["The initial fall in the reproduction rate is subtended by lockdown in the first instance, followed by an acquisition of population immunity in the effective population.", [["The initial fall", "PROBLEM", 0, 16], ["population immunity", "TREATMENT", 120, 139], ["fall", "OBSERVATION", 12, 16]]], ["Figure 7 illustrates the underlying or latent causes of the predicted fatality rates over 18 months for the most likely (three-month) loss of immunity.", [["loss of immunity", "PROBLEM", 134, 150], ["latent", "OBSERVATION_MODIFIER", 39, 45]]], ["In this model, the latent states are factorized into various locations, different states of infection, symptom expression and the states that underwrite the generation of test results.", [["infection", "DISEASE", 92, 101], ["infection", "PROBLEM", 92, 101], ["symptom expression", "PROBLEM", 103, 121], ["latent", "OBSERVATION_MODIFIER", 19, 25], ["different", "OBSERVATION_MODIFIER", 72, 81], ["infection", "OBSERVATION", 92, 101]]], ["It is evident from these posterior predictions that the UK might expect a second wave in about eight months (around January 2021).", [["UK", "GENE_OR_GENE_PRODUCT", 56, 58], ["posterior", "ANATOMY_MODIFIER", 25, 34]]], ["This is important because there is a window of opportunity in the next few months during which nonpharmacological interventions-especially, tracking and tracing-will, in principle, be in a position to defer or delay the second wave indefinitely (or until an effective treatment or vaccination programme is in place).", [["nonpharmacological interventions", "TREATMENT", 95, 127], ["tracing", "TEST", 153, 160], ["an effective treatment", "TREATMENT", 255, 277], ["vaccination programme", "TREATMENT", 281, 302]]], ["Note that this model includes a latent state of immunity that peaks around 11% and then falls gently as immunity is lost (yellow line in the infection panel).", [["infection", "DISEASE", 141, 150], ["yellow line", "OBSERVATION", 122, 133]]], ["In contrast, the resistant proportion (purple line) slowly accumulates people who recover from a mild illness and are removed from the susceptible proportion of the effective population.FIGURE 7Latent causes: this figure reproduces the predictions of the second wave for the United Kingdom in Figure 4 .", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77], ["a mild illness", "PROBLEM", 95, 109], ["resistant", "OBSERVATION_MODIFIER", 17, 26], ["proportion", "OBSERVATION_MODIFIER", 27, 37], ["purple line", "OBSERVATION", 39, 50], ["mild", "OBSERVATION_MODIFIER", 97, 101], ["illness", "OBSERVATION", 102, 109], ["effective", "OBSERVATION_MODIFIER", 165, 174], ["population", "OBSERVATION", 175, 185]]], ["These latent or expected states generate the observable outcomes in the upper two panels.", [["upper", "ANATOMY_MODIFIER", 72, 77]]], ["The solid lines are colour-coded and correspond to the states of the four factors in Figure 1 .", [["solid lines", "ANATOMY", 4, 15], ["solid lines", "CELL", 4, 15], ["solid lines", "CELL_LINE", 4, 15], ["solid lines", "OBSERVATION", 4, 15]]], ["For example, under the location factor, the probability of being found at work declines steeply from about 25% to 3% at the onset of the outbreak.", [["outbreak", "OBSERVATION", 137, 145]]], ["At this time, the probability of isolating oneself rises to about 3% during the peak of the pandemic.", [["isolating oneself rises", "PROBLEM", 33, 56]]], ["After about six weeks, the implicit lockdown starts to relax and slowly tails off, with accompanying falls in morbidity (in terms of symptoms) and mortality (in terms of death rate).", [["death", "DISEASE", 170, 175], ["accompanying falls in morbidity", "PROBLEM", 88, 119], ["symptoms", "PROBLEM", 133, 141], ["death rate", "TEST", 170, 180]]], ["As population immunity (yellow line in the infection panel) declines, the prevalence of infection accelerates to generate a second wave that peaks at about 50 weeks.", [["infection", "DISEASE", 43, 52], ["infection", "DISEASE", 88, 97], ["the infection panel", "TEST", 39, 58], ["infection accelerates", "PROBLEM", 88, 109], ["yellow line", "OBSERVATION", 24, 35], ["infection", "OBSERVATION", 88, 97]]], ["Note that the amplitude of the second wave is much smaller than the first.FIGURE 7The predictions above are generated from the parameters of a single country.", [["amplitude", "OBSERVATION_MODIFIER", 14, 23], ["second", "OBSERVATION_MODIFIER", 31, 37], ["wave", "OBSERVATION_MODIFIER", 38, 42], ["much", "OBSERVATION_MODIFIER", 46, 50], ["smaller", "OBSERVATION_MODIFIER", 51, 58]]], ["However, these predictions conceal a large amount of between-country variability due to the non-linear relationship between the model parameters and trajectories of latent causes and states.", [["large", "OBSERVATION_MODIFIER", 37, 42], ["amount", "OBSERVATION_MODIFIER", 43, 49], ["latent", "OBSERVATION_MODIFIER", 165, 171]]], ["Note that there is considerable variation in the onset of the second wave due to country-specific differences in the underlying epidemiological parameters.", [["considerable", "OBSERVATION_MODIFIER", 19, 31], ["variation", "OBSERVATION_MODIFIER", 32, 41]]], ["For countries like the United Kingdom, this analysis suggests that one can anticipate a second wave in early 2021, which is later than the prediction for Germany, which might experience a second wave in October of this year (2020).TABLE 2List of countries and the dates of predicted fatality peaks of first and second waves.", [["this analysis", "TEST", 39, 52]]], ["The first column lists the proportion of the effective population that are immune at the peak of population immunity.", [["the effective population", "PROBLEM", 41, 65], ["effective", "OBSERVATION_MODIFIER", 45, 54], ["population", "OBSERVATION", 55, 65]]], ["These range from 7 to 17% (4.5% to 5% of the total population), in line with current serological data 11 .", [["current serological data", "TEST", 77, 101], ["range", "OBSERVATION_MODIFIER", 6, 11]]], ["The subsequent two columns make the point that the peak fatality rates at the second wave (based upon posterior predictions) are considerably smaller than the corresponding peak fatality rates at the first wave.", [["the peak fatality rates", "PROBLEM", 47, 70], ["peak", "OBSERVATION_MODIFIER", 51, 55], ["posterior", "ANATOMY_MODIFIER", 102, 111], ["considerably", "OBSERVATION_MODIFIER", 129, 141], ["smaller", "OBSERVATION_MODIFIER", 142, 149], ["peak fatality", "OBSERVATION", 173, 186]]], ["For most countries, this second peak is in the order of tens of deaths per day, as opposed to hundreds.CountryThe proportion of the susceptible population who cannot transmit the virus ranges from 47% to 61% (noncontagious column).", [["deaths", "DISEASE", 64, 70], ["susceptible", "OBSERVATION_MODIFIER", 132, 143], ["population", "OBSERVATION", 144, 154]]], ["This reflects heterogeneity in transmission.", [["heterogeneity", "OBSERVATION", 14, 27]]], ["The corresponding heterogeneity of susceptibility is reflected in the proportion of the effective population that are not susceptible to infection (non-susceptible column).", [["infection", "DISEASE", 137, 146], ["susceptibility", "PROBLEM", 35, 49], ["the effective population", "PROBLEM", 84, 108], ["infection (non-susceptible column)", "PROBLEM", 137, 171], ["heterogeneity", "OBSERVATION_MODIFIER", 18, 31], ["susceptibility", "OBSERVATION", 35, 49], ["effective", "OBSERVATION_MODIFIER", 88, 97], ["population", "OBSERVATION", 98, 108], ["not susceptible to", "UNCERTAINTY", 118, 136], ["infection", "OBSERVATION", 137, 146], ["non-susceptible column", "OBSERVATION_MODIFIER", 148, 170]]], ["Finally, the difference between the effective and total population size reflects heterogeneity of exposure.", [["effective", "OBSERVATION_MODIFIER", 36, 45], ["total", "OBSERVATION_MODIFIER", 50, 55], ["population", "OBSERVATION_MODIFIER", 56, 66], ["size", "OBSERVATION_MODIFIER", 67, 71], ["heterogeneity", "OBSERVATION_MODIFIER", 81, 94]]], ["In most instances, the effective population constitutes a large proportion of the total population (largest in Brazil, Spain, and Italy), with the exception of Canada, where the effective population is only four out of 38 million.TABLE 3List of countries and posterior estimates and population size.", [["posterior estimates", "TEST", 259, 278], ["most instances", "OBSERVATION_MODIFIER", 3, 17], ["effective", "OBSERVATION_MODIFIER", 23, 32], ["population", "OBSERVATION", 33, 43], ["large", "OBSERVATION_MODIFIER", 58, 63], ["proportion", "OBSERVATION_MODIFIER", 64, 74], ["total", "OBSERVATION_MODIFIER", 82, 87], ["population", "OBSERVATION_MODIFIER", 88, 98], ["largest", "OBSERVATION_MODIFIER", 100, 107], ["effective", "OBSERVATION_MODIFIER", 178, 187], ["population", "OBSERVATION", 188, 198], ["posterior", "ANATOMY_MODIFIER", 259, 268], ["population", "OBSERVATION_MODIFIER", 283, 293], ["size", "OBSERVATION_MODIFIER", 294, 298]]], ["The non-contagious proportion is a percentage of the susceptible population, while the non-susceptible proportion is a percentage of the effective population.", [["the susceptible population", "PROBLEM", 49, 75], ["percentage", "OBSERVATION_MODIFIER", 35, 45], ["susceptible", "OBSERVATION_MODIFIER", 53, 64], ["population", "OBSERVATION", 65, 75], ["effective", "OBSERVATION_MODIFIER", 137, 146], ["population", "OBSERVATION", 147, 157]]], ["The numbers in brackets express the effective population as a percentage of the total (census) population.Conclusion and limitationsThere are clearly many limitations to the modelling here.", [["numbers", "OBSERVATION_MODIFIER", 4, 11], ["effective", "OBSERVATION_MODIFIER", 36, 45], ["population", "OBSERVATION", 46, 56]]], ["These include modelling each outbreak as a point process and ignoring geospatial aspects and waves of infection .", [["infection", "DISEASE", 102, 111], ["a point process", "PROBLEM", 41, 56], ["infection", "PROBLEM", 102, 111], ["infection", "OBSERVATION", 102, 111]]], ["Furthermore, we have assumed idealised dynamics that do not consider interactions with seasonal influenza or any other annual fluctuations (Kissler et al., 2020) .", [["influenza", "DISEASE", 96, 105], ["seasonal influenza", "PROBLEM", 87, 105]]], ["As with all dynamic causal modelling studies, the conclusions based upon Bayesian model comparison and posterior inferences are limited to the models considered.", [["all dynamic causal modelling studies", "TEST", 8, 44], ["Bayesian model comparison", "TEST", 73, 98], ["posterior", "ANATOMY_MODIFIER", 103, 112]]], ["Finally, the posterior predictions will change as more data becomes available.", [["posterior", "ANATOMY_MODIFIER", 13, 22]]], ["Having said this, it is interesting to note, irrespective of the modelling, that there is sufficient information-in the current epidemiological trajectories-to support fairly precise posterior beliefs about how quickly we will lose immunity.Conclusion and limitationsDeath rates in the United Kingdom over the next few weeks will be telling: if they can be suppressed to zero, then it is possible that the effective (population) immunity will be enduring, and we may elude a second wave.", [["Death", "DISEASE", 267, 272], ["Death rates", "TEST", 267, 278]]], ["If, on the other hand, fatality rates continue above 20 a day, then according to the model presented here, it is likely we will see a slow increase in the reproduction rate and a second wave after Christmas.", [["fatality rates", "TEST", 23, 37], ["a slow increase", "PROBLEM", 132, 147]]], ["Note that the analyses in this report are predicated on a track and trace process whose efficacy is estimated based upon the data to date.", [["the analyses", "TEST", 10, 22]]], ["As discussed in (Friston et al., 2020c) and elsewhere, any second wave could be deferred by introducing a more efficacious tracking and tracing protocol, even in the context of a relatively rapid loss of population immunity, such as the three month period estimated here.", [["tracing protocol", "TEST", 136, 152], ["a relatively rapid loss of population immunity", "PROBLEM", 177, 223], ["relatively", "OBSERVATION_MODIFIER", 179, 189], ["rapid", "OBSERVATION_MODIFIER", 190, 195], ["loss", "OBSERVATION", 196, 200]]], ["This deferment rests upon finding a substantial proportion of infected individuals before they can transmit the virus by identifying local outbreaks and clusters.", [["infected individuals", "PROBLEM", 62, 82], ["the virus", "PROBLEM", 108, 117], ["local outbreaks and clusters", "PROBLEM", 133, 161], ["infected", "OBSERVATION", 62, 70]]], ["On one view, this takes us out of the arena of ensemble dynamics and epidemiological modelling into the pragmatic considerations of an effective local surveillance and public health response.Software noteThe figures in this report can be reproduced using annotated (MATLAB/Octave) code available as part of the free and open source academic software SPM (https://www.fil.ion.ucl.ac.uk/spm/), released under the terms of the GNU General Public License version 2 or later.", [["effective", "OBSERVATION_MODIFIER", 135, 144]]], ["At the time of writing, these routines are undergoing software validation in our internal source version control system-that will be released in the next public release of SPM (and via GitHub at https://github.com/spm/).", [["software validation", "TEST", 54, 73]]]], "PMC7523255": [["The proliferation of research on COVID-19 treatment and prevention since SARS-CoV-2 first emerged has been unprecedented.", [["COVID-19", "CHEMICAL", 33, 41], ["SARS", "DISEASE", 73, 77], ["COVID-19", "CELL", 33, 41], ["SARS-CoV-2", "ORGANISM", 73, 83], ["SARS-CoV", "SPECIES", 73, 81], ["COVID-19 treatment", "TREATMENT", 33, 51], ["prevention", "TREATMENT", 56, 66], ["SARS", "PROBLEM", 73, 77], ["CoV", "TEST", 78, 81], ["proliferation", "OBSERVATION_MODIFIER", 4, 17]]], ["Since SARS-CoV-2 first emerged in Wuhan, China, and triggered a global pandemic, nearly 3000 trials have been registered on ClinicalTrials.gov.", [["SARS-CoV-2", "ORGANISM", 6, 16], ["SARS-CoV", "SPECIES", 6, 14]]], ["While this volume of research is impressive, there are risks of inefficient duplication, and important work may also be impeded if efforts are not synchronized.", [["inefficient duplication", "PROBLEM", 64, 87], ["impressive", "OBSERVATION_MODIFIER", 33, 43], ["inefficient duplication", "OBSERVATION", 64, 87]]], ["Ongoing efforts to conduct rigorous randomized trials of COVID-19 post-exposure prophylaxis (PEP) provide illustrative examples.", [["rigorous randomized trials", "TREATMENT", 27, 53], ["COVID", "TREATMENT", 57, 62], ["-exposure prophylaxis", "TREATMENT", 70, 91]]]], "PMC7326304": [["Our heads are round so our thoughts can change direction.", [["round", "OBSERVATION_MODIFIER", 14, 19]]]], "PMC7361196": [["INTRODUCTIONInfections with the severe acute respiratory syndrome coronavirus\u20102 (SARS\u2010CoV\u20102) and the resulting clinical condition coronavirus disease (COVID\u201019) have resulted in a worldwide pandemic with nearly 3.8 million confirmed infections worldwide and 270 000 deaths as of May 8, 2020.1These numbers are expected to continue to grow, though at differing rates and patterns depending on the mitigation strategies employed.2Viral RNA shedding may continue after recovery from disease leading to issues with possible reinfection or, more likely, residual infection.3Not only has the morbidity of this disease stressed patients, families, and underprepared healthcare systems, but it also has the potential to enact long\u2010term, fundamental change in daily life for billions of people.4The observed morbidity of COVID\u201019 will be further magnified in vulnerable populations: namely the elderly, patients with cancer undergoing treatment, patients of low socioeconomic status with poor access to care and chronic conditions, as well as in countries in which health system preparedness is lacking and where the economic impacts might be devasting.5,6,7,8", [["cancer", "ANATOMY", 908, 914], ["acute respiratory syndrome coronavirus\u20102", "DISEASE", 39, 79], ["SARS", "DISEASE", 81, 85], ["coronavirus disease", "DISEASE", 130, 149], ["infections", "DISEASE", 233, 243], ["deaths", "DISEASE", 266, 272], ["infection", "DISEASE", 558, 567], ["cancer", "DISEASE", 908, 914], ["5,6,7,8", "CHEMICAL", 1144, 1151], ["patients", "ORGANISM", 621, 629], ["people", "ORGANISM", 778, 784], ["patients", "ORGANISM", 894, 902], ["cancer", "CANCER", 908, 914], ["patients", "ORGANISM", 937, 945], ["5,6,7,8", "SIMPLE_CHEMICAL", 1144, 1151], ["patients", "SPECIES", 621, 629], ["people", "SPECIES", 778, 784], ["patients", "SPECIES", 894, 902], ["patients", "SPECIES", 937, 945], ["severe acute respiratory syndrome coronavirus\u20102 (SARS\u2010CoV", "SPECIES", 32, 89], ["the severe acute respiratory syndrome coronavirus\u20102", "PROBLEM", 28, 79], ["SARS\u2010CoV\u2010", "TEST", 81, 90], ["the resulting clinical condition coronavirus disease", "PROBLEM", 97, 149], ["a worldwide pandemic", "PROBLEM", 178, 198], ["infections", "PROBLEM", 233, 243], ["the mitigation strategies", "TREATMENT", 392, 417], ["2Viral RNA shedding", "PROBLEM", 427, 446], ["disease", "PROBLEM", 480, 487], ["reinfection", "PROBLEM", 520, 531], ["residual infection", "PROBLEM", 549, 567], ["cancer", "PROBLEM", 908, 914], ["treatment", "TREATMENT", 926, 935], ["low socioeconomic status", "PROBLEM", 949, 973], ["chronic conditions", "PROBLEM", 1003, 1021], ["severe", "OBSERVATION_MODIFIER", 32, 38], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["respiratory syndrome", "OBSERVATION", 45, 65], ["coronavirus disease", "OBSERVATION", 130, 149], ["infections", "OBSERVATION", 233, 243], ["reinfection", "OBSERVATION", 520, 531], ["more likely", "UNCERTAINTY", 536, 547], ["residual", "OBSERVATION_MODIFIER", 549, 557], ["infection", "OBSERVATION", 558, 567], ["morbidity", "OBSERVATION", 586, 595], ["cancer", "OBSERVATION", 908, 914]]]], "2d02ec4b81d3dfbbbbc38bc6e65986a0d1139bbf": [["In earlier work I investigated the influence of superspreaders on infectious disease outbreaks 11 .", [["infectious disease", "DISEASE", 66, 84], ["infectious disease outbreaks", "PROBLEM", 66, 94], ["infectious", "OBSERVATION", 66, 76]]], ["These analyses showed that superspreaders can lead to a new type of infectious disease dynamics that is better described by a power law rather than the canonical exponential growth.", [["These analyses", "TEST", 0, 14], ["infectious disease dynamics", "PROBLEM", 68, 95], ["new", "OBSERVATION_MODIFIER", 56, 59], ["infectious", "OBSERVATION", 68, 78], ["exponential", "OBSERVATION_MODIFIER", 162, 173], ["growth", "OBSERVATION_MODIFIER", 174, 180]]], ["To understand how that happens let us have a look at the two trees of disease transmission in Fig. 1A Here ' represents the number of patients zero.", [["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142]]]], "dcfdc4f2f0731b3a73c9ccd0a94c5a0a21926e2a": [["INTRODUCTIONChronic lung diseases, such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis (CF), and interstitial lung diseases (ILD), affect many individuals worldwide.", [["lung", "ANATOMY", 20, 24], ["pulmonary", "ANATOMY", 63, 72], ["cystic", "ANATOMY", 97, 103], ["interstitial lung", "ANATOMY", 123, 140], ["lung diseases", "DISEASE", 20, 33], ["chronic obstructive pulmonary disease", "DISEASE", 43, 80], ["COPD", "DISEASE", 82, 86], ["asthma", "DISEASE", 89, 95], ["cystic fibrosis", "DISEASE", 97, 112], ["CF", "DISEASE", 114, 116], ["interstitial lung diseases", "DISEASE", 123, 149], ["ILD", "DISEASE", 151, 154], ["lung", "ORGAN", 20, 24], ["pulmonary", "ORGAN", 63, 72], ["lung", "ORGAN", 136, 140], ["INTRODUCTIONChronic lung diseases", "PROBLEM", 0, 33], ["chronic obstructive pulmonary disease", "PROBLEM", 43, 80], ["COPD)", "PROBLEM", 82, 87], ["asthma", "PROBLEM", 89, 95], ["cystic fibrosis (CF)", "PROBLEM", 97, 117], ["interstitial lung diseases", "PROBLEM", 123, 149], ["ILD)", "PROBLEM", 151, 155], ["lung", "ANATOMY", 20, 24], ["diseases", "OBSERVATION", 25, 33], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["obstructive", "OBSERVATION_MODIFIER", 51, 62], ["pulmonary", "ANATOMY", 63, 72], ["disease", "OBSERVATION", 73, 80], ["COPD", "OBSERVATION", 82, 86], ["asthma", "OBSERVATION", 89, 95], ["cystic", "OBSERVATION_MODIFIER", 97, 103], ["fibrosis", "OBSERVATION", 104, 112], ["interstitial", "ANATOMY_MODIFIER", 123, 135], ["lung", "ANATOMY", 136, 140], ["diseases", "OBSERVATION", 141, 149]]], ["Patients with these chronic lung diseases are susceptible to respiratory lung infections and some of these viral infections can contribute to disease pathogenesis.", [["lung", "ANATOMY", 28, 32], ["respiratory lung", "ANATOMY", 61, 77], ["chronic lung diseases", "DISEASE", 20, 41], ["respiratory lung infections", "DISEASE", 61, 88], ["viral infections", "DISEASE", 107, 123], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 28, 32], ["lung", "ORGAN", 73, 77], ["Patients", "SPECIES", 0, 8], ["these chronic lung diseases", "PROBLEM", 14, 41], ["respiratory lung infections", "PROBLEM", 61, 88], ["these viral infections", "PROBLEM", 101, 123], ["disease pathogenesis", "PROBLEM", 142, 162], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["lung", "ANATOMY", 28, 32], ["diseases", "OBSERVATION", 33, 41], ["respiratory", "ANATOMY_MODIFIER", 61, 72], ["lung", "ANATOMY", 73, 77], ["infections", "OBSERVATION", 78, 88], ["viral", "OBSERVATION_MODIFIER", 107, 112], ["infections", "OBSERVATION", 113, 123]]], ["This review highlights the associations of lung infections and the respective chronic lung diseases and how infection in the different lung diseases affects disease exacerbation and progression.CHRONIC OBSTRUCTIVE PULMONARY DISEASECOPD is one of the leading causes of mortality and morbidity worldwide.", [["lung", "ANATOMY", 43, 47], ["lung", "ANATOMY", 86, 90], ["lung", "ANATOMY", 135, 139], ["lung infections", "DISEASE", 43, 58], ["chronic lung diseases", "DISEASE", 78, 99], ["infection", "DISEASE", 108, 117], ["lung diseases", "DISEASE", 135, 148], ["lung", "ORGAN", 43, 47], ["lung", "ORGAN", 86, 90], ["lung", "ORGAN", 135, 139], ["lung infections", "PROBLEM", 43, 58], ["the respective chronic lung diseases", "PROBLEM", 63, 99], ["how infection", "PROBLEM", 104, 117], ["the different lung diseases", "PROBLEM", 121, 148], ["disease exacerbation", "PROBLEM", 157, 177], ["CHRONIC OBSTRUCTIVE PULMONARY DISEASECOPD", "PROBLEM", 194, 235], ["lung", "ANATOMY", 43, 47], ["infections", "OBSERVATION", 48, 58], ["respective", "OBSERVATION_MODIFIER", 67, 77], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["lung", "ANATOMY", 86, 90], ["diseases", "OBSERVATION", 91, 99], ["infection", "OBSERVATION", 108, 117], ["different", "OBSERVATION_MODIFIER", 125, 134], ["lung", "ANATOMY", 135, 139], ["diseases", "OBSERVATION", 140, 148], ["progression", "OBSERVATION_MODIFIER", 182, 193], ["OBSTRUCTIVE", "OBSERVATION_MODIFIER", 202, 213], ["PULMONARY", "ANATOMY", 214, 223], ["DISEASECOPD", "OBSERVATION", 224, 235]]], ["1,2 Among several risk factors, cigarette smoking is the most important one.", [["smoking", "CHEMICAL", 42, 49], ["cigarette", "ORGANISM", 32, 41]]], ["However, smoking alone does not explain all the aspects of COPD.", [["smoking", "CHEMICAL", 9, 16], ["COPD", "DISEASE", 59, 63], ["COPD", "PROBLEM", 59, 63], ["COPD", "OBSERVATION", 59, 63]]], ["COPD can develop even in nonsmokers, especially in the context of biomass exposure in some parts of the world.", [["COPD", "DISEASE", 0, 4], ["COPD", "PROBLEM", 0, 4], ["biomass exposure", "PROBLEM", 66, 82], ["biomass exposure", "OBSERVATION", 66, 82]]], ["More than half of smokers do not develop COPD.", [["COPD", "DISEASE", 41, 45], ["smokers", "ORGANISM", 18, 25], ["COPD", "PROBLEM", 41, 45], ["COPD", "OBSERVATION", 41, 45]]], ["A subset of patients with COPD exhibits persistent inflammation despite smoking cessation.", [["COPD", "DISEASE", 26, 30], ["inflammation", "DISEASE", 51, 63], ["smoking", "CHEMICAL", 72, 79], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["COPD", "PROBLEM", 26, 30], ["persistent inflammation", "PROBLEM", 40, 63], ["COPD", "OBSERVATION", 26, 30], ["persistent", "OBSERVATION_MODIFIER", 40, 50], ["inflammation", "OBSERVATION", 51, 63]]], ["3, 4 In addition, accelerated loss of lung function may occur independent of smoking and occur with acute COPD exacerbations.", [["lung", "ANATOMY", 38, 42], ["loss of lung function", "DISEASE", 30, 51], ["smoking", "CHEMICAL", 77, 84], ["COPD", "DISEASE", 106, 110], ["lung", "ORGAN", 38, 42], ["accelerated loss of lung function", "PROBLEM", 18, 51], ["acute COPD exacerbations", "PROBLEM", 100, 124], ["accelerated", "OBSERVATION_MODIFIER", 18, 29], ["loss", "OBSERVATION", 30, 34], ["lung", "ANATOMY", 38, 42], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["COPD", "OBSERVATION", 106, 110]]], ["5 It is important to elucidate additional contributive factors besides smoking to control the disease.", [["the disease", "PROBLEM", 90, 101], ["disease", "OBSERVATION", 94, 101]]], ["COPD is characterized by chronic inflammation of the small airways.", [["small airways", "ANATOMY", 53, 66], ["COPD", "DISEASE", 0, 4], ["airways", "MULTI-TISSUE_STRUCTURE", 59, 66], ["COPD", "PROBLEM", 0, 4], ["chronic inflammation of the small airways", "PROBLEM", 25, 66], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["inflammation", "OBSERVATION", 33, 45], ["small", "ANATOMY_MODIFIER", 53, 58], ["airways", "ANATOMY", 59, 66]]], ["Respiratory tract infection is an important cause of acute exacerbation and progression of the disease.", [["Respiratory tract", "ANATOMY", 0, 17], ["Respiratory tract infection", "DISEASE", 0, 27], ["Respiratory tract infection", "PROBLEM", 0, 27], ["acute exacerbation", "PROBLEM", 53, 71], ["the disease", "PROBLEM", 91, 102], ["tract", "OBSERVATION_MODIFIER", 12, 17], ["infection", "OBSERVATION", 18, 27], ["important cause of", "UNCERTAINTY", 34, 52], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["exacerbation", "OBSERVATION", 59, 71], ["progression", "OBSERVATION_MODIFIER", 76, 87], ["disease", "OBSERVATION", 95, 102]]], ["6Common Viral Infections and Chronic Obstructive Pulmonary Disease ExacerbationsHistorically, bacteria have been considered the main infectious cause of COPD exacerbations.", [["Pulmonary", "ANATOMY", 49, 58], ["Viral Infections", "DISEASE", 8, 24], ["Chronic Obstructive Pulmonary Disease", "DISEASE", 29, 66], ["COPD", "DISEASE", 153, 157], ["6Common Viral Infections", "PROBLEM", 0, 24], ["Chronic Obstructive Pulmonary Disease ExacerbationsHistorically", "PROBLEM", 29, 92], ["bacteria", "PROBLEM", 94, 102], ["COPD exacerbations", "PROBLEM", 153, 171], ["Viral", "OBSERVATION_MODIFIER", 8, 13], ["Infections", "OBSERVATION", 14, 24], ["Chronic", "OBSERVATION_MODIFIER", 29, 36], ["Obstructive", "OBSERVATION_MODIFIER", 37, 48], ["Pulmonary", "ANATOMY", 49, 58], ["Disease", "OBSERVATION", 59, 66], ["main", "OBSERVATION_MODIFIER", 128, 132], ["infectious", "OBSERVATION_MODIFIER", 133, 143], ["COPD", "OBSERVATION", 153, 157]]], ["7 A growing body of evidence, however, implicates viral upper respiratory tract infections (URIs) as the predominant risk factor associated with exacerbations of COPD.", [["upper respiratory tract", "ANATOMY", 56, 79], ["viral upper respiratory tract infections", "DISEASE", 50, 90], ["URIs", "DISEASE", 92, 96], ["COPD", "DISEASE", 162, 166], ["upper respiratory tract", "ORGANISM_SUBDIVISION", 56, 79], ["viral upper respiratory tract infections", "PROBLEM", 50, 90], ["COPD", "PROBLEM", 162, 166], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["upper", "ANATOMY_MODIFIER", 56, 61], ["respiratory tract", "ANATOMY", 62, 79], ["infections", "OBSERVATION", 80, 90], ["COPD", "OBSERVATION", 162, 166]]], ["8 Approximately 40% to 60% of all COPD exacerbations are associated with upper respiratory infections (URIs) and viral infections have been suggested to be important contributors to COPD exacerbations.", [["respiratory", "ANATOMY", 79, 90], ["COPD", "DISEASE", 34, 38], ["upper respiratory infections", "DISEASE", 73, 101], ["URIs", "DISEASE", 103, 107], ["viral infections", "DISEASE", 113, 129], ["COPD", "DISEASE", 182, 186], ["all COPD exacerbations", "PROBLEM", 30, 52], ["upper respiratory infections (URIs)", "PROBLEM", 73, 108], ["viral infections", "PROBLEM", 113, 129], ["COPD exacerbations", "PROBLEM", 182, 200], ["COPD", "OBSERVATION", 34, 38], ["upper", "ANATOMY_MODIFIER", 73, 78], ["respiratory", "ANATOMY", 79, 90], ["infections", "OBSERVATION", 91, 101], ["viral infections", "OBSERVATION", 113, 129]]], ["9 In fact, it has been shown that respiratory viruses, including rhinovirus, influenza, and respiratory syncytial virus (RSV) cause COPD exacerbations.", [["respiratory viruses", "DISEASE", 34, 53], ["influenza", "DISEASE", 77, 86], ["respiratory syncytial virus", "DISEASE", 92, 119], ["RSV", "DISEASE", 121, 124], ["COPD", "DISEASE", 132, 136], ["rhinovirus", "ORGANISM", 65, 75], ["respiratory syncytial virus", "ORGANISM", 92, 119], ["RSV", "ORGANISM", 121, 124], ["respiratory syncytial virus", "SPECIES", 92, 119], ["respiratory syncytial virus", "SPECIES", 92, 119], ["RSV", "SPECIES", 121, 124], ["respiratory viruses", "PROBLEM", 34, 53], ["rhinovirus", "PROBLEM", 65, 75], ["influenza", "PROBLEM", 77, 86], ["respiratory syncytial virus (RSV)", "PROBLEM", 92, 125], ["COPD exacerbations", "PROBLEM", 132, 150], ["respiratory viruses", "OBSERVATION", 34, 53], ["respiratory syncytial virus", "OBSERVATION", 92, 119]]], ["[10] [11] [12] These exacerbations are more severe, last longer, and are associated with more heightened airway and systemic inflammatory responses than exacerbations due to other nonviral causes.", [["airway", "ANATOMY", 105, 111], ["airway", "MULTI-TISSUE_STRUCTURE", 105, 111], ["These exacerbations", "PROBLEM", 15, 34], ["systemic inflammatory responses", "PROBLEM", 116, 147], ["exacerbations", "PROBLEM", 153, 166], ["other nonviral causes", "PROBLEM", 174, 195], ["exacerbations", "OBSERVATION", 21, 34], ["more severe", "OBSERVATION_MODIFIER", 39, 50], ["airway", "ANATOMY", 105, 111], ["systemic", "OBSERVATION_MODIFIER", 116, 124], ["inflammatory", "OBSERVATION", 125, 137]]], ["[13] [14] [15] These differences cannot be attributed solely to pulmonary structural alterations in patients with COPD because healthy smokers also experience exaggerated symptomatic responses after viral infections.", [["pulmonary", "ANATOMY", 64, 73], ["pulmonary structural alterations", "DISEASE", 64, 96], ["COPD", "DISEASE", 114, 118], ["viral infections", "DISEASE", 199, 215], ["[13] [14] [15]", "SIMPLE_CHEMICAL", 0, 14], ["pulmonary", "ORGAN", 64, 73], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["pulmonary structural alterations", "PROBLEM", 64, 96], ["COPD", "PROBLEM", 114, 118], ["exaggerated symptomatic responses", "PROBLEM", 159, 192], ["viral infections", "PROBLEM", 199, 215], ["pulmonary", "ANATOMY", 64, 73], ["viral infections", "OBSERVATION", 199, 215]]], ["[16] [17] [18] Detection rates of virus in COPD exacerbation are variable between approximately 22% and 64%.", [["COPD", "DISEASE", 43, 47], ["Detection rates", "TEST", 15, 30], ["virus", "PROBLEM", 34, 39], ["COPD exacerbation", "PROBLEM", 43, 60], ["COPD", "OBSERVATION", 43, 47]]], ["9, 11, [19] [20] [21] [22] [23] [24] [25] [26] [27] The detection rates depend on onset to presentation, type of samples, and season.", [["9, 11, [19] [20", "CHEMICAL", 0, 15], ["9, 11, [19] [20] [21] [22] [23]", "CHEMICAL", 0, 31], ["[19] [20] [21] [22] [23] [24] [25] [26] [27]", "SIMPLE_CHEMICAL", 7, 51], ["The detection rates", "TEST", 52, 71]]], ["The most commonly identified viruses in exacerbation of COPD include rhinovirus, influenza viruses, RSV, parainfluenza, adenovirus, metapneumovirus, and coronavirus.", [["COPD", "DISEASE", 56, 60], ["rhinovirus", "DISEASE", 69, 79], ["influenza viruses", "DISEASE", 81, 98], ["RSV, parainfluenza, adenovirus, metapneumovirus, and coronavirus", "DISEASE", 100, 164], ["rhinovirus", "ORGANISM", 69, 79], ["influenza viruses", "ORGANISM", 81, 98], ["RSV", "ORGANISM", 100, 103], ["parainfluenza", "ORGANISM", 105, 118], ["adenovirus", "ORGANISM", 120, 130], ["metapneumovirus", "ORGANISM", 132, 147], ["RSV", "SPECIES", 100, 103], ["parainfluenza", "SPECIES", 105, 118], ["adenovirus, metapneumovirus", "SPECIES", 120, 147], ["coronavirus", "SPECIES", 153, 164], ["RSV", "SPECIES", 100, 103], ["COPD", "PROBLEM", 56, 60], ["rhinovirus", "PROBLEM", 69, 79], ["influenza viruses", "PROBLEM", 81, 98], ["RSV", "PROBLEM", 100, 103], ["parainfluenza", "PROBLEM", 105, 118], ["adenovirus", "PROBLEM", 120, 130], ["metapneumovirus", "PROBLEM", 132, 147], ["coronavirus", "PROBLEM", 153, 164], ["most commonly", "OBSERVATION_MODIFIER", 4, 17], ["viruses", "OBSERVATION", 29, 36], ["COPD", "OBSERVATION", 56, 60], ["rhinovirus", "OBSERVATION", 69, 79], ["influenza viruses", "OBSERVATION", 81, 98]]], ["Among them, rhinovirus and metapneumovirus are the most common viral pathogens in studies using polymerase chain reaction (PCR).", [["rhinovirus and metapneumovirus", "DISEASE", 12, 42], ["rhinovirus", "ORGANISM", 12, 22], ["metapneumovirus", "ORGANISM", 27, 42], ["rhinovirus", "SPECIES", 12, 22], ["rhinovirus", "PROBLEM", 12, 22], ["metapneumovirus", "PROBLEM", 27, 42], ["polymerase chain reaction", "PROBLEM", 96, 121], ["PCR", "TEST", 123, 126], ["rhinovirus", "OBSERVATION", 12, 22], ["metapneumovirus", "OBSERVATION", 27, 42]]], ["12, 13, 25 In these studies, rhinovirus was detected in 8% to 44% in the events of COPD acute exacerbation.", [["COPD", "DISEASE", 83, 87], ["rhinovirus", "ORGANISM", 29, 39], ["these studies", "TEST", 14, 27], ["rhinovirus", "PROBLEM", 29, 39], ["COPD acute exacerbation", "PROBLEM", 83, 106], ["rhinovirus", "OBSERVATION", 29, 39], ["COPD", "OBSERVATION", 83, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["exacerbation", "OBSERVATION", 94, 106]]], ["Influenza vaccination rate can also affect the prevalence.", [["Influenza", "DISEASE", 0, 9], ["Influenza vaccination rate", "TREATMENT", 0, 26]]], ["A Hong Kong study showed that influenza was the most common virus in hospitalized patients with COPD; meanwhile, a cohort from a London outpatient clinic showed low prevalence due to relatively high influenza vaccination rate (74%).", [["influenza", "DISEASE", 30, 39], ["COPD", "DISEASE", 96, 100], ["influenza", "DISEASE", 199, 208], ["influenza", "ORGANISM", 30, 39], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["A Hong Kong study", "TEST", 0, 17], ["influenza", "PROBLEM", 30, 39], ["COPD", "PROBLEM", 96, 100], ["relatively high influenza vaccination rate", "PROBLEM", 183, 225], ["influenza", "OBSERVATION", 30, 39], ["COPD", "OBSERVATION", 96, 100], ["high", "OBSERVATION_MODIFIER", 194, 198], ["influenza", "OBSERVATION", 199, 208]]], ["11, 15 Many COPD exacerbations also include virus and bacteria coinfection.", [["COPD exacerbations", "DISEASE", 12, 30], ["coinfection", "DISEASE", 63, 74], ["Many COPD exacerbations", "PROBLEM", 7, 30], ["virus", "PROBLEM", 44, 49], ["bacteria coinfection", "PROBLEM", 54, 74], ["COPD", "OBSERVATION", 12, 16], ["virus", "OBSERVATION", 44, 49], ["bacteria", "OBSERVATION_MODIFIER", 54, 62], ["coinfection", "OBSERVATION", 63, 74]]], ["Approximately 25% of the hospitalized patients with COPD exacerbations showed coinfection.", [["COPD", "DISEASE", 52, 56], ["coinfection", "DISEASE", 78, 89], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["COPD exacerbations", "PROBLEM", 52, 70], ["coinfection", "PROBLEM", 78, 89], ["COPD", "OBSERVATION", 52, 56], ["coinfection", "OBSERVATION", 78, 89]]], ["The clinical impact of coinfection is longer hospital stay and severe functional impairment.", [["coinfection", "DISEASE", 23, 34], ["functional impairment", "DISEASE", 70, 91], ["coinfection", "PROBLEM", 23, 34], ["severe functional impairment", "PROBLEM", 63, 91], ["coinfection", "OBSERVATION", 23, 34], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["functional", "OBSERVATION_MODIFIER", 70, 80], ["impairment", "OBSERVATION", 81, 91]]], ["28 Symptoms of COPD exacerbation include cough, increased sputum volume and purulence, and dyspnea; however, it is not easy to differentiate viral and nonviral causes of COPD exacerbation by symptoms.", [["sputum", "ANATOMY", 58, 64], ["COPD", "DISEASE", 15, 19], ["cough", "DISEASE", 41, 46], ["dyspnea", "DISEASE", 91, 98], ["COPD", "DISEASE", 170, 174], ["COPD exacerbation", "PROBLEM", 15, 32], ["cough", "PROBLEM", 41, 46], ["increased sputum volume", "PROBLEM", 48, 71], ["purulence", "PROBLEM", 76, 85], ["dyspnea", "PROBLEM", 91, 98], ["COPD exacerbation", "PROBLEM", 170, 187], ["symptoms", "PROBLEM", 191, 199], ["COPD", "OBSERVATION", 15, 19], ["cough", "OBSERVATION", 41, 46], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["sputum volume", "OBSERVATION", 58, 71], ["purulence", "OBSERVATION", 76, 85], ["dyspnea", "OBSERVATION", 91, 98], ["COPD", "OBSERVATION", 170, 174]]], ["Typical \"common-cold\" symptoms, including fever, nasal congestion, or rhinorrhea, are prevalent in patients with COPD when virus is detected, but those symptoms also can be noted in nonviral exacerbation, so their usefulness in diagnosis remains limited.", [["nasal", "ANATOMY", 49, 54], ["fever", "DISEASE", 42, 47], ["nasal congestion", "DISEASE", 49, 65], ["rhinorrhea", "DISEASE", 70, 80], ["COPD", "DISEASE", 113, 117], ["nasal", "ORGANISM_SUBDIVISION", 49, 54], ["patients", "ORGANISM", 99, 107], ["patients", "SPECIES", 99, 107], ["cold\" symptoms", "PROBLEM", 16, 30], ["fever", "PROBLEM", 42, 47], ["nasal congestion", "PROBLEM", 49, 65], ["rhinorrhea", "PROBLEM", 70, 80], ["COPD", "PROBLEM", 113, 117], ["virus", "PROBLEM", 123, 128], ["those symptoms", "PROBLEM", 146, 160], ["nonviral exacerbation", "PROBLEM", 182, 203], ["nasal", "ANATOMY", 49, 54], ["congestion", "OBSERVATION", 55, 65], ["rhinorrhea", "OBSERVATION", 70, 80], ["COPD", "OBSERVATION", 113, 117]]], ["13, 29 Sputum purulence has been suggested as evidence for bacterial infection in COPD exacerbation, but sputum also can be purulent due to neutrophilia irrespective of causal organism.", [["sputum", "ANATOMY", 105, 111], ["bacterial infection", "DISEASE", 59, 78], ["COPD", "DISEASE", 82, 86], ["neutrophilia", "DISEASE", 140, 152], ["sputum", "ORGANISM_SUBSTANCE", 105, 111], ["Sputum purulence", "PROBLEM", 7, 23], ["bacterial infection", "PROBLEM", 59, 78], ["COPD exacerbation", "PROBLEM", 82, 99], ["sputum", "TEST", 105, 111], ["purulent", "PROBLEM", 124, 132], ["neutrophilia", "PROBLEM", 140, 152], ["causal organism", "PROBLEM", 169, 184], ["purulence", "OBSERVATION", 14, 23], ["evidence for", "UNCERTAINTY", 46, 58], ["bacterial", "OBSERVATION_MODIFIER", 59, 68], ["infection", "OBSERVATION", 69, 78], ["COPD", "OBSERVATION", 82, 86], ["purulent", "OBSERVATION", 124, 132], ["neutrophilia", "OBSERVATION", 140, 152], ["causal organism", "OBSERVATION", 169, 184]]], ["30 Furthermore, almost all COPD exacerbations can be marked with change in sputum characteristics.", [["sputum", "ANATOMY", 75, 81], ["COPD", "DISEASE", 27, 31], ["all COPD exacerbations", "PROBLEM", 23, 45], ["change in sputum characteristics", "PROBLEM", 65, 97], ["COPD", "OBSERVATION", 27, 31], ["marked", "OBSERVATION_MODIFIER", 53, 59], ["sputum", "OBSERVATION", 75, 81]]], ["31 Therefore, the sputum characteristics are not a useful marker to differentiate viral and bacterial infection.", [["sputum", "ANATOMY", 18, 24], ["viral and bacterial infection", "DISEASE", 82, 111], ["the sputum characteristics", "TEST", 14, 40], ["viral and bacterial infection", "PROBLEM", 82, 111], ["bacterial", "OBSERVATION_MODIFIER", 92, 101], ["infection", "OBSERVATION", 102, 111]]], ["On the other hand, sputum purulence may be used to decide the usage of antibiotics.", [["sputum", "ANATOMY", 19, 25], ["sputum purulence", "PROBLEM", 19, 35], ["antibiotics", "TREATMENT", 71, 82], ["purulence", "OBSERVATION", 26, 35]]], ["32 Although neutrophils are the predominantly increased cell type in sputum during COPD exacerbations, one report showed increased eosinophilia during viral exacerbations.", [["neutrophils", "ANATOMY", 12, 23], ["cell", "ANATOMY", 56, 60], ["sputum", "ANATOMY", 69, 75], ["COPD", "DISEASE", 83, 87], ["eosinophilia", "DISEASE", 131, 143], ["viral exacerbations", "DISEASE", 151, 170], ["neutrophils", "CELL", 12, 23], ["cell type", "CELL", 56, 65], ["sputum", "ORGANISM_SUBSTANCE", 69, 75], ["neutrophils", "CELL_TYPE", 12, 23], ["neutrophils", "TEST", 12, 23], ["increased cell type in sputum", "PROBLEM", 46, 75], ["COPD exacerbations", "PROBLEM", 83, 101], ["increased eosinophilia", "PROBLEM", 121, 143], ["viral exacerbations", "PROBLEM", 151, 170], ["neutrophils", "OBSERVATION", 12, 23], ["predominantly", "OBSERVATION_MODIFIER", 32, 45], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["cell type", "OBSERVATION", 56, 65], ["sputum", "OBSERVATION", 69, 75], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["eosinophilia", "OBSERVATION", 131, 143], ["viral exacerbations", "OBSERVATION", 151, 170]]], ["28 Viral exacerbations also are associated with frequent exacerbations, severe exacerbations, and a prolonged time for symptom recovery.", [["Viral exacerbations", "DISEASE", 3, 22], ["Viral exacerbations", "PROBLEM", 3, 22], ["frequent exacerbations", "PROBLEM", 48, 70], ["severe exacerbations", "PROBLEM", 72, 92], ["symptom recovery", "PROBLEM", 119, 135], ["Viral exacerbations", "OBSERVATION", 3, 22], ["associated with", "UNCERTAINTY", 32, 47], ["frequent", "OBSERVATION_MODIFIER", 48, 56], ["exacerbations", "OBSERVATION", 57, 70], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["exacerbations", "OBSERVATION", 79, 92]]], ["13 Viruses also can be detected in stable COPD.", [["COPD", "DISEASE", 42, 46], ["Viruses", "OBSERVATION", 3, 10], ["stable", "OBSERVATION_MODIFIER", 35, 41], ["COPD", "OBSERVATION", 42, 46]]], ["Patients with RSV infection had higher plasma fibrinogen, serum interleukin (IL)-6, and hypercapnia in stable state.", [["plasma", "ANATOMY", 39, 45], ["serum", "ANATOMY", 58, 63], ["RSV infection", "DISEASE", 14, 27], ["Patients", "ORGANISM", 0, 8], ["RSV", "ORGANISM", 14, 17], ["plasma", "ORGANISM_SUBSTANCE", 39, 45], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 46, 56], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 64, 82], ["plasma fibrinogen", "PROTEIN", 39, 56], ["serum interleukin (IL)-6", "PROTEIN", 58, 82], ["Patients", "SPECIES", 0, 8], ["RSV", "SPECIES", 14, 17], ["RSV infection", "PROBLEM", 14, 27], ["plasma fibrinogen", "TEST", 39, 56], ["serum interleukin (IL)", "TEST", 58, 80], ["hypercapnia", "PROBLEM", 88, 99], ["RSV", "ANATOMY", 14, 17], ["infection", "OBSERVATION", 18, 27], ["hypercapnia", "OBSERVATION", 88, 99], ["stable", "OBSERVATION_MODIFIER", 103, 109]]], ["13 This suggests that asymptomatic viral colonization can potentially have a role in chronic inflammation and disease progression of COPD.", [["inflammation", "DISEASE", 93, 105], ["COPD", "DISEASE", 133, 137], ["asymptomatic viral colonization", "PROBLEM", 22, 53], ["chronic inflammation", "PROBLEM", 85, 105], ["COPD", "PROBLEM", 133, 137], ["asymptomatic", "OBSERVATION_MODIFIER", 22, 34], ["viral colonization", "OBSERVATION", 35, 53], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["inflammation", "OBSERVATION", 93, 105], ["COPD", "OBSERVATION", 133, 137]]], ["Another study that supports this showed a relationship between frequent RSV detection and accelerated lung function decline (101.4 mL/y vs 51.2 mL/y, P = .01).", [["lung", "ANATOMY", 102, 106], ["RSV", "ORGANISM", 72, 75], ["lung", "ORGAN", 102, 106], ["RSV", "SPECIES", 72, 75], ["Another study", "TEST", 0, 13], ["frequent RSV detection", "PROBLEM", 63, 85], ["accelerated lung function decline", "PROBLEM", 90, 123], ["P", "TEST", 150, 151], ["RSV", "OBSERVATION", 72, 75], ["lung", "ANATOMY", 102, 106]]], ["33 It has been proposed that the alveolar epithelial cells of smokers and patients with severe emphysema are more frequently latently infected with adenovirus as compared with smokers without airflow obstruction.", [["alveolar epithelial cells", "ANATOMY", 33, 58], ["emphysema", "DISEASE", 95, 104], ["airflow obstruction", "DISEASE", 192, 211], ["alveolar epithelial cells", "CELL", 33, 58], ["patients", "ORGANISM", 74, 82], ["adenovirus", "ORGANISM", 148, 158], ["alveolar epithelial cells", "CELL_TYPE", 33, 58], ["patients", "SPECIES", 74, 82], ["adenovirus", "SPECIES", 148, 158], ["severe emphysema", "PROBLEM", 88, 104], ["adenovirus", "PROBLEM", 148, 158], ["airflow obstruction", "PROBLEM", 192, 211], ["alveolar epithelial cells", "OBSERVATION", 33, 58], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["emphysema", "OBSERVATION", 95, 104], ["without", "UNCERTAINTY", 184, 191], ["airflow obstruction", "OBSERVATION", 192, 211]]], ["34, 35 They found COPD lung epithelial cells express adenoviral E1A protein, and that this was associated with specific lung inflammation.", [["lung epithelial cells", "ANATOMY", 23, 44], ["lung", "ANATOMY", 120, 124], ["COPD", "DISEASE", 18, 22], ["lung inflammation", "DISEASE", 120, 137], ["lung epithelial cells", "CELL", 23, 44], ["adenoviral", "ORGANISM", 53, 63], ["E1A", "GENE_OR_GENE_PRODUCT", 64, 67], ["lung", "ORGAN", 120, 124], ["COPD lung epithelial cells", "CELL_TYPE", 18, 44], ["adenoviral E1A protein", "PROTEIN", 53, 75], ["COPD lung epithelial cells", "PROBLEM", 18, 44], ["adenoviral E1A protein", "PROBLEM", 53, 75], ["specific lung inflammation", "PROBLEM", 111, 137], ["COPD", "OBSERVATION", 18, 22], ["lung", "ANATOMY", 23, 27], ["epithelial cells", "OBSERVATION", 28, 44], ["adenoviral E1A protein", "OBSERVATION", 53, 75], ["associated with", "UNCERTAINTY", 95, 110], ["specific", "OBSERVATION_MODIFIER", 111, 119], ["lung", "ANATOMY", 120, 124], ["inflammation", "OBSERVATION", 125, 137]]], ["The investigators propose such adenoviral infections in patients with COPD contribute to the amplification of the lung inflammatory responses.Common Viral Infections and Chronic Obstructive Pulmonary Disease ExacerbationsPCR of respiratory samples is the main tool to detect causal viruses.", [["lung", "ANATOMY", 114, 118], ["Pulmonary", "ANATOMY", 190, 199], ["respiratory samples", "ANATOMY", 228, 247], ["adenoviral infections", "DISEASE", 31, 52], ["COPD", "DISEASE", 70, 74], ["Viral Infections", "DISEASE", 149, 165], ["Obstructive Pulmonary Disease", "DISEASE", 178, 207], ["adenoviral", "ORGANISM", 31, 41], ["patients", "ORGANISM", 56, 64], ["lung", "ORGAN", 114, 118], ["Pulmonary", "ORGAN", 190, 199], ["patients", "SPECIES", 56, 64], ["adenoviral", "SPECIES", 31, 41], ["adenoviral infections", "PROBLEM", 31, 52], ["COPD", "PROBLEM", 70, 74], ["the lung inflammatory responses", "PROBLEM", 110, 141], ["Common Viral Infections", "PROBLEM", 142, 165], ["Chronic Obstructive Pulmonary Disease", "PROBLEM", 170, 207], ["respiratory samples", "TEST", 228, 247], ["causal viruses", "PROBLEM", 275, 289], ["lung", "ANATOMY", 114, 118], ["inflammatory", "OBSERVATION", 119, 131], ["Viral", "OBSERVATION_MODIFIER", 149, 154], ["Infections", "OBSERVATION", 155, 165], ["Chronic", "OBSERVATION_MODIFIER", 170, 177], ["Obstructive", "OBSERVATION_MODIFIER", 178, 189], ["Pulmonary", "ANATOMY", 190, 199], ["Disease", "OBSERVATION", 200, 207], ["respiratory samples", "OBSERVATION", 228, 247], ["viruses", "OBSERVATION", 282, 289]]], ["Before the widespread use of PCR technique, low virus-detection rates underestimated their role in COPD.", [["COPD", "DISEASE", 99, 103], ["PCR technique", "TREATMENT", 29, 42], ["low virus", "PROBLEM", 44, 53], ["COPD", "PROBLEM", 99, 103], ["COPD", "OBSERVATION", 99, 103]]], ["The introduction of PCR helped revolutionize viral diagnostics; PCR is far more sensitive and equally specific to the traditional techniques that include culture, antigen-detection tests, and serology.", [["PCR", "TEST", 20, 23], ["viral diagnostics", "TEST", 45, 62], ["PCR", "TEST", 64, 67], ["culture", "TEST", 154, 161], ["antigen", "TEST", 163, 170], ["detection tests", "TEST", 171, 186], ["serology", "TEST", 192, 200]]], ["36, 37 Rhinovirus is one of the most common viruses in COPD exacerbation, but it is difficult to culture and serology is not possible due to the presence of more than 100 serotypes.", [["COPD", "DISEASE", 55, 59], ["Rhinovirus", "PROBLEM", 7, 17], ["COPD exacerbation", "PROBLEM", 55, 72], ["culture", "TEST", 97, 104], ["serology", "TEST", 109, 117], ["Rhinovirus", "OBSERVATION", 7, 17], ["most common", "OBSERVATION_MODIFIER", 32, 43], ["viruses", "OBSERVATION", 44, 51], ["COPD", "OBSERVATION", 55, 59]]], ["Without PCR, these viruses cannot be identified.", [["PCR", "PROBLEM", 8, 11], ["these viruses", "PROBLEM", 13, 26], ["viruses", "OBSERVATION", 19, 26], ["cannot be", "UNCERTAINTY", 27, 36]]], ["As a result, early studies using other diagnostic methods underestimated the prevalence of rhinovirus.", [["rhinovirus", "DISEASE", 91, 101], ["rhinovirus", "ORGANISM", 91, 101], ["early studies", "TEST", 13, 26], ["diagnostic methods", "TEST", 39, 57], ["rhinovirus", "PROBLEM", 91, 101], ["rhinovirus", "OBSERVATION", 91, 101]]], ["15 Among various methods to obtain samples, such as nasal lavage, throat swab, or induced sputum, it is not yet evident which method is superior.", [["samples", "ANATOMY", 35, 42], ["nasal lavage", "ANATOMY", 52, 64], ["throat swab", "ANATOMY", 66, 77], ["sputum", "ANATOMY", 90, 96], ["nasal lavage", "ORGANISM_SUBSTANCE", 52, 64], ["samples", "TEST", 35, 42], ["nasal lavage, throat swab", "TEST", 52, 77], ["induced sputum", "PROBLEM", 82, 96], ["nasal", "ANATOMY", 52, 57], ["lavage", "OBSERVATION", 58, 64], ["throat", "ANATOMY", 66, 72]]], ["Some viruses, especially RSV, can directly invade the lower respiratory tract; therefore, obtaining a simultaneous lower respiratory tract sample can increase the sensitivity of these assays.", [["lower respiratory tract", "ANATOMY", 54, 77], ["lower respiratory tract sample", "ANATOMY", 115, 145], ["RSV", "ORGANISM", 25, 28], ["lower", "ORGANISM_SUBDIVISION", 54, 59], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["respiratory tract", "ORGANISM_SUBDIVISION", 121, 138], ["RSV", "SPECIES", 25, 28], ["Some viruses", "PROBLEM", 0, 12], ["RSV", "PROBLEM", 25, 28], ["a simultaneous lower respiratory tract sample", "PROBLEM", 100, 145], ["these assays", "TEST", 178, 190], ["viruses", "OBSERVATION", 5, 12], ["RSV", "OBSERVATION", 25, 28], ["lower", "ANATOMY_MODIFIER", 54, 59], ["respiratory tract", "ANATOMY", 60, 77], ["respiratory tract", "ANATOMY", 121, 138]]], ["The big challenge of this molecular diagnostic approach is that it cannot discriminate causative organisms from colonization.", [["colonization", "PROBLEM", 112, 124]]], ["Antiviral therapy is not necessary in most immunocompetent and asymptomatic patients with COPD.", [["COPD", "DISEASE", 90, 94], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["Antiviral therapy", "TREATMENT", 0, 17], ["COPD", "PROBLEM", 90, 94], ["COPD", "OBSERVATION", 90, 94]]], ["Antiviral therapy is not indicated solely on the basis of a known diagnosis of COPD.", [["COPD", "DISEASE", 79, 83], ["Antiviral therapy", "TREATMENT", 0, 17], ["COPD", "PROBLEM", 79, 83], ["COPD", "OBSERVATION", 79, 83]]], ["Most endemic viral infections are self-limiting, and pharmacologic management is not necessary.", [["viral infections", "DISEASE", 13, 29], ["Most endemic viral infections", "PROBLEM", 0, 29], ["pharmacologic management", "TREATMENT", 53, 77], ["endemic", "OBSERVATION_MODIFIER", 5, 12], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["infections", "OBSERVATION", 19, 29]]], ["In the case of severe and progressive pandemic influenza virus, oseltamivir is indicated when the clinical diagnosis is made.", [["influenza", "DISEASE", 47, 56], ["oseltamivir", "CHEMICAL", 64, 75], ["oseltamivir", "CHEMICAL", 64, 75], ["influenza virus", "ORGANISM", 47, 62], ["oseltamivir", "SIMPLE_CHEMICAL", 64, 75], ["pandemic influenza virus", "SPECIES", 38, 62], ["severe and progressive pandemic influenza virus", "PROBLEM", 15, 62], ["oseltamivir", "TREATMENT", 64, 75], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["progressive", "OBSERVATION_MODIFIER", 26, 37], ["pandemic", "OBSERVATION_MODIFIER", 38, 46], ["influenza virus", "OBSERVATION", 47, 62]]], ["38 One of the difficult decisions is not to prescribe antibiotics when they are not necessary.", [["antibiotics", "TREATMENT", 54, 65]]], ["When the causative organism is a virus, antibiotics are not usually necessary unless one is concerned about postviral secondary bacterial lung infections.", [["lung", "ANATOMY", 138, 142], ["bacterial lung infections", "DISEASE", 128, 153], ["lung", "ORGAN", 138, 142], ["the causative organism", "PROBLEM", 5, 27], ["a virus", "PROBLEM", 31, 38], ["antibiotics", "TREATMENT", 40, 51], ["postviral secondary bacterial lung infections", "PROBLEM", 108, 153], ["bacterial", "OBSERVATION_MODIFIER", 128, 137], ["lung", "ANATOMY", 138, 142], ["infections", "OBSERVATION", 143, 153]]], ["Although sputum characteristics do not indicate the causative organisms, sputum purulence can be suggested to decide the usage of antibiotics.", [["sputum", "ANATOMY", 9, 15], ["sputum", "ANATOMY", 73, 79], ["sputum characteristics", "TEST", 9, 31], ["the causative organisms", "PROBLEM", 48, 71], ["sputum purulence", "PROBLEM", 73, 89], ["antibiotics", "TREATMENT", 130, 141]]], ["32 Influenza vaccination is highly recommended in patients with COPD and other chronic lung diseases.ASTHMAAsthma is defined as reversible airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation.", [["lung", "ANATOMY", 87, 91], ["bronchial", "ANATOMY", 160, 169], ["Influenza", "DISEASE", 3, 12], ["COPD", "DISEASE", 64, 68], ["chronic lung diseases", "DISEASE", 79, 100], ["ASTHMAAsthma", "DISEASE", 101, 113], ["airflow obstruction", "DISEASE", 139, 158], ["bronchial hyperresponsiveness", "DISEASE", 160, 189], ["inflammation", "DISEASE", 206, 218], ["patients", "ORGANISM", 50, 58], ["lung", "ORGAN", 87, 91], ["patients", "SPECIES", 50, 58], ["Influenza vaccination", "TREATMENT", 3, 24], ["COPD", "PROBLEM", 64, 68], ["other chronic lung diseases", "PROBLEM", 73, 100], ["ASTHMAAsthma", "PROBLEM", 101, 113], ["reversible airflow obstruction", "PROBLEM", 128, 158], ["bronchial hyperresponsiveness", "PROBLEM", 160, 189], ["underlying inflammation", "PROBLEM", 195, 218], ["COPD", "OBSERVATION", 64, 68], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["lung", "ANATOMY", 87, 91], ["diseases", "OBSERVATION", 92, 100], ["reversible", "OBSERVATION_MODIFIER", 128, 138], ["airflow", "OBSERVATION_MODIFIER", 139, 146], ["obstruction", "OBSERVATION", 147, 158], ["bronchial", "ANATOMY", 160, 169], ["hyperresponsiveness", "OBSERVATION", 170, 189], ["inflammation", "OBSERVATION", 206, 218]]], ["Asthma continues to be a serious global health problem for all age groups, and its prevalence is still increasing in many countries.", [["Asthma", "DISEASE", 0, 6], ["Asthma", "PROBLEM", 0, 6], ["a serious global health problem", "PROBLEM", 23, 54], ["serious", "OBSERVATION_MODIFIER", 25, 32], ["increasing", "OBSERVATION_MODIFIER", 103, 113]]], ["Worldwide asthma affects approximately 300 million people, with an increased incidence in the developed world.", [["asthma", "DISEASE", 10, 16], ["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["Worldwide asthma", "PROBLEM", 0, 16], ["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["Through the development of inhaled medications, hospitalization and mortality have decreased, but overall asthma control remains suboptimal.", [["asthma", "DISEASE", 106, 112], ["inhaled medications", "TREATMENT", 27, 46], ["hospitalization", "TREATMENT", 48, 63], ["overall asthma control", "PROBLEM", 98, 120], ["inhaled medications", "OBSERVATION", 27, 46], ["decreased", "OBSERVATION_MODIFIER", 83, 92]]], ["Many studies supported the evidence that viral infection has several important roles in disease development, exacerbation, and progression.Virus Infection and Asthma DevelopmentThe \"hygiene hypothesis\" proposes that a lower incidence of infections in early childhood explains the rise in allergic diseases such as asthma.", [["viral infection", "DISEASE", 41, 56], ["Virus Infection", "DISEASE", 139, 154], ["Asthma", "DISEASE", 159, 165], ["infections", "DISEASE", 237, 247], ["allergic diseases", "DISEASE", 288, 305], ["asthma", "DISEASE", 314, 320], ["Many studies", "TEST", 0, 12], ["viral infection", "PROBLEM", 41, 56], ["disease development", "PROBLEM", 88, 107], ["exacerbation", "PROBLEM", 109, 121], ["Virus Infection", "PROBLEM", 139, 154], ["Asthma", "PROBLEM", 159, 165], ["infections", "PROBLEM", 237, 247], ["allergic diseases", "PROBLEM", 288, 305], ["asthma", "PROBLEM", 314, 320], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infection", "OBSERVATION", 47, 56], ["exacerbation", "OBSERVATION_MODIFIER", 109, 121], ["progression", "OBSERVATION_MODIFIER", 127, 138], ["Infection", "OBSERVATION", 145, 154], ["Asthma", "OBSERVATION", 159, 165], ["lower", "OBSERVATION_MODIFIER", 218, 223], ["infections", "OBSERVATION", 237, 247], ["allergic diseases", "OBSERVATION", 288, 305], ["asthma", "OBSERVATION", 314, 320]]], ["39 The thought is that repeated exposures to infections are associated with a healthier immune system with protection against allergic and autoimmune diseases.", [["infections", "DISEASE", 45, 55], ["allergic and autoimmune diseases", "DISEASE", 126, 158], ["infections", "PROBLEM", 45, 55], ["allergic", "PROBLEM", 126, 134], ["autoimmune diseases", "PROBLEM", 139, 158], ["infections", "OBSERVATION", 45, 55], ["autoimmune diseases", "OBSERVATION", 139, 158]]], ["Specifically, microbes encountered could elicit a more T-helper type 1 (T H 1) immune response that could downregulate the T-helper type 2 (T H 2) immune responses that favor asthma development.", [["asthma", "DISEASE", 175, 181], ["T-helper type 1", "GENE_OR_GENE_PRODUCT", 55, 70], ["T H 1", "GENE_OR_GENE_PRODUCT", 72, 77], ["T-helper type 2", "GENE_OR_GENE_PRODUCT", 123, 138], ["T H 2", "GENE_OR_GENE_PRODUCT", 140, 145], ["immune response", "PROBLEM", 79, 94], ["immune responses", "PROBLEM", 147, 163], ["asthma development", "PROBLEM", 175, 193], ["asthma", "OBSERVATION", 175, 181]]], ["The hygiene hypothesis is focused on a lack of T H 1 stimulation that caused an overactive T H 2 response and could lead to a more allergic immune response.", [["allergic", "DISEASE", 131, 139], ["H 2", "CHEMICAL", 93, 96], ["T H 1", "GENE_OR_GENE_PRODUCT", 47, 52], ["T H 2", "GENE_OR_GENE_PRODUCT", 91, 96], ["T H 1 stimulation", "TREATMENT", 47, 64], ["an overactive T H 2 response", "PROBLEM", 77, 105], ["a more allergic immune response", "PROBLEM", 124, 155], ["overactive", "OBSERVATION", 80, 90]]], ["What role viruses play in the T H 2 response has been long debated and studied.", [["T H 2", "GENE_OR_GENE_PRODUCT", 30, 35]]], ["Whether early viral infections set in motion a T H 2-driven immune response or whether a lack of a T H 1 response causes a more symptomatic response to viral infections has been unclear.", [["viral infections", "DISEASE", 14, 30], ["viral infections", "DISEASE", 152, 168], ["T H 2", "GENE_OR_GENE_PRODUCT", 47, 52], ["T H 1", "GENE_OR_GENE_PRODUCT", 99, 104], ["T H 1", "SPECIES", 99, 104], ["early viral infections", "PROBLEM", 8, 30], ["a T H", "TEST", 45, 50], ["a more symptomatic response", "PROBLEM", 121, 148], ["viral infections", "PROBLEM", 152, 168], ["early", "OBSERVATION_MODIFIER", 8, 13], ["viral", "OBSERVATION_MODIFIER", 14, 19], ["infections", "OBSERVATION", 20, 30], ["viral infections", "OBSERVATION", 152, 168]]], ["Similarly, the debate over whether an asthma exacerbation is the result of an immune-deficient response or an exaggerated immune response continues.", [["asthma", "DISEASE", 38, 44], ["an asthma exacerbation", "PROBLEM", 35, 57], ["an immune-deficient response", "PROBLEM", 75, 103], ["an exaggerated immune response", "PROBLEM", 107, 137], ["asthma", "OBSERVATION", 38, 44], ["exaggerated", "OBSERVATION_MODIFIER", 110, 121], ["immune response", "OBSERVATION", 122, 137]]], ["Many studies supported the evidence that viral infection has several important roles in disease development, exacerbation, and progression.Common Viral Pathogens in AsthmaViral infection is closely associated with wheezing episodes, which resembles the manifestations of asthma.", [["viral infection", "DISEASE", 41, 56], ["AsthmaViral infection", "DISEASE", 165, 186], ["wheezing", "DISEASE", 214, 222], ["asthma", "DISEASE", 271, 277], ["Many studies", "TEST", 0, 12], ["viral infection", "PROBLEM", 41, 56], ["disease development", "PROBLEM", 88, 107], ["exacerbation", "PROBLEM", 109, 121], ["Common Viral Pathogens", "PROBLEM", 139, 161], ["AsthmaViral infection", "PROBLEM", 165, 186], ["wheezing episodes", "PROBLEM", 214, 231], ["asthma", "PROBLEM", 271, 277], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["infection", "OBSERVATION", 47, 56], ["exacerbation", "OBSERVATION_MODIFIER", 109, 121], ["progression", "OBSERVATION_MODIFIER", 127, 138], ["Viral", "OBSERVATION_MODIFIER", 146, 151], ["Pathogens", "OBSERVATION", 152, 161], ["AsthmaViral", "OBSERVATION_MODIFIER", 165, 176], ["infection", "OBSERVATION", 177, 186], ["asthma", "OBSERVATION", 271, 277]]], ["Especially in younger groups, these episodes can be related to the later development of asthma.", [["asthma", "DISEASE", 88, 94], ["asthma", "PROBLEM", 88, 94], ["asthma", "OBSERVATION", 88, 94]]], ["Among viruses causing respiratory infection, RSV and rhinovirus are well-documented to increase the risk of asthma though early adulthood.", [["respiratory", "ANATOMY", 22, 33], ["respiratory infection", "DISEASE", 22, 43], ["asthma", "DISEASE", 108, 114], ["RSV", "ORGANISM", 45, 48], ["rhinovirus", "ORGANISM", 53, 63], ["RSV", "SPECIES", 45, 48], ["RSV", "SPECIES", 45, 48], ["Among viruses", "PROBLEM", 0, 13], ["respiratory infection", "PROBLEM", 22, 43], ["RSV", "PROBLEM", 45, 48], ["rhinovirus", "PROBLEM", 53, 63], ["asthma", "PROBLEM", 108, 114], ["respiratory", "ANATOMY", 22, 33], ["infection", "OBSERVATION", 34, 43], ["rhinovirus", "OBSERVATION", 53, 63], ["asthma", "OBSERVATION", 108, 114]]], ["In an 18-year longitudinal study, severe early RSV bronchiolitis is associated with an increased prevalence of allergic asthma persisting into childhood, and even early adulthood.", [["bronchiolitis", "DISEASE", 51, 64], ["allergic asthma", "DISEASE", 111, 126], ["RSV", "ORGANISM", 47, 50], ["RSV", "SPECIES", 47, 50], ["longitudinal study", "TEST", 14, 32], ["severe early RSV bronchiolitis", "PROBLEM", 34, 64], ["allergic asthma", "PROBLEM", 111, 126], ["severe", "OBSERVATION_MODIFIER", 34, 40], ["early", "OBSERVATION_MODIFIER", 41, 46], ["RSV bronchiolitis", "OBSERVATION", 47, 64], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["allergic asthma", "OBSERVATION", 111, 126], ["early", "OBSERVATION_MODIFIER", 163, 168], ["adulthood", "OBSERVATION_MODIFIER", 169, 178]]], ["40, 41 Among viral wheezing illnesses in infancy and early childhood, those caused by RSV infections are the most significant predictors of the subsequent development of asthma.", [["wheezing illnesses", "DISEASE", 19, 37], ["RSV infections", "DISEASE", 86, 100], ["asthma", "DISEASE", 170, 176], ["RSV", "ORGANISM", 86, 89], ["RSV", "SPECIES", 86, 89], ["Among viral wheezing illnesses", "PROBLEM", 7, 37], ["RSV infections", "PROBLEM", 86, 100], ["asthma", "PROBLEM", 170, 176], ["viral", "OBSERVATION_MODIFIER", 13, 18], ["wheezing", "OBSERVATION", 19, 27], ["RSV infections", "OBSERVATION", 86, 100], ["asthma", "OBSERVATION", 170, 176]]], ["42 Host factors may also affect the pathogenesis of asthma in connection with viruses.", [["asthma", "DISEASE", 52, 58], ["asthma", "PROBLEM", 52, 58], ["viruses", "PROBLEM", 78, 85], ["may also affect", "UNCERTAINTY", 16, 31], ["asthma", "OBSERVATION", 52, 58], ["viruses", "OBSERVATION", 78, 85]]], ["Children with wheezing illness with rhinovirus were associated with asthma development if they had certain variants at chromosome 17q21.", [["chromosome 17q21", "ANATOMY", 119, 135], ["wheezing illness", "DISEASE", 14, 30], ["rhinovirus", "DISEASE", 36, 46], ["asthma", "DISEASE", 68, 74], ["Children", "ORGANISM", 0, 8], ["rhinovirus", "ORGANISM", 36, 46], ["chromosome 17q21", "CELLULAR_COMPONENT", 119, 135], ["chromosome 17q21", "DNA", 119, 135], ["Children", "SPECIES", 0, 8], ["wheezing illness", "PROBLEM", 14, 30], ["rhinovirus", "PROBLEM", 36, 46], ["asthma", "PROBLEM", 68, 74], ["rhinovirus", "OBSERVATION", 36, 46]]], ["43Virus Infection and ExacerbationAsthma exacerbations may be triggered by respiratory infections as well as by atmospheric and domiciliary environmental factors.", [["respiratory", "ANATOMY", 75, 86], ["ExacerbationAsthma exacerbations", "DISEASE", 22, 54], ["respiratory infections", "DISEASE", 75, 97], ["Infection", "PROBLEM", 8, 17], ["ExacerbationAsthma exacerbations", "PROBLEM", 22, 54], ["respiratory infections", "PROBLEM", 75, 97], ["Infection", "OBSERVATION", 8, 17], ["respiratory", "ANATOMY", 75, 86], ["infections", "OBSERVATION", 87, 97]]], ["Viral infections may cause a loss of asthma control, and most exacerbations, particularly in children with allergic asthma, coincide with respiratory viral infections.", [["Viral infections", "DISEASE", 0, 16], ["loss of asthma", "DISEASE", 29, 43], ["allergic asthma", "DISEASE", 107, 122], ["respiratory viral infections", "DISEASE", 138, 166], ["Viral", "ORGANISM", 0, 5], ["children", "ORGANISM", 93, 101], ["children", "SPECIES", 93, 101], ["Viral infections", "PROBLEM", 0, 16], ["a loss of asthma control", "PROBLEM", 27, 51], ["allergic asthma", "PROBLEM", 107, 122], ["respiratory viral infections", "PROBLEM", 138, 166], ["infections", "OBSERVATION", 6, 16], ["loss", "OBSERVATION_MODIFIER", 29, 33], ["asthma", "OBSERVATION", 37, 43], ["allergic asthma", "OBSERVATION", 107, 122], ["viral infections", "OBSERVATION", 150, 166]]], ["Studies of asthma exacerbation showed higher virus-detection rates than those of COPD.", [["asthma", "DISEASE", 11, 17], ["COPD", "DISEASE", 81, 85], ["asthma exacerbation", "PROBLEM", 11, 30], ["higher virus", "PROBLEM", 38, 50], ["COPD", "PROBLEM", 81, 85], ["asthma", "OBSERVATION", 11, 17], ["higher virus", "OBSERVATION", 38, 50], ["COPD", "OBSERVATION", 81, 85]]], ["PCR showed the presence of viruses in 80% to 85% in children and 60% to 80% in adults.", [["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["PCR", "TEST", 0, 3], ["viruses", "PROBLEM", 27, 34], ["viruses", "OBSERVATION", 27, 34]]], ["[44] [45] [46] The most common viruses included rhinovirus, influenza, RSV, and corona virus, although some seasonal variation is present.", [["rhinovirus, influenza, RSV, and corona virus", "DISEASE", 48, 92], ["[44] [45] [46]", "SIMPLE_CHEMICAL", 0, 14], ["rhinovirus", "ORGANISM", 48, 58], ["influenza", "ORGANISM", 60, 69], ["RSV", "ORGANISM", 71, 74], ["corona virus", "ORGANISM", 80, 92], ["RSV", "SPECIES", 71, 74], ["RSV", "SPECIES", 71, 74], ["corona virus", "SPECIES", 80, 92], ["rhinovirus", "PROBLEM", 48, 58], ["influenza", "PROBLEM", 60, 69], ["RSV", "PROBLEM", 71, 74], ["corona virus", "PROBLEM", 80, 92], ["some seasonal variation", "PROBLEM", 103, 126], ["rhinovirus", "OBSERVATION", 48, 58], ["corona virus", "ANATOMY", 80, 92], ["seasonal variation", "OBSERVATION", 108, 126]]], ["In patients with asthma, URI symptoms persisted longer and were more severe than in healthy controls.", [["asthma", "DISEASE", 17, 23], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["asthma", "PROBLEM", 17, 23], ["URI symptoms", "PROBLEM", 25, 37], ["asthma", "OBSERVATION", 17, 23], ["more severe", "OBSERVATION_MODIFIER", 64, 75]]], ["Like COPD, PCR for respiratory samples is the preferred diagnostic modality.", [["respiratory samples", "ANATOMY", 19, 38], ["COPD", "DISEASE", 5, 9], ["COPD", "PROBLEM", 5, 9], ["PCR", "TEST", 11, 14], ["respiratory samples", "TEST", 19, 38], ["COPD", "OBSERVATION", 5, 9]]], ["Before the use of PCR technology, the etiology of respiratory infections was established by viral cultures, which are difficult to perform.", [["respiratory", "ANATOMY", 50, 61], ["respiratory infections", "DISEASE", 50, 72], ["PCR technology", "TREATMENT", 18, 32], ["respiratory infections", "PROBLEM", 50, 72], ["viral cultures", "TEST", 92, 106], ["respiratory", "ANATOMY", 50, 61], ["infections", "OBSERVATION", 62, 72]]], ["PCR showed a high sensitivity and specificity, although it may not be quantitative in all cases.Virus Infection and ExacerbationMany studies have attempted to find the pathologic immune response to viruses that cause exacerbations, but the mechanisms for exacerbations remain poorly understood.", [["Virus Infection", "DISEASE", 96, 111], ["Exacerbation", "DISEASE", 116, 128], ["Virus", "ORGANISM", 96, 101], ["PCR", "TEST", 0, 3], ["a high sensitivity", "PROBLEM", 11, 29], ["Virus Infection", "PROBLEM", 96, 111], ["Exacerbation", "PROBLEM", 116, 128], ["Many studies", "TEST", 128, 140], ["viruses", "PROBLEM", 198, 205], ["exacerbations", "PROBLEM", 217, 230], ["exacerbations", "PROBLEM", 255, 268], ["high sensitivity", "OBSERVATION_MODIFIER", 13, 29], ["may not be", "UNCERTAINTY", 59, 69], ["Infection", "OBSERVATION", 102, 111], ["Exacerbation", "OBSERVATION_MODIFIER", 116, 128]]], ["It is not clear if asthma exacerbations triggered by viruses are a manifestation of impaired or overactive immune responses.", [["asthma", "DISEASE", 19, 25], ["asthma exacerbations", "PROBLEM", 19, 39], ["viruses", "PROBLEM", 53, 60], ["impaired or overactive immune responses", "PROBLEM", 84, 123], ["not clear", "UNCERTAINTY", 6, 15]]], ["There is evidence that the T H 2 pathway causes downregulation of antiviral interferon (IFN)-\u03b2 and IFN-\u03bb and higher viral loads in vitro; however, this has not been reproducible in in vivo studies.", [["T H 2", "GENE_OR_GENE_PRODUCT", 27, 32], ["interferon (IFN)-\u03b2", "GENE_OR_GENE_PRODUCT", 76, 94], ["IFN-\u03bb", "GENE_OR_GENE_PRODUCT", 99, 104], ["antiviral interferon (IFN)-\u03b2", "PROTEIN", 66, 94], ["IFN", "PROTEIN", 99, 102], ["antiviral interferon (IFN", "TREATMENT", 66, 91], ["\u03b2", "PROBLEM", 93, 94], ["IFN", "PROBLEM", 99, 102], ["higher viral loads", "PROBLEM", 109, 127], ["antiviral interferon", "OBSERVATION", 66, 86], ["viral loads", "OBSERVATION", 116, 127]]], ["On the other hand, there is evidence to suggest that increased T H 2 cytokines and chemokines produced in response to viral illnesses can activate an inflammatory cascade thought to be associated with asthma exacerbations.Virus Infection and ExacerbationInhaled corticosteroids (ICS) are commonly used in the treatment of asthma, and this treatment should be continued in the case of viral infection.", [["viral illnesses", "DISEASE", 118, 133], ["asthma", "DISEASE", 201, 207], ["Infection", "DISEASE", 228, 237], ["ExacerbationInhaled corticosteroids", "CHEMICAL", 242, 277], ["ICS", "CHEMICAL", 279, 282], ["asthma", "DISEASE", 322, 328], ["viral infection", "DISEASE", 384, 399], ["corticosteroids", "CHEMICAL", 262, 277], ["T H 2", "GENE_OR_GENE_PRODUCT", 63, 68], ["Virus", "ORGANISM", 222, 227], ["ExacerbationInhaled corticosteroids", "SIMPLE_CHEMICAL", 242, 277], ["T H 2 cytokines", "PROTEIN", 63, 78], ["chemokines", "PROTEIN", 83, 93], ["increased T H 2 cytokines", "PROBLEM", 53, 78], ["chemokines", "PROBLEM", 83, 93], ["viral illnesses", "PROBLEM", 118, 133], ["an inflammatory cascade", "PROBLEM", 147, 170], ["asthma exacerbations", "PROBLEM", 201, 221], ["Virus Infection", "PROBLEM", 222, 237], ["ExacerbationInhaled corticosteroids (ICS)", "TREATMENT", 242, 283], ["asthma", "PROBLEM", 322, 328], ["this treatment", "TREATMENT", 334, 348], ["viral infection", "PROBLEM", 384, 399], ["evidence to suggest", "UNCERTAINTY", 28, 47], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["viral illnesses", "OBSERVATION", 118, 133], ["inflammatory", "OBSERVATION", 150, 162], ["thought to be associated with", "UNCERTAINTY", 171, 200], ["asthma", "OBSERVATION", 201, 207], ["Infection", "OBSERVATION", 228, 237], ["asthma", "OBSERVATION", 322, 328], ["viral", "OBSERVATION_MODIFIER", 384, 389], ["infection", "OBSERVATION", 390, 399]]], ["Pretreatment with the ICS was shown to improve airway hyperresponsiveness and eosinophilic inflammation in patients with atopic asthma experimentally infected with rhinovirus.", [["airway", "ANATOMY", 47, 53], ["eosinophilic", "ANATOMY", 78, 90], ["ICS", "CHEMICAL", 22, 25], ["inflammation", "DISEASE", 91, 103], ["atopic asthma experimentally infected", "DISEASE", 121, 158], ["airway", "MULTI-TISSUE_STRUCTURE", 47, 53], ["eosinophilic", "PATHOLOGICAL_FORMATION", 78, 90], ["patients", "ORGANISM", 107, 115], ["rhinovirus", "ORGANISM", 164, 174], ["patients", "SPECIES", 107, 115], ["Pretreatment", "TREATMENT", 0, 12], ["the ICS", "TREATMENT", 18, 25], ["airway hyperresponsiveness", "PROBLEM", 47, 73], ["eosinophilic inflammation", "PROBLEM", 78, 103], ["atopic asthma", "PROBLEM", 121, 134], ["rhinovirus", "PROBLEM", 164, 174], ["airway", "ANATOMY", 47, 53], ["hyperresponsiveness", "OBSERVATION", 54, 73], ["eosinophilic inflammation", "OBSERVATION", 78, 103], ["rhinovirus", "OBSERVATION", 164, 174]]], ["47 In acute exacerbation, oral or intravenous (IV) corticosteroids are usually indicated, and the immunosuppressive function of these medications does not preclude their use in viral infectious exacerbation.", [["oral", "ANATOMY", 26, 30], ["intravenous", "ANATOMY", 34, 45], ["viral infectious exacerbation", "DISEASE", 177, 206], ["oral", "ORGANISM_SUBDIVISION", 26, 30], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 34, 45], ["acute exacerbation", "PROBLEM", 6, 24], ["oral or intravenous (IV) corticosteroids", "TREATMENT", 26, 66], ["these medications", "TREATMENT", 128, 145], ["viral infectious exacerbation", "PROBLEM", 177, 206], ["acute", "OBSERVATION_MODIFIER", 6, 11], ["exacerbation", "OBSERVATION", 12, 24], ["viral", "OBSERVATION_MODIFIER", 177, 182], ["infectious", "OBSERVATION", 183, 193]]], ["Most viral infection is self-limiting; therefore, antiviral medications are not necessary except during severe epidemic cases.", [["viral infection", "DISEASE", 5, 20], ["Most viral infection", "PROBLEM", 0, 20], ["antiviral medications", "TREATMENT", 50, 71], ["severe epidemic cases", "PROBLEM", 104, 125], ["viral", "OBSERVATION_MODIFIER", 5, 10], ["infection", "OBSERVATION", 11, 20], ["self-limiting", "OBSERVATION_MODIFIER", 24, 37]]], ["Influenza vaccination is recommended because influenza can cause asthma exacerbation.", [["Influenza", "DISEASE", 0, 9], ["influenza", "DISEASE", 45, 54], ["asthma", "DISEASE", 65, 71], ["Influenza vaccination", "TREATMENT", 0, 21], ["influenza", "PROBLEM", 45, 54], ["asthma exacerbation", "PROBLEM", 65, 84]]], ["However, the available evidence is not sufficient to assert that vaccination can reduce the frequency or severity of asthma exacerbations.", [["asthma", "DISEASE", 117, 123], ["vaccination", "TREATMENT", 65, 76], ["asthma exacerbations", "PROBLEM", 117, 137], ["asthma", "OBSERVATION", 117, 123]]], ["48CYSTIC FIBROSISCF is the most common fatal genetic disease in the United States, with 28,676 patients living with CF in the United States in 2014.", [["CF", "DISEASE", 116, 118], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["FIBROSISCF", "OBSERVATION", 9, 19], ["most common", "OBSERVATION_MODIFIER", 27, 38], ["fatal", "OBSERVATION_MODIFIER", 39, 44], ["genetic disease", "OBSERVATION", 45, 60]]], ["49 CF is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance regulator gene (CFTR) that lead to abnormalities in epithelial chloride transport, causing multiorgan dysfunction.", [["epithelial", "ANATOMY", 149, 159], ["multiorgan", "ANATOMY", 188, 198], ["CF", "DISEASE", 3, 5], ["autosomal recessive disorder", "DISEASE", 12, 40], ["chloride", "CHEMICAL", 160, 168], ["multiorgan dysfunction", "DISEASE", 188, 210], ["chloride", "CHEMICAL", 160, 168], ["CF transmembrane conductance regulator gene", "GENE_OR_GENE_PRODUCT", 68, 111], ["CFTR", "GENE_OR_GENE_PRODUCT", 113, 117], ["epithelial", "TISSUE", 149, 159], ["chloride", "SIMPLE_CHEMICAL", 160, 168], ["multiorgan", "ORGAN", 188, 198], ["CF transmembrane conductance regulator gene", "DNA", 68, 111], ["CFTR", "DNA", 113, 117], ["an autosomal recessive disorder", "PROBLEM", 9, 40], ["mutations in the CF transmembrane conductance regulator gene (CFTR)", "PROBLEM", 51, 118], ["abnormalities in epithelial chloride transport", "PROBLEM", 132, 178], ["multiorgan dysfunction", "PROBLEM", 188, 210], ["autosomal", "OBSERVATION_MODIFIER", 12, 21], ["recessive disorder", "OBSERVATION", 22, 40], ["epithelial", "ANATOMY_MODIFIER", 149, 159], ["multiorgan dysfunction", "OBSERVATION", 188, 210]]], ["[50] [51] [52] The lungs are particularly affected, with evidence of chronic inflammation, recurrent infections, impaired mucociliary clearance, and innate immune impairments that directly affect host defense against respiratory pathogens.", [["lungs", "ANATOMY", 19, 24], ["mucociliary", "ANATOMY", 122, 133], ["respiratory", "ANATOMY", 217, 228], ["inflammation", "DISEASE", 77, 89], ["infections", "DISEASE", 101, 111], ["respiratory pathogens", "DISEASE", 217, 238], ["lungs", "ORGAN", 19, 24], ["mucociliary", "MULTI-TISSUE_STRUCTURE", 122, 133], ["chronic inflammation", "PROBLEM", 69, 89], ["recurrent infections", "PROBLEM", 91, 111], ["impaired mucociliary clearance", "PROBLEM", 113, 143], ["innate immune impairments", "PROBLEM", 149, 174], ["respiratory pathogens", "PROBLEM", 217, 238], ["lungs", "ANATOMY", 19, 24], ["evidence of", "UNCERTAINTY", 57, 68], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["inflammation", "OBSERVATION", 77, 89], ["recurrent", "OBSERVATION_MODIFIER", 91, 100], ["infections", "OBSERVATION", 101, 111], ["impaired", "OBSERVATION_MODIFIER", 113, 121], ["mucociliary clearance", "OBSERVATION", 122, 143]]], ["51,53-55 Pulmonary infections remain the greatest cause of morbidity and mortality leading to premature death in CF.", [["Pulmonary", "ANATOMY", 9, 18], ["51,53-55", "CHEMICAL", 0, 8], ["Pulmonary infections", "DISEASE", 9, 29], ["death", "DISEASE", 104, 109], ["CF", "DISEASE", 113, 115], ["Pulmonary", "ORGAN", 9, 18], ["Pulmonary infections", "PROBLEM", 9, 29], ["morbidity", "PROBLEM", 59, 68], ["premature death in CF", "PROBLEM", 94, 115], ["infections", "OBSERVATION", 19, 29], ["morbidity", "OBSERVATION", 59, 68]]], ["56Common Viral Pathogens in Cystic FibrosisSimilar to individuals without CF, viral respiratory infections are common in CF.", [["respiratory", "ANATOMY", 84, 95], ["Cystic FibrosisSimilar", "DISEASE", 28, 50], ["CF", "DISEASE", 74, 76], ["viral respiratory infections", "DISEASE", 78, 106], ["Viral Pathogens", "PROBLEM", 9, 24], ["Cystic FibrosisSimilar to individuals", "PROBLEM", 28, 65], ["CF", "PROBLEM", 74, 76], ["viral respiratory infections", "PROBLEM", 78, 106], ["Viral Pathogens", "OBSERVATION", 9, 24], ["Cystic", "OBSERVATION_MODIFIER", 28, 34], ["without", "UNCERTAINTY", 66, 73], ["viral", "OBSERVATION_MODIFIER", 78, 83], ["respiratory infections", "OBSERVATION", 84, 106]]], ["A variety of studies dating to 1981 reported variable incidences of common respiratory pathogens, including influenza A and B (12%-77%), RSV (9%-58%), parainfluenza virus (PIV), rhinovirus, metapneumovirus, coronavirus, and adenovirus.", [["respiratory", "ANATOMY", 75, 86], ["respiratory pathogens", "DISEASE", 75, 96], ["influenza A and B", "DISEASE", 108, 125], ["RSV", "DISEASE", 137, 140], ["parainfluenza virus (PIV), rhinovirus, metapneumovirus, coronavirus", "DISEASE", 151, 218], ["B", "GENE_OR_GENE_PRODUCT", 124, 125], ["RSV", "ORGANISM", 137, 140], ["parainfluenza virus", "ORGANISM", 151, 170], ["rhinovirus", "ORGANISM", 178, 188], ["metapneumovirus", "ORGANISM", 190, 205], ["coronavirus", "ORGANISM", 207, 218], ["adenovirus", "ORGANISM", 224, 234], ["parainfluenza virus", "SPECIES", 151, 170], ["rhinovirus, metapneumovirus", "SPECIES", 178, 205], ["coronavirus", "SPECIES", 207, 218], ["RSV", "SPECIES", 137, 140], ["parainfluenza virus", "SPECIES", 151, 170], ["PIV", "SPECIES", 172, 175], ["adenovirus", "SPECIES", 224, 234], ["common respiratory pathogens", "PROBLEM", 68, 96], ["influenza A", "TEST", 108, 119], ["B", "TEST", 124, 125], ["RSV", "TEST", 137, 140], ["parainfluenza virus (PIV)", "PROBLEM", 151, 176], ["rhinovirus", "PROBLEM", 178, 188], ["metapneumovirus", "PROBLEM", 190, 205], ["coronavirus", "PROBLEM", 207, 218], ["adenovirus", "PROBLEM", 224, 234], ["respiratory pathogens", "OBSERVATION", 75, 96], ["parainfluenza virus", "OBSERVATION", 151, 170], ["metapneumovirus", "OBSERVATION", 190, 205]]], ["[57] [58] [59] [60] [61] [62] [63] [64] In these studies, the incidence of specific viral isolates varied greatly from one study to the next due to multiple factors, including methodology, seasonal variation, geographic location, and different age groups.", [["[57] [58] [59] [60] [61] [62]", "CHEMICAL", 0, 29], ["[57] [58] [59] [60] [61] [62] [63] [64]", "SIMPLE_CHEMICAL", 0, 39], ["these studies", "TEST", 43, 56], ["specific viral isolates", "PROBLEM", 75, 98], ["one study", "TEST", 119, 128], ["seasonal variation", "PROBLEM", 189, 207], ["seasonal variation", "OBSERVATION", 189, 207]]], ["In a recent study of 100 adults with CF, followed prospectively for 12 months, rhinovirus accounted for 72.5% of confirmed viral infections, followed by metapneumovirus (13.2%), and adenovirus (4.1%).", [["CF", "DISEASE", 37, 39], ["viral infections", "DISEASE", 123, 139], ["metapneumovirus", "DISEASE", 153, 168], ["rhinovirus", "ORGANISM", 79, 89], ["metapneumovirus", "ORGANISM", 153, 168], ["adenovirus", "ORGANISM", 182, 192], ["adenovirus", "SPECIES", 182, 192], ["a recent study", "TEST", 3, 17], ["CF", "PROBLEM", 37, 39], ["rhinovirus", "PROBLEM", 79, 89], ["viral infections", "PROBLEM", 123, 139], ["metapneumovirus", "TEST", 153, 168], ["adenovirus", "TEST", 182, 192], ["viral infections", "OBSERVATION", 123, 139]]], ["Unlike previous studies, influenza virus A and B, PIV, and RSV together accounted for only 10.6% of viral isolates.", [["influenza virus A", "ORGANISM", 25, 42], ["B", "GENE_OR_GENE_PRODUCT", 47, 48], ["PIV", "ORGANISM", 50, 53], ["RSV", "ORGANISM", 59, 62], ["influenza virus", "SPECIES", 25, 40], ["influenza virus A", "SPECIES", 25, 42], ["PIV", "SPECIES", 50, 53], ["RSV", "SPECIES", 59, 62], ["previous studies", "TEST", 7, 23], ["influenza virus", "PROBLEM", 25, 40], ["PIV", "TREATMENT", 50, 53], ["RSV", "TREATMENT", 59, 62], ["viral isolates", "PROBLEM", 100, 114], ["viral isolates", "OBSERVATION", 100, 114]]], ["65, 66 Previous studies have shown that individuals with CF are no more susceptible to viral infections than healthy controls.", [["CF", "DISEASE", 57, 59], ["viral infections", "DISEASE", 87, 103], ["Previous studies", "TEST", 7, 23], ["CF", "PROBLEM", 57, 59], ["viral infections", "PROBLEM", 87, 103], ["no more", "UNCERTAINTY", 64, 71], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["infections", "OBSERVATION", 93, 103]]], ["In a prospective study of school-aged individuals with CF compared with age-matched controls, there was no difference in the frequency of culturedocumented and sero-positive viral infections.", [["CF", "DISEASE", 55, 57], ["viral infections", "DISEASE", 174, 190], ["individuals", "ORGANISM", 38, 49], ["a prospective study", "TEST", 3, 22], ["CF", "PROBLEM", 55, 57], ["culturedocumented", "PROBLEM", 138, 155], ["sero-positive viral infections", "PROBLEM", 160, 190], ["no", "UNCERTAINTY", 104, 106], ["sero-positive viral infections", "OBSERVATION", 160, 190]]], ["Younger patients had a higher incidence of viral infections in both groups; however, this did not translate into accelerated lung function decline in the patients with CF.", [["lung", "ANATOMY", 125, 129], ["viral infections", "DISEASE", 43, 59], ["lung function decline", "DISEASE", 125, 146], ["CF", "DISEASE", 168, 170], ["patients", "ORGANISM", 8, 16], ["lung", "ORGAN", 125, 129], ["patients", "ORGANISM", 154, 162], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 154, 162], ["viral infections", "PROBLEM", 43, 59], ["accelerated lung function decline", "PROBLEM", 113, 146], ["CF", "PROBLEM", 168, 170], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infections", "OBSERVATION", 49, 59], ["lung", "ANATOMY", 125, 129], ["function", "OBSERVATION", 130, 138]]], ["59 A later study evaluating the impact of viral infections on pulmonary function in infants with CF similarly showed no difference in the incidence of viral infections.", [["pulmonary", "ANATOMY", 62, 71], ["viral infections", "DISEASE", 42, 58], ["CF", "DISEASE", 97, 99], ["viral infections", "DISEASE", 151, 167], ["pulmonary", "ORGAN", 62, 71], ["infants", "ORGANISM", 84, 91], ["infants", "SPECIES", 84, 91], ["A later study", "TEST", 3, 16], ["viral infections", "PROBLEM", 42, 58], ["pulmonary function", "TEST", 62, 80], ["viral infections", "PROBLEM", 151, 167], ["viral", "OBSERVATION_MODIFIER", 42, 47], ["infections", "OBSERVATION", 48, 58], ["pulmonary", "ANATOMY", 62, 71], ["viral", "OBSERVATION_MODIFIER", 151, 156], ["infections", "OBSERVATION", 157, 167]]], ["However, infants with CF had an increased frequency of respiratory symptoms.", [["respiratory", "ANATOMY", 55, 66], ["CF", "DISEASE", 22, 24], ["respiratory symptoms", "DISEASE", 55, 75], ["infants", "ORGANISM", 9, 16], ["infants", "SPECIES", 9, 16], ["respiratory symptoms", "PROBLEM", 55, 75], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["respiratory symptoms", "OBSERVATION", 55, 75]]], ["Whereas controls did not demonstrate an association between respiratory illness and lung function, infants with CF who suffered an RSV infection and developed respiratory symptoms had a reduction in lung function.", [["respiratory", "ANATOMY", 60, 71], ["lung", "ANATOMY", 84, 88], ["respiratory", "ANATOMY", 159, 170], ["lung", "ANATOMY", 199, 203], ["respiratory illness", "DISEASE", 60, 79], ["CF", "DISEASE", 112, 114], ["RSV infection", "DISEASE", 131, 144], ["respiratory symptoms", "DISEASE", 159, 179], ["lung", "ORGAN", 84, 88], ["infants", "ORGANISM", 99, 106], ["RSV", "ORGANISM", 131, 134], ["lung", "ORGAN", 199, 203], ["infants", "SPECIES", 99, 106], ["RSV", "SPECIES", 131, 134], ["respiratory illness", "PROBLEM", 60, 79], ["CF", "PROBLEM", 112, 114], ["an RSV infection", "PROBLEM", 128, 144], ["respiratory symptoms", "PROBLEM", 159, 179], ["a reduction in lung function", "PROBLEM", 184, 212], ["respiratory", "ANATOMY", 60, 71], ["illness", "OBSERVATION", 72, 79], ["lung", "ANATOMY", 84, 88], ["RSV", "OBSERVATION", 131, 134], ["infection", "OBSERVATION", 135, 144], ["reduction", "OBSERVATION_MODIFIER", 186, 195], ["lung", "ANATOMY", 199, 203], ["function", "OBSERVATION", 204, 212]]], ["67 A prospective study examining the impact of RSV infection on lung function in a pediatric population demonstrated again that subjects with CF had an increased frequency of respiratory symptoms despite similar rates of viral isolation from cultures and serology in healthy controls.", [["lung", "ANATOMY", 64, 68], ["respiratory", "ANATOMY", 175, 186], ["RSV infection", "DISEASE", 47, 60], ["CF", "DISEASE", 142, 144], ["respiratory symptoms", "DISEASE", 175, 195], ["RSV", "ORGANISM", 47, 50], ["lung", "ORGAN", 64, 68], ["RSV", "SPECIES", 47, 50], ["A prospective study", "TEST", 3, 22], ["RSV infection", "PROBLEM", 47, 60], ["CF", "PROBLEM", 142, 144], ["respiratory symptoms", "PROBLEM", 175, 195], ["viral isolation", "PROBLEM", 221, 236], ["cultures", "TEST", 242, 250], ["serology", "TEST", 255, 263], ["RSV", "OBSERVATION_MODIFIER", 47, 50], ["infection", "OBSERVATION", 51, 60], ["lung", "ANATOMY", 64, 68], ["increased", "OBSERVATION_MODIFIER", 152, 161], ["viral isolation", "OBSERVATION", 221, 236]]], ["The investigators demonstrated clear associations between RSV infection and worsening clinical severity score, lung function measurements, and rates and duration of hospitalizations for respiratory exacerbations.", [["lung", "ANATOMY", 111, 115], ["respiratory", "ANATOMY", 186, 197], ["RSV infection", "DISEASE", 58, 71], ["respiratory exacerbations", "DISEASE", 186, 211], ["RSV", "ORGANISM", 58, 61], ["lung", "ORGAN", 111, 115], ["RSV", "SPECIES", 58, 61], ["RSV infection", "PROBLEM", 58, 71], ["worsening clinical severity score", "PROBLEM", 76, 109], ["lung function measurements", "TEST", 111, 137], ["respiratory exacerbations", "PROBLEM", 186, 211], ["clear", "OBSERVATION", 31, 36], ["RSV infection", "OBSERVATION", 58, 71], ["worsening", "OBSERVATION_MODIFIER", 76, 85], ["lung", "ANATOMY", 111, 115]]], ["68Viruses, Exacerbations, and Clinical Deterioration in Cystic FibrosisCF respiratory exacerbations are acute clinical deteriorations in a patient's clinical condition characterized by increased respiratory symptoms and sputum production, and declines in lung function.", [["respiratory", "ANATOMY", 195, 206], ["sputum", "ANATOMY", 220, 226], ["lung", "ANATOMY", 255, 259], ["respiratory exacerbations", "DISEASE", 74, 99], ["patient", "ORGANISM", 139, 146], ["sputum", "ORGANISM_SUBSTANCE", 220, 226], ["lung", "ORGAN", 255, 259], ["patient", "SPECIES", 139, 146], ["Exacerbations", "PROBLEM", 11, 24], ["Clinical Deterioration", "PROBLEM", 30, 52], ["Cystic FibrosisCF respiratory exacerbations", "PROBLEM", 56, 99], ["acute clinical deteriorations", "PROBLEM", 104, 133], ["a patient's clinical condition", "PROBLEM", 137, 167], ["increased respiratory symptoms", "PROBLEM", 185, 215], ["sputum production", "PROBLEM", 220, 237], ["Exacerbations", "OBSERVATION", 11, 24], ["Deterioration", "OBSERVATION_MODIFIER", 39, 52], ["Cystic", "OBSERVATION_MODIFIER", 56, 62], ["FibrosisCF", "OBSERVATION_MODIFIER", 63, 73], ["respiratory exacerbations", "OBSERVATION", 74, 99], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["increased", "OBSERVATION_MODIFIER", 185, 194], ["respiratory symptoms", "OBSERVATION", 195, 215], ["lung", "ANATOMY", 255, 259]]], ["Exacerbations are commonly precipitated by acquisition of new organisms or changes in respiratory flora.", [["respiratory", "ANATOMY", 86, 97], ["Exacerbations", "PROBLEM", 0, 13], ["new organisms", "PROBLEM", 58, 71], ["changes in respiratory flora", "PROBLEM", 75, 103], ["new", "OBSERVATION_MODIFIER", 58, 61], ["organisms", "OBSERVATION", 62, 71], ["respiratory flora", "OBSERVATION", 86, 103]]], ["69-71 CF pulmonary exacerbation rates are increased during winter and have been linked to the influenza season.", [["pulmonary", "ANATOMY", 9, 18], ["influenza", "DISEASE", 94, 103], ["pulmonary", "ORGAN", 9, 18], ["CF pulmonary exacerbation rates", "PROBLEM", 6, 37], ["pulmonary", "ANATOMY", 9, 18], ["exacerbation", "OBSERVATION", 19, 31], ["increased", "OBSERVATION_MODIFIER", 42, 51]]], ["72, 73 The viruses most frequently implicated in causing respiratory symptoms in CF include rhinovirus, RSV, adenovirus, PIV, influenza A and B, and metapneumovirus.", [["respiratory", "ANATOMY", 57, 68], ["respiratory symptoms", "DISEASE", 57, 77], ["CF", "DISEASE", 81, 83], ["influenza A and B", "DISEASE", 126, 143], ["rhinovirus", "ORGANISM", 92, 102], ["RSV", "ORGANISM", 104, 107], ["adenovirus", "ORGANISM", 109, 119], ["PIV", "ORGANISM", 121, 124], ["influenza A", "ORGANISM", 126, 137], ["B", "GENE_OR_GENE_PRODUCT", 142, 143], ["metapneumovirus", "ORGANISM", 149, 164], ["RSV", "SPECIES", 104, 107], ["RSV", "SPECIES", 104, 107], ["adenovirus", "SPECIES", 109, 119], ["PIV", "SPECIES", 121, 124], ["The viruses", "PROBLEM", 7, 18], ["respiratory symptoms", "PROBLEM", 57, 77], ["CF", "PROBLEM", 81, 83], ["rhinovirus", "PROBLEM", 92, 102], ["RSV", "PROBLEM", 104, 107], ["adenovirus", "PROBLEM", 109, 119], ["PIV", "TREATMENT", 121, 124], ["influenza A", "PROBLEM", 126, 137], ["metapneumovirus", "PROBLEM", 149, 164], ["viruses", "OBSERVATION", 11, 18], ["rhinovirus", "OBSERVATION", 92, 102], ["metapneumovirus", "OBSERVATION", 149, 164]]], ["57-61,66,67 Viral infections are frequently detected during CF exacerbations and viral detection has improved with significant leaps in diagnostic technologies.", [["57-61,66,67", "CHEMICAL", 0, 11], ["Viral infections", "DISEASE", 12, 28], ["Viral", "ORGANISM", 12, 17], ["Viral infections", "PROBLEM", 12, 28], ["CF exacerbations", "PROBLEM", 60, 76], ["viral detection", "TEST", 81, 96], ["infections", "OBSERVATION", 18, 28], ["significant", "OBSERVATION_MODIFIER", 115, 126], ["leaps", "OBSERVATION_MODIFIER", 127, 132]]], ["The implementation of quantitative real-time PCR studies for viral detection in the CF population achieved the highest detection rate of 46% compared with existing literature that previously relied on serologic testing or viral isolation.", [["quantitative real-time PCR studies", "TEST", 22, 56], ["viral detection", "TEST", 61, 76], ["the CF population", "TEST", 80, 97], ["serologic testing", "TEST", 201, 218], ["viral isolation", "TREATMENT", 222, 237], ["viral isolation", "OBSERVATION", 222, 237]]], ["61 Identification of a respiratory virus during exacerbation purports clinical deterioration and increased duration of IV antibiotic compared with virus-negative exacerbations.", [["respiratory virus", "DISEASE", 23, 40], ["a respiratory virus", "PROBLEM", 21, 40], ["exacerbation", "PROBLEM", 48, 60], ["clinical deterioration", "PROBLEM", 70, 92], ["IV antibiotic", "TREATMENT", 119, 132], ["virus", "PROBLEM", 147, 152], ["exacerbations", "PROBLEM", 162, 175], ["respiratory virus", "OBSERVATION", 23, 40], ["increased", "OBSERVATION_MODIFIER", 97, 106]]], ["60 In a study of 103 children with CF respiratory exacerbations, 61.3% had a positive viral isolation.", [["respiratory", "ANATOMY", 38, 49], ["CF respiratory exacerbations", "DISEASE", 35, 63], ["children", "ORGANISM", 21, 29], ["children", "SPECIES", 21, 29], ["a study", "TEST", 6, 13], ["CF respiratory exacerbations", "PROBLEM", 35, 63], ["a positive viral isolation", "PROBLEM", 75, 101], ["respiratory", "ANATOMY", 38, 49], ["exacerbations", "OBSERVATION", 50, 63], ["viral isolation", "OBSERVATION", 86, 101]]], ["74 Two studies in adult patients with CF reported viral isolation rates during exacerbation of 30.5% (n = 100) and 50% (n = 30).", [["CF", "DISEASE", 38, 40], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["Two studies", "TEST", 3, 14], ["viral isolation rates", "PROBLEM", 50, 71], ["exacerbation", "PROBLEM", 79, 91], ["viral isolation", "OBSERVATION", 50, 65]]], ["66, 75 Although virus-positive exacerbations were associated with higher respiratory symptom scores and serum biomarkers of inflammation, viral infection did not increase rates of lung function decline compared with virus-negative exacerbation.", [["respiratory", "ANATOMY", 73, 84], ["serum", "ANATOMY", 104, 109], ["lung", "ANATOMY", 180, 184], ["inflammation", "DISEASE", 124, 136], ["viral infection", "DISEASE", 138, 153], ["lung function decline", "DISEASE", 180, 201], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["lung", "ORGAN", 180, 184], ["virus", "PROBLEM", 16, 21], ["positive exacerbations", "PROBLEM", 22, 44], ["higher respiratory symptom scores", "PROBLEM", 66, 99], ["serum biomarkers", "TEST", 104, 120], ["inflammation", "PROBLEM", 124, 136], ["viral infection", "PROBLEM", 138, 153], ["lung function decline", "PROBLEM", 180, 201], ["virus", "TEST", 216, 221], ["exacerbation", "PROBLEM", 231, 243], ["inflammation", "OBSERVATION", 124, 136], ["viral", "OBSERVATION_MODIFIER", 138, 143], ["infection", "OBSERVATION", 144, 153], ["lung", "ANATOMY", 180, 184]]], ["Similarly, there was no significant association between viral infection and accelerated lung function decline in long-term follow-up.", [["lung", "ANATOMY", 88, 92], ["viral infection", "DISEASE", 56, 71], ["lung", "ORGAN", 88, 92], ["viral infection", "PROBLEM", 56, 71], ["accelerated lung function decline", "PROBLEM", 76, 109], ["no", "UNCERTAINTY", 21, 23], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["infection", "OBSERVATION", 62, 71], ["accelerated", "OBSERVATION_MODIFIER", 76, 87], ["lung", "ANATOMY", 88, 92], ["function", "OBSERVATION_MODIFIER", 93, 101], ["decline", "OBSERVATION_MODIFIER", 102, 109]]], ["66 A recent study combining pediatric and adult populations reported even higher incidence of virus-positive exacerbations, with 68% in adults and 72% in children.", [["exacerbations", "DISEASE", 109, 122], ["children", "ORGANISM", 154, 162], ["children", "SPECIES", 154, 162], ["A recent study", "TEST", 3, 17], ["adult populations", "PROBLEM", 42, 59], ["virus", "PROBLEM", 94, 99], ["positive exacerbations", "PROBLEM", 100, 122], ["virus", "OBSERVATION", 94, 99], ["positive", "OBSERVATION_MODIFIER", 100, 108], ["exacerbations", "OBSERVATION", 109, 122]]], ["76 RSV is the most common cause of lower respiratory tract infection in young children.", [["lower respiratory tract", "ANATOMY", 35, 58], ["RSV", "DISEASE", 3, 6], ["lower respiratory tract infection", "DISEASE", 35, 68], ["RSV", "ORGANISM", 3, 6], ["lower", "ORGANISM_SUBDIVISION", 35, 40], ["respiratory tract", "ORGANISM_SUBDIVISION", 41, 58], ["children", "ORGANISM", 78, 86], ["children", "SPECIES", 78, 86], ["RSV", "SPECIES", 3, 6], ["RSV", "PROBLEM", 3, 6], ["lower respiratory tract infection", "PROBLEM", 35, 68], ["RSV", "OBSERVATION", 3, 6], ["most common", "OBSERVATION_MODIFIER", 14, 25], ["lower", "ANATOMY_MODIFIER", 35, 40], ["respiratory tract", "ANATOMY", 41, 58], ["infection", "OBSERVATION", 59, 68]]], ["77 In children with CF, RSV and influenza have been shown to have the most significant effect in lung function.", [["lung", "ANATOMY", 97, 101], ["CF", "DISEASE", 20, 22], ["RSV", "DISEASE", 24, 27], ["influenza", "DISEASE", 32, 41], ["children", "ORGANISM", 6, 14], ["RSV", "ORGANISM", 24, 27], ["lung", "ORGAN", 97, 101], ["children", "SPECIES", 6, 14], ["RSV", "SPECIES", 24, 27], ["RSV", "SPECIES", 24, 27], ["CF", "PROBLEM", 20, 22], ["RSV", "PROBLEM", 24, 27], ["influenza", "PROBLEM", 32, 41], ["RSV", "OBSERVATION", 24, 27], ["lung", "ANATOMY", 97, 101], ["function", "OBSERVATION", 102, 110]]], ["In infants with CF, RSV infection accounted for up to one-third of hospitalizations, respiratory failure, and chronic supplemental oxygen requirement when followed for more than 2 years.", [["respiratory", "ANATOMY", 85, 96], ["CF", "DISEASE", 16, 18], ["RSV infection", "DISEASE", 20, 33], ["respiratory failure", "DISEASE", 85, 104], ["oxygen", "CHEMICAL", 131, 137], ["oxygen", "CHEMICAL", 131, 137], ["infants", "ORGANISM", 3, 10], ["RSV", "ORGANISM", 20, 23], ["oxygen", "SIMPLE_CHEMICAL", 131, 137], ["infants", "SPECIES", 3, 10], ["RSV", "SPECIES", 20, 23], ["CF", "PROBLEM", 16, 18], ["RSV infection", "PROBLEM", 20, 33], ["respiratory failure", "PROBLEM", 85, 104], ["chronic supplemental oxygen requirement", "PROBLEM", 110, 149], ["RSV infection", "OBSERVATION", 20, 33], ["respiratory failure", "OBSERVATION", 85, 104], ["chronic", "OBSERVATION_MODIFIER", 110, 117], ["supplemental", "OBSERVATION_MODIFIER", 118, 130], ["oxygen requirement", "OBSERVATION", 131, 149]]], ["78 In addition to RSV, influenza A and B infection has been detected in 12% to 23% of CF exacerbations.", [["influenza A and B infection", "DISEASE", 23, 50], ["CF", "DISEASE", 86, 88], ["RSV", "ORGANISM", 18, 21], ["influenza A", "ORGANISM", 23, 34], ["B", "GENE_OR_GENE_PRODUCT", 39, 40], ["CF", "PATHOLOGICAL_FORMATION", 86, 88], ["RSV", "SPECIES", 18, 21], ["influenza A", "SPECIES", 23, 34], ["RSV", "PROBLEM", 18, 21], ["influenza A", "PROBLEM", 23, 34], ["B infection", "PROBLEM", 39, 50], ["CF exacerbations", "PROBLEM", 86, 102], ["RSV", "OBSERVATION", 18, 21], ["influenza", "OBSERVATION", 23, 32], ["infection", "OBSERVATION", 41, 50]]], ["61, 79, 80 Influenza also has been associated with acute and sustained declines in lung function, as well as respiratory failure, and subsequent supplemental oxygen requirement.", [["lung", "ANATOMY", 83, 87], ["respiratory", "ANATOMY", 109, 120], ["respiratory failure", "DISEASE", 109, 128], ["oxygen", "CHEMICAL", 158, 164], ["oxygen", "CHEMICAL", 158, 164], ["Influenza", "ORGANISM", 11, 20], ["lung", "ORGAN", 83, 87], ["oxygen", "SIMPLE_CHEMICAL", 158, 164], ["Influenza", "PROBLEM", 11, 20], ["acute and sustained declines in lung function", "PROBLEM", 51, 96], ["respiratory failure", "PROBLEM", 109, 128], ["subsequent supplemental oxygen requirement", "PROBLEM", 134, 176], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["sustained", "OBSERVATION_MODIFIER", 61, 70], ["declines", "OBSERVATION", 71, 79], ["lung", "ANATOMY", 83, 87], ["function", "OBSERVATION", 88, 96], ["respiratory failure", "OBSERVATION", 109, 128], ["supplemental", "OBSERVATION_MODIFIER", 145, 157], ["oxygen requirement", "OBSERVATION", 158, 176]]], ["In a study of 54 pediatric patients, those with an influenza virus-positive exacerbation had larger declines in lung function (26% vs 6% with other viruses).", [["lung", "ANATOMY", 112, 116], ["influenza virus-positive", "DISEASE", 51, 75], ["declines in lung function", "DISEASE", 100, 125], ["patients", "ORGANISM", 27, 35], ["influenza virus", "ORGANISM", 51, 66], ["lung", "ORGAN", 112, 116], ["patients", "SPECIES", 27, 35], ["influenza virus", "SPECIES", 51, 66], ["a study", "TEST", 3, 10], ["an influenza virus", "PROBLEM", 48, 66], ["positive exacerbation", "PROBLEM", 67, 88], ["lung function", "TEST", 112, 125], ["other viruses", "PROBLEM", 142, 155], ["influenza virus", "OBSERVATION", 51, 66], ["larger", "OBSERVATION_MODIFIER", 93, 99], ["declines", "OBSERVATION_MODIFIER", 100, 108], ["lung", "ANATOMY", 112, 116]]], ["In addition, influenza infection was more frequently associated with larger drops in forced expiratory volume in 1 second (FEV 1 ) than the other viral infections.", [["influenza infection", "DISEASE", 13, 32], ["viral infections", "DISEASE", 146, 162], ["influenza infection", "PROBLEM", 13, 32], ["larger drops in forced expiratory volume", "PROBLEM", 69, 109], ["the other viral infections", "PROBLEM", 136, 162], ["influenza", "OBSERVATION_MODIFIER", 13, 22], ["infection", "OBSERVATION", 23, 32], ["larger", "OBSERVATION_MODIFIER", 69, 75], ["drops", "OBSERVATION_MODIFIER", 76, 81], ["forced", "OBSERVATION_MODIFIER", 85, 91], ["expiratory volume", "OBSERVATION", 92, 109], ["viral", "OBSERVATION_MODIFIER", 146, 151], ["infections", "OBSERVATION", 152, 162]]], ["81 According to data from the European Cystic Fibrosis Society, the influenza A (H1N1) pandemic in 2009 had a severe impact on adult and pediatric patients with CF.", [["Cystic Fibrosis", "DISEASE", 39, 54], ["influenza A (H1N1) pandemic", "DISEASE", 68, 95], ["CF", "DISEASE", 161, 163], ["influenza A (H1N1", "ORGANISM", 68, 85], ["patients", "ORGANISM", 147, 155], ["influenza A (H1N1", "SPECIES", 68, 85], ["patients", "SPECIES", 147, 155], ["CF", "PROBLEM", 161, 163], ["Cystic", "OBSERVATION_MODIFIER", 39, 45], ["Fibrosis", "OBSERVATION", 46, 54]]], ["The prevalence of infection among 25 centers in multiple countries ranged from 0% to 9.4%.", [["infection", "DISEASE", 18, 27], ["infection", "PROBLEM", 18, 27], ["multiple countries", "TEST", 48, 66], ["infection", "OBSERVATION", 18, 27], ["multiple", "OBSERVATION_MODIFIER", 48, 56]]], ["Among the 110 cases reported, the incidence of exacerbations was 53%; 48% of these patients required hospitalization, and 31% required supplemental oxygen.", [["exacerbations", "DISEASE", 47, 60], ["oxygen", "CHEMICAL", 148, 154], ["oxygen", "CHEMICAL", 148, 154], ["patients", "ORGANISM", 83, 91], ["oxygen", "SIMPLE_CHEMICAL", 148, 154], ["patients", "SPECIES", 83, 91], ["exacerbations", "PROBLEM", 47, 60], ["supplemental oxygen", "TREATMENT", 135, 154]]], ["There were 6 incidences of respiratory failure and 3 fatalities.", [["respiratory", "ANATOMY", 27, 38], ["respiratory failure", "DISEASE", 27, 46], ["fatalities", "DISEASE", 53, 63], ["respiratory failure", "PROBLEM", 27, 46], ["respiratory failure", "OBSERVATION", 27, 46]]], ["Patients with advanced lung disease were more likely to suffer a severe clinical course.", [["lung", "ANATOMY", 23, 27], ["lung disease", "DISEASE", 23, 35], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 23, 27], ["Patients", "SPECIES", 0, 8], ["advanced lung disease", "PROBLEM", 14, 35], ["a severe clinical course", "PROBLEM", 63, 87], ["advanced", "OBSERVATION_MODIFIER", 14, 22], ["lung", "ANATOMY", 23, 27], ["disease", "OBSERVATION", 28, 35], ["severe", "OBSERVATION_MODIFIER", 65, 71]]], ["Interestingly, most of the patients recovered lung function to preinfection values.", [["lung", "ANATOMY", 46, 50], ["patients", "ORGANISM", 27, 35], ["lung", "ORGAN", 46, 50], ["patients", "SPECIES", 27, 35], ["preinfection values", "TEST", 63, 82], ["lung", "ANATOMY", 46, 50], ["function", "OBSERVATION", 51, 59]]], ["82, 83 Rhinovirus is increasingly reported as a significant pathogen in the CF population.", [["Rhinovirus", "PROBLEM", 7, 17], ["a significant pathogen in the CF population", "PROBLEM", 46, 89], ["Rhinovirus", "OBSERVATION", 7, 17], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["pathogen", "OBSERVATION", 60, 68]]], ["Rhinovirus has now been associated with increased respiratory symptoms, lung function decline, and frequency of exacerbations.", [["respiratory", "ANATOMY", 50, 61], ["lung", "ANATOMY", 72, 76], ["Rhinovirus", "CHEMICAL", 0, 10], ["lung function decline", "DISEASE", 72, 93], ["exacerbations", "DISEASE", 112, 125], ["lung", "ORGAN", 72, 76], ["Rhinovirus", "PROBLEM", 0, 10], ["increased respiratory symptoms", "PROBLEM", 40, 70], ["lung function decline", "PROBLEM", 72, 93], ["exacerbations", "PROBLEM", 112, 125], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["respiratory symptoms", "OBSERVATION", 50, 70], ["lung", "ANATOMY", 72, 76], ["function decline", "OBSERVATION", 77, 93]]], ["66, 74, 76 This may be due to improvements in detection techniques and inclusion of a more recently detected species, rhinovirus C. 74Interactions Between Viruses and BacteriaThe clinical significance of viral infections in CF extends beyond their immediate morbidity, as viral infections have been proposed to play a role new bacterial acquisition and worsening clinical outcomes.", [["viral infections", "DISEASE", 204, 220], ["CF", "DISEASE", 224, 226], ["viral infections", "DISEASE", 272, 288], ["detection techniques", "TEST", 46, 66], ["a more recently detected species", "PROBLEM", 84, 116], ["rhinovirus C.", "PROBLEM", 118, 131], ["Bacteria", "PROBLEM", 167, 175], ["viral infections in CF", "PROBLEM", 204, 226], ["viral infections", "PROBLEM", 272, 288], ["worsening clinical outcomes", "PROBLEM", 353, 380], ["may be due to", "UNCERTAINTY", 16, 29], ["viral", "OBSERVATION_MODIFIER", 204, 209], ["infections", "OBSERVATION", 210, 220], ["immediate", "OBSERVATION_MODIFIER", 248, 257], ["morbidity", "OBSERVATION", 258, 267]]], ["The new acquisition of Pseudomonas aeruginosa in CF has been associated with the winter months, coinciding with the peak of respiratory viral infections.", [["respiratory viral infections", "DISEASE", 124, 152], ["Pseudomonas aeruginosa", "ORGANISM", 23, 45], ["CF", "PATHOLOGICAL_FORMATION", 49, 51], ["Pseudomonas aeruginosa", "SPECIES", 23, 45], ["Pseudomonas aeruginosa", "SPECIES", 23, 45], ["Pseudomonas aeruginosa in CF", "PROBLEM", 23, 51], ["respiratory viral infections", "PROBLEM", 124, 152], ["new", "OBSERVATION_MODIFIER", 4, 7], ["Pseudomonas aeruginosa", "OBSERVATION", 23, 45], ["respiratory viral infections", "OBSERVATION", 124, 152]]], ["84 Some have proposed that RSV could facilitate the initial infection of the CF airway by P aeruginosa 64 ; however, a study of 35 adults with CF showed no change in sputum density of P aeruginosa when concurrent viral infection was present.", [["CF airway", "ANATOMY", 77, 86], ["sputum", "ANATOMY", 166, 172], ["infection", "DISEASE", 60, 69], ["CF", "DISEASE", 143, 145], ["viral infection", "DISEASE", 213, 228], ["RSV", "ORGANISM", 27, 30], ["CF airway", "MULTI-TISSUE_STRUCTURE", 77, 86], ["adults", "ORGANISM", 131, 137], ["sputum", "ORGANISM_SUBSTANCE", 166, 172], ["RSV", "SPECIES", 27, 30], ["P aeruginosa", "SPECIES", 90, 102], ["P aeruginosa", "SPECIES", 184, 196], ["RSV", "PROBLEM", 27, 30], ["the initial infection of the CF airway", "PROBLEM", 48, 86], ["P aeruginosa", "TEST", 90, 102], ["a study", "TEST", 117, 124], ["CF", "TEST", 143, 145], ["change in sputum density of P aeruginosa", "PROBLEM", 156, 196], ["concurrent viral infection", "PROBLEM", 202, 228], ["RSV", "OBSERVATION", 27, 30], ["infection", "OBSERVATION", 60, 69], ["CF airway", "ANATOMY", 77, 86], ["no", "UNCERTAINTY", 153, 155], ["change", "OBSERVATION_MODIFIER", 156, 162], ["sputum", "OBSERVATION", 166, 172], ["viral", "OBSERVATION_MODIFIER", 213, 218], ["infection", "OBSERVATION", 219, 228]]], ["75 A retrospective study in older patients with chronic P aeruginosa infection reported an acute deterioration in clinical status in association with influenza A virus infection.", [["chronic P aeruginosa infection", "DISEASE", 48, 78], ["influenza A virus infection", "DISEASE", 150, 177], ["patients", "ORGANISM", 34, 42], ["influenza A virus", "ORGANISM", 150, 167], ["patients", "SPECIES", 34, 42], ["influenza A virus", "SPECIES", 150, 167], ["P aeruginosa", "SPECIES", 56, 68], ["influenza A virus", "SPECIES", 150, 167], ["A retrospective study", "TEST", 3, 24], ["chronic P aeruginosa infection", "PROBLEM", 48, 78], ["an acute deterioration", "PROBLEM", 88, 110], ["influenza A virus infection", "PROBLEM", 150, 177], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["acute", "OBSERVATION_MODIFIER", 91, 96], ["deterioration", "OBSERVATION", 97, 110]]], ["85 Punch and colleagues 86 used a multiplex reverse-transcriptase PCR (RT-PCR) assay combined with an enzyme-linked amplicon hybridization assay (ELAHA) for the identification of 7 common respiratory viruses in the sputum of 38 patients with CF.", [["sputum", "ANATOMY", 215, 221], ["respiratory viruses", "DISEASE", 188, 207], ["CF", "DISEASE", 242, 244], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 228, 236], ["a multiplex reverse", "TEST", 32, 51], ["transcriptase PCR", "TEST", 52, 69], ["RT-PCR", "TEST", 71, 77], ["an enzyme", "TEST", 99, 108], ["amplicon hybridization assay", "TEST", 116, 144], ["the identification", "TEST", 157, 175], ["7 common respiratory viruses", "PROBLEM", 179, 207], ["the sputum", "TEST", 211, 221], ["CF", "PROBLEM", 242, 244], ["respiratory viruses", "OBSERVATION", 188, 207]]], ["Fifty-three sputum samples were collected over 2 seasons and 12 (23%) samples from 12 patients were positive for a respiratory virus (4 for influenza B, 3 for parainfluenza type 1, 3 for influenza A, and 2 for RSV).", [["sputum samples", "ANATOMY", 12, 26], ["samples", "ANATOMY", 70, 77], ["respiratory virus", "DISEASE", 115, 132], ["influenza B", "DISEASE", 140, 151], ["parainfluenza", "DISEASE", 159, 172], ["influenza A", "DISEASE", 187, 198], ["sputum samples", "CANCER", 12, 26], ["samples", "CANCER", 70, 77], ["patients", "ORGANISM", 86, 94], ["parainfluenza", "ORGANISM", 159, 172], ["RSV", "ORGANISM", 210, 213], ["patients", "SPECIES", 86, 94], ["parainfluenza", "SPECIES", 159, 172], ["parainfluenza type 1", "SPECIES", 159, 179], ["RSV", "SPECIES", 210, 213], ["three sputum samples", "TEST", 6, 26], ["samples", "TEST", 70, 77], ["a respiratory virus", "PROBLEM", 113, 132], ["influenza B", "PROBLEM", 140, 151], ["parainfluenza type", "TEST", 159, 177], ["influenza", "PROBLEM", 187, 196], ["RSV", "PROBLEM", 210, 213], ["respiratory virus", "OBSERVATION", 115, 132]]], ["There were no statistical associations between virus status and demographics, clinical variables, or isolation rates for P aeruginosa, Staphylococcus aureus or Aspergillus fumigatus.", [["Staphylococcus aureus", "DISEASE", 135, 156], ["Aspergillus fumigatus", "DISEASE", 160, 181], ["Staphylococcus aureus", "ORGANISM", 135, 156], ["Aspergillus fumigatus", "ORGANISM", 160, 181], ["Staphylococcus aureus", "SPECIES", 135, 156], ["Aspergillus fumigatus", "SPECIES", 160, 181], ["P aeruginosa", "SPECIES", 121, 133], ["Staphylococcus aureus", "SPECIES", 135, 156], ["Aspergillus fumigatus", "SPECIES", 160, 181], ["statistical associations between virus status", "PROBLEM", 14, 59], ["clinical variables", "TEST", 78, 96], ["isolation rates", "TEST", 101, 116], ["P aeruginosa", "PROBLEM", 121, 133], ["Staphylococcus aureus", "PROBLEM", 135, 156], ["Aspergillus fumigatus", "PROBLEM", 160, 181], ["no", "UNCERTAINTY", 11, 13], ["Aspergillus fumigatus", "OBSERVATION", 160, 181]]], ["Retrospective study in older patients with chronic P aeruginosa infection reported an acute deterioration in clinical status in association with influenza virus infection.", [["chronic P aeruginosa infection", "DISEASE", 43, 73], ["influenza virus infection", "DISEASE", 145, 170], ["patients", "ORGANISM", 29, 37], ["influenza virus", "ORGANISM", 145, 160], ["patients", "SPECIES", 29, 37], ["P aeruginosa", "SPECIES", 51, 63], ["influenza virus", "SPECIES", 145, 160], ["Retrospective study", "TEST", 0, 19], ["chronic P aeruginosa infection", "PROBLEM", 43, 73], ["an acute deterioration", "PROBLEM", 83, 105], ["influenza virus infection", "PROBLEM", 145, 170], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["deterioration", "OBSERVATION", 92, 105], ["influenza virus", "OBSERVATION", 145, 160]]], ["85PULMONARY FIBROSISPulmonary fibrosis is the end stage of several diffuse parenchymal lung diseases characterized by excessive matrix deposition, lung parenchymal destruction, and progressive respiratory insufficiency.", [["diffuse parenchymal lung", "ANATOMY", 67, 91], ["matrix", "ANATOMY", 128, 134], ["lung parenchymal", "ANATOMY", 147, 163], ["respiratory", "ANATOMY", 193, 204], ["fibrosis", "DISEASE", 30, 38], ["parenchymal lung diseases", "DISEASE", 75, 100], ["lung parenchymal destruction", "DISEASE", 147, 175], ["respiratory insufficiency", "DISEASE", 193, 218], ["lung", "ORGAN", 87, 91], ["matrix", "CELLULAR_COMPONENT", 128, 134], ["lung parenchymal", "MULTI-TISSUE_STRUCTURE", 147, 163], ["PULMONARY FIBROSISPulmonary fibrosis", "PROBLEM", 2, 38], ["several diffuse parenchymal lung diseases", "PROBLEM", 59, 100], ["excessive matrix deposition", "PROBLEM", 118, 145], ["lung parenchymal destruction", "PROBLEM", 147, 175], ["progressive respiratory insufficiency", "PROBLEM", 181, 218], ["PULMONARY", "ANATOMY", 2, 11], ["FIBROSISPulmonary", "ANATOMY_MODIFIER", 12, 29], ["fibrosis", "OBSERVATION", 30, 38], ["end stage", "OBSERVATION_MODIFIER", 46, 55], ["several", "OBSERVATION_MODIFIER", 59, 66], ["diffuse", "OBSERVATION_MODIFIER", 67, 74], ["parenchymal", "ANATOMY_MODIFIER", 75, 86], ["lung", "ANATOMY", 87, 91], ["diseases", "OBSERVATION", 92, 100], ["excessive", "OBSERVATION_MODIFIER", 118, 127], ["matrix deposition", "OBSERVATION", 128, 145], ["lung", "ANATOMY", 147, 151], ["parenchymal", "ANATOMY_MODIFIER", 152, 163], ["destruction", "OBSERVATION", 164, 175], ["progressive", "OBSERVATION_MODIFIER", 181, 192], ["respiratory insufficiency", "OBSERVATION", 193, 218]]], ["87 Idiopathic pulmonary fibrosis (IPF) is a form of pulmonary fibrosis with overall poor survival rate and its etiology remains poorly understood.", [["pulmonary", "ANATOMY", 14, 23], ["pulmonary", "ANATOMY", 52, 61], ["Idiopathic pulmonary fibrosis", "DISEASE", 3, 32], ["IPF", "DISEASE", 34, 37], ["pulmonary fibrosis", "DISEASE", 52, 70], ["pulmonary", "ORGAN", 14, 23], ["pulmonary", "ORGAN", 52, 61], ["Idiopathic pulmonary fibrosis", "PROBLEM", 3, 32], ["IPF", "PROBLEM", 34, 37], ["pulmonary fibrosis", "PROBLEM", 52, 70], ["overall poor survival rate", "PROBLEM", 76, 102], ["Idiopathic", "OBSERVATION_MODIFIER", 3, 13], ["pulmonary", "ANATOMY", 14, 23], ["fibrosis", "OBSERVATION", 24, 32], ["IPF", "OBSERVATION", 34, 37], ["pulmonary", "ANATOMY", 52, 61], ["fibrosis", "OBSERVATION", 62, 70], ["overall", "OBSERVATION_MODIFIER", 76, 83], ["poor", "OBSERVATION_MODIFIER", 84, 88], ["survival rate", "OBSERVATION", 89, 102]]], ["Several risk and predisposing factors of pulmonary fibrosis include environmental, tobacco smoking, viral infections, family history, and genetics.", [["pulmonary", "ANATOMY", 41, 50], ["pulmonary fibrosis", "DISEASE", 41, 59], ["viral infections", "DISEASE", 100, 116], ["pulmonary", "ORGAN", 41, 50], ["tobacco", "ORGANISM", 83, 90], ["tobacco", "SPECIES", 83, 90], ["pulmonary fibrosis", "PROBLEM", 41, 59], ["viral infections", "PROBLEM", 100, 116], ["pulmonary", "ANATOMY", 41, 50], ["fibrosis", "OBSERVATION", 51, 59]]], ["Pulmonary fibrosis is characterized by progressive lung decline over time, with many patients experiencing disease stability punctuated by episodes of acute worsening of clinical symptoms and radiographic changes on chest imaging.PULMONARY FIBROSISAcute exacerbation of pulmonary fibrosis has been defined to be when no obvious identifiable cause is found for the pulmonary worsening.", [["Pulmonary", "ANATOMY", 0, 9], ["lung", "ANATOMY", 51, 55], ["chest", "ANATOMY", 216, 221], ["pulmonary", "ANATOMY", 270, 279], ["pulmonary", "ANATOMY", 364, 373], ["Pulmonary fibrosis", "DISEASE", 0, 18], ["lung decline", "DISEASE", 51, 63], ["pulmonary fibrosis", "DISEASE", 270, 288], ["Pulmonary", "ORGAN", 0, 9], ["lung", "ORGAN", 51, 55], ["patients", "ORGANISM", 85, 93], ["chest", "ORGANISM_SUBDIVISION", 216, 221], ["pulmonary", "ORGAN", 270, 279], ["pulmonary", "ORGAN", 364, 373], ["patients", "SPECIES", 85, 93], ["Pulmonary fibrosis", "PROBLEM", 0, 18], ["progressive lung decline", "PROBLEM", 39, 63], ["disease stability", "PROBLEM", 107, 124], ["acute worsening of clinical symptoms", "PROBLEM", 151, 187], ["radiographic changes", "PROBLEM", 192, 212], ["chest imaging", "TEST", 216, 229], ["PULMONARY FIBROSISAcute exacerbation", "PROBLEM", 230, 266], ["pulmonary fibrosis", "PROBLEM", 270, 288], ["the pulmonary worsening", "PROBLEM", 360, 383], ["fibrosis", "OBSERVATION", 10, 18], ["progressive", "OBSERVATION_MODIFIER", 39, 50], ["lung", "ANATOMY", 51, 55], ["decline", "OBSERVATION", 56, 63], ["disease", "OBSERVATION", 107, 114], ["acute", "OBSERVATION_MODIFIER", 151, 156], ["worsening", "OBSERVATION_MODIFIER", 157, 166], ["chest", "ANATOMY", 216, 221], ["FIBROSISAcute", "OBSERVATION_MODIFIER", 240, 253], ["exacerbation", "OBSERVATION", 254, 266], ["pulmonary", "ANATOMY", 270, 279], ["fibrosis", "OBSERVATION", 280, 288], ["pulmonary", "ANATOMY", 364, 373], ["worsening", "OBSERVATION", 374, 383]]], ["88, 89 Up to 10% of patients with IPF develop acute ex-acerbations each year with some resulting in deaths.", [["IPF", "DISEASE", 34, 37], ["ex-acerbations", "DISEASE", 52, 66], ["deaths", "DISEASE", 100, 106], ["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["IPF", "PROBLEM", 34, 37], ["acute ex-acerbations", "PROBLEM", 46, 66], ["IPF", "OBSERVATION", 34, 37], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["ex-acerbations", "OBSERVATION", 52, 66]]], ["However, it is unclear if these exacerbations truly accelerate the underlying fibrotic and proliferative process in pulmonary fibrosis or if it is due to complications such as infections, given IPF exacerbations are often accompanied by cough and fever.", [["pulmonary", "ANATOMY", 116, 125], ["pulmonary fibrosis", "DISEASE", 116, 134], ["infections", "DISEASE", 176, 186], ["IPF", "DISEASE", 194, 197], ["cough", "DISEASE", 237, 242], ["fever", "DISEASE", 247, 252], ["pulmonary", "ORGAN", 116, 125], ["these exacerbations", "PROBLEM", 26, 45], ["the underlying fibrotic and proliferative process", "PROBLEM", 63, 112], ["pulmonary fibrosis", "PROBLEM", 116, 134], ["complications", "PROBLEM", 154, 167], ["infections", "PROBLEM", 176, 186], ["IPF exacerbations", "PROBLEM", 194, 211], ["cough", "PROBLEM", 237, 242], ["fever", "PROBLEM", 247, 252], ["fibrotic", "OBSERVATION", 78, 86], ["proliferative", "OBSERVATION_MODIFIER", 91, 104], ["pulmonary", "ANATOMY", 116, 125], ["fibrosis", "OBSERVATION", 126, 134], ["infections", "OBSERVATION", 176, 186], ["cough", "OBSERVATION", 237, 242], ["fever", "OBSERVATION", 247, 252]]], ["Initially it has been suspected that respiratory viruses are likely causes of IPF ex-acerbations.", [["respiratory viruses", "DISEASE", 37, 56], ["IPF", "DISEASE", 78, 81], ["respiratory viruses", "PROBLEM", 37, 56], ["IPF ex-acerbations", "PROBLEM", 78, 96], ["respiratory viruses", "OBSERVATION", 37, 56], ["likely causes of", "UNCERTAINTY", 61, 77], ["IPF", "OBSERVATION", 78, 81]]], ["Compared with the strong association between viruses and exacerbations of obstructive lung diseases, such as asthma and COPD, there is currently very little research to suggest possible cause for exacerbations in IPF.PULMONARY FIBROSISThere have been several investigations on the role of pulmonary viruses in acute exacerbations that have resulted, however, in mixed results.", [["lung", "ANATOMY", 86, 90], ["pulmonary", "ANATOMY", 289, 298], ["obstructive lung diseases", "DISEASE", 74, 99], ["asthma", "DISEASE", 109, 115], ["COPD", "DISEASE", 120, 124], ["IPF", "DISEASE", 213, 216], ["pulmonary viruses", "DISEASE", 289, 306], ["lung", "ORGAN", 86, 90], ["pulmonary", "ORGAN", 289, 298], ["viruses", "PROBLEM", 45, 52], ["obstructive lung diseases", "PROBLEM", 74, 99], ["asthma", "PROBLEM", 109, 115], ["COPD", "PROBLEM", 120, 124], ["exacerbations", "PROBLEM", 196, 209], ["IPF", "PROBLEM", 213, 216], ["pulmonary viruses", "PROBLEM", 289, 306], ["acute exacerbations", "PROBLEM", 310, 329], ["viruses", "OBSERVATION", 45, 52], ["obstructive", "OBSERVATION_MODIFIER", 74, 85], ["lung", "ANATOMY", 86, 90], ["diseases", "OBSERVATION", 91, 99], ["asthma", "OBSERVATION", 109, 115], ["COPD", "OBSERVATION", 120, 124], ["suggest possible cause for", "UNCERTAINTY", 169, 195], ["exacerbations", "OBSERVATION", 196, 209], ["IPF", "OBSERVATION", 213, 216], ["FIBROSISThere", "OBSERVATION", 227, 240], ["several", "OBSERVATION_MODIFIER", 251, 258], ["pulmonary", "ANATOMY", 289, 298], ["viruses", "OBSERVATION", 299, 306], ["acute", "OBSERVATION_MODIFIER", 310, 315], ["exacerbations", "OBSERVATION", 316, 329]]], ["90 Gene expression analyses of stable IPF versus exacerbation in patients with IPF did find evidence of infectious or overwhelming inflammatory etiology.", [["IPF", "DISEASE", 38, 41], ["IPF", "DISEASE", 79, 82], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["stable IPF", "PROBLEM", 31, 41], ["exacerbation", "PROBLEM", 49, 61], ["IPF", "PROBLEM", 79, 82], ["infectious", "PROBLEM", 104, 114], ["overwhelming inflammatory etiology", "PROBLEM", 118, 152], ["stable", "OBSERVATION_MODIFIER", 31, 37], ["IPF", "OBSERVATION", 38, 41], ["IPF", "OBSERVATION", 79, 82], ["evidence of", "UNCERTAINTY", 92, 103], ["infectious", "OBSERVATION", 104, 114], ["overwhelming", "OBSERVATION_MODIFIER", 118, 130], ["inflammatory", "OBSERVATION_MODIFIER", 131, 143]]], ["Although the antimicrobial peptide, alpha defensing, was found to be increased in the epithelium and the peripheral blood, 91 using multiplex PCR and pan-viral microarray discovery platform and next-generation deep sequencing to increase viral detection sensitivity, viral infection was not detected in most cases of acute IPF exacerbations.", [["epithelium", "ANATOMY", 86, 96], ["peripheral blood", "ANATOMY", 105, 121], ["viral infection", "DISEASE", 267, 282], ["IPF", "DISEASE", 323, 326], ["alpha", "GENE_OR_GENE_PRODUCT", 36, 41], ["epithelium", "TISSUE", 86, 96], ["peripheral blood", "ORGANISM_SUBSTANCE", 105, 121], ["the antimicrobial peptide", "TEST", 9, 34], ["alpha defensing", "TEST", 36, 51], ["the peripheral blood", "TEST", 101, 121], ["multiplex PCR", "TEST", 132, 145], ["pan-viral microarray discovery platform", "TEST", 150, 189], ["next-generation deep sequencing", "TREATMENT", 194, 225], ["viral detection sensitivity", "TEST", 238, 265], ["viral infection", "PROBLEM", 267, 282], ["acute IPF exacerbations", "PROBLEM", 317, 340], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["epithelium", "ANATOMY_MODIFIER", 86, 96], ["peripheral", "ANATOMY_MODIFIER", 105, 115], ["blood", "ANATOMY", 116, 121], ["viral", "OBSERVATION_MODIFIER", 267, 272], ["infection", "OBSERVATION", 273, 282], ["acute", "OBSERVATION_MODIFIER", 317, 322], ["IPF", "OBSERVATION", 323, 326]]], ["Four of 43 patients with IPF acute exacerbations had evidence of common respiratory viral infections (2 rhinovirus, 1 coronavirus, 1 parainfluenza), whereas no viruses were detected in bronchoalveolar lavage fluid from stable patients.", [["bronchoalveolar lavage fluid", "ANATOMY", 185, 213], ["IPF", "DISEASE", 25, 28], ["respiratory viral infections", "DISEASE", 72, 100], ["parainfluenza", "DISEASE", 133, 146], ["patients", "ORGANISM", 11, 19], ["parainfluenza", "ORGANISM", 133, 146], ["bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 185, 213], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 11, 19], ["1 coronavirus", "SPECIES", 116, 129], ["parainfluenza", "SPECIES", 133, 146], ["patients", "SPECIES", 226, 234], ["IPF acute exacerbations", "PROBLEM", 25, 48], ["common respiratory viral infections", "PROBLEM", 65, 100], ["2 rhinovirus", "PROBLEM", 102, 114], ["1 coronavirus", "PROBLEM", 116, 129], ["1 parainfluenza)", "PROBLEM", 131, 147], ["viruses", "PROBLEM", 160, 167], ["bronchoalveolar lavage fluid", "TEST", 185, 213], ["IPF", "OBSERVATION_MODIFIER", 25, 28], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["exacerbations", "OBSERVATION", 35, 48], ["evidence of", "UNCERTAINTY", 53, 64], ["common", "ANATOMY_MODIFIER", 65, 71], ["respiratory", "ANATOMY", 72, 83], ["viral infections", "OBSERVATION", 84, 100], ["no", "UNCERTAINTY", 157, 159], ["viruses", "OBSERVATION", 160, 167], ["bronchoalveolar lavage", "OBSERVATION", 185, 207], ["stable", "OBSERVATION_MODIFIER", 219, 225]]], ["92 Interestingly, torque teno virus (TTV), a relatively new single-stranded DNA virus, was found to be more common in patients with acute exacerbations than in stable controls.", [["torque teno virus", "ORGANISM", 18, 35], ["TTV", "ORGANISM", 37, 40], ["DNA", "CELLULAR_COMPONENT", 76, 79], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["torque teno virus", "SPECIES", 18, 35], ["TTV", "SPECIES", 37, 40], ["torque teno virus (TTV", "PROBLEM", 18, 40], ["a relatively new single-stranded DNA virus", "PROBLEM", 43, 85], ["acute exacerbations", "PROBLEM", 132, 151], ["new", "OBSERVATION_MODIFIER", 56, 59], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["exacerbations", "OBSERVATION", 138, 151], ["stable", "OBSERVATION_MODIFIER", 160, 166]]], ["However, TTV also can be detected in patients with acute respiratory distress syndrome, suggesting that this virus is not specific to IPF.", [["respiratory", "ANATOMY", 57, 68], ["acute respiratory distress syndrome", "DISEASE", 51, 86], ["IPF", "DISEASE", 134, 137], ["TTV", "ORGANISM", 9, 12], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["TTV", "SPECIES", 9, 12], ["TTV", "TEST", 9, 12], ["acute respiratory distress syndrome", "PROBLEM", 51, 86], ["this virus", "PROBLEM", 104, 114], ["IPF", "PROBLEM", 134, 137], ["TTV", "OBSERVATION", 9, 12], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["respiratory distress", "OBSERVATION", 57, 77]]], ["Deep sequencing of the lungs from patients with acute exacerbation of IPF did not reveal any evidence for viral pathogens.PULMONARY FIBROSISWhether viral infections truly have no major role in IPF pathogenesis remains unclear, although evidence suggests this is the case given the studies thus far.", [["lungs", "ANATOMY", 23, 28], ["IPF", "DISEASE", 70, 73], ["viral infections", "DISEASE", 148, 164], ["IPF", "DISEASE", 193, 196], ["lungs", "ORGAN", 23, 28], ["patients", "ORGANISM", 34, 42], ["IPF", "CANCER", 193, 196], ["patients", "SPECIES", 34, 42], ["Deep sequencing of the lungs", "TEST", 0, 28], ["acute exacerbation", "PROBLEM", 48, 66], ["IPF", "PROBLEM", 70, 73], ["viral pathogens", "PROBLEM", 106, 121], ["PULMONARY FIBROSISWhether viral infections", "PROBLEM", 122, 164], ["IPF pathogenesis", "PROBLEM", 193, 209], ["the studies", "TEST", 277, 288], ["lungs", "ANATOMY", 23, 28], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["exacerbation", "OBSERVATION", 54, 66], ["IPF", "OBSERVATION", 70, 73], ["evidence for", "UNCERTAINTY", 93, 105], ["viral", "OBSERVATION_MODIFIER", 106, 111], ["pathogens", "OBSERVATION", 112, 121], ["viral infections", "OBSERVATION", 148, 164], ["no major", "UNCERTAINTY", 176, 184], ["IPF", "OBSERVATION", 193, 196]]], ["It is still possible viral associations have not been clearly proven due to the timing of sampling of IPF patients during their exacerbations or possible incorrect compartment sampling to identify viruses (bronchoalveolar fluid vs interstitial disease).", [["bronchoalveolar fluid", "ANATOMY", 206, 227], ["interstitial", "ANATOMY", 231, 243], ["IPF", "DISEASE", 102, 105], ["interstitial disease", "DISEASE", 231, 251], ["patients", "ORGANISM", 106, 114], ["bronchoalveolar fluid", "MULTI-TISSUE_STRUCTURE", 206, 227], ["patients", "SPECIES", 106, 114], ["viral associations", "PROBLEM", 21, 39], ["IPF patients", "PROBLEM", 102, 114], ["their exacerbations", "PROBLEM", 122, 141], ["incorrect compartment sampling", "PROBLEM", 154, 184], ["viruses (bronchoalveolar fluid vs interstitial disease", "PROBLEM", 197, 251], ["bronchoalveolar fluid", "OBSERVATION", 206, 227], ["interstitial disease", "OBSERVATION", 231, 251]]], ["Gene expression studies of lung tissues show suggestive of type II alveolar epithelial cell injury or proliferation, endothelial cell injury, and coagulation in patients with acute exacerbation of IPF that is distinct from patients with acute lung injury.", [["lung tissues", "ANATOMY", 27, 39], ["alveolar epithelial cell", "ANATOMY", 67, 91], ["endothelial cell", "ANATOMY", 117, 133], ["lung", "ANATOMY", 243, 247], ["IPF", "DISEASE", 197, 200], ["acute lung injury", "DISEASE", 237, 254], ["lung tissues", "TISSUE", 27, 39], ["type II alveolar epithelial cell", "CELL", 59, 91], ["endothelial cell", "CELL", 117, 133], ["patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 223, 231], ["lung", "ORGAN", 243, 247], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 223, 231], ["Gene expression studies of lung tissues", "TEST", 0, 39], ["type II alveolar epithelial cell injury", "PROBLEM", 59, 98], ["proliferation", "PROBLEM", 102, 115], ["endothelial cell injury", "PROBLEM", 117, 140], ["acute exacerbation", "PROBLEM", 175, 193], ["IPF", "PROBLEM", 197, 200], ["acute lung injury", "PROBLEM", 237, 254], ["lung", "ANATOMY", 27, 31], ["suggestive of", "UNCERTAINTY", 45, 58], ["type II", "OBSERVATION_MODIFIER", 59, 66], ["alveolar", "ANATOMY_MODIFIER", 67, 75], ["epithelial cell injury", "OBSERVATION", 76, 98], ["proliferation", "OBSERVATION_MODIFIER", 102, 115], ["endothelial cell injury", "OBSERVATION", 117, 140], ["acute", "OBSERVATION_MODIFIER", 175, 180], ["exacerbation", "OBSERVATION", 181, 193], ["IPF", "OBSERVATION", 197, 200], ["distinct", "OBSERVATION_MODIFIER", 209, 217], ["acute", "OBSERVATION_MODIFIER", 237, 242], ["lung", "ANATOMY", 243, 247], ["injury", "OBSERVATION", 248, 254]]], ["93 It is possible there are no major associations with conventional respiratory viruses with IPF.", [["IPF", "DISEASE", 93, 96], ["conventional respiratory viruses", "PROBLEM", 55, 87], ["IPF", "PROBLEM", 93, 96], ["no major", "UNCERTAINTY", 28, 36], ["respiratory viruses", "OBSERVATION", 68, 87], ["IPF", "OBSERVATION", 93, 96]]], ["However, there have been reports of the presence of certain human herpesviruses, such as Epstein-Barr virus (EBV), in patients with IPF and animal models of fibrosis.", [["IPF", "DISEASE", 132, 135], ["fibrosis", "DISEASE", 157, 165], ["human", "ORGANISM", 60, 65], ["Epstein-Barr virus", "ORGANISM", 89, 107], ["EBV", "ORGANISM", 109, 112], ["patients", "ORGANISM", 118, 126], ["human", "SPECIES", 60, 65], ["patients", "SPECIES", 118, 126], ["human herpesviruses", "SPECIES", 60, 79], ["Epstein-Barr virus", "SPECIES", 89, 107], ["EBV", "SPECIES", 109, 112], ["certain human herpesviruses", "PROBLEM", 52, 79], ["Epstein-Barr virus", "PROBLEM", 89, 107], ["IPF", "PROBLEM", 132, 135], ["fibrosis", "PROBLEM", 157, 165], ["human herpesviruses", "OBSERVATION", 60, 79], ["Barr virus", "OBSERVATION", 97, 107], ["IPF", "OBSERVATION", 132, 135], ["animal models", "OBSERVATION_MODIFIER", 140, 153], ["fibrosis", "OBSERVATION", 157, 165]]], ["94 Another study showed patients with IPF who underwent lung transplantation were found to be positive for EBV (11/12) and human herpesvirus (HHV)-6B (10/12) compared with control lung samples that were positive for HHV-6B (3/10) and negative for EBV (0/10).", [["lung", "ANATOMY", 56, 60], ["lung samples", "ANATOMY", 180, 192], ["IPF", "DISEASE", 38, 41], ["patients", "ORGANISM", 24, 32], ["lung", "ORGAN", 56, 60], ["EBV", "ORGANISM", 107, 110], ["human herpesvirus (HHV)-6B", "ORGANISM", 123, 149], ["lung samples", "CANCER", 180, 192], ["HHV-6B", "GENE_OR_GENE_PRODUCT", 216, 222], ["EBV", "ORGANISM", 247, 250], ["patients", "SPECIES", 24, 32], ["human", "SPECIES", 123, 128], ["EBV", "SPECIES", 107, 110], ["human herpesvirus (HHV)-6B", "SPECIES", 123, 149], ["HHV-6B", "SPECIES", 216, 222], ["EBV", "SPECIES", 247, 250], ["Another study", "TEST", 3, 16], ["IPF", "PROBLEM", 38, 41], ["lung transplantation", "TREATMENT", 56, 76], ["EBV", "PROBLEM", 107, 110], ["human herpesvirus (HHV", "TEST", 123, 145], ["control lung samples", "TEST", 172, 192], ["HHV", "TEST", 216, 219], ["EBV", "PROBLEM", 247, 250], ["IPF", "OBSERVATION", 38, 41], ["lung", "ANATOMY", 56, 60], ["transplantation", "OBSERVATION", 61, 76], ["lung", "ANATOMY", 180, 184]]], ["95 They suggest that herpesviruses could contribute to the lung epithelial injury that initiates profibrotic responses in IPF.", [["lung epithelial", "ANATOMY", 59, 74], ["epithelial injury", "DISEASE", 64, 81], ["IPF", "DISEASE", 122, 125], ["herpesviruses", "ORGANISM", 21, 34], ["lung epithelial", "TISSUE", 59, 74], ["herpesviruses", "PROBLEM", 21, 34], ["the lung epithelial injury", "PROBLEM", 55, 81], ["IPF", "PROBLEM", 122, 125], ["lung", "ANATOMY", 59, 63], ["epithelial", "ANATOMY_MODIFIER", 64, 74], ["injury", "OBSERVATION", 75, 81], ["profibrotic", "OBSERVATION_MODIFIER", 97, 108], ["IPF", "OBSERVATION", 122, 125]]], ["Whether or not IPF acute exacerbation represents reactivation of latent herpesviruses remains unknown and requires further explorations.PULMONARY FIBROSISIt is interesting the evidence associating respiratory viruses with IPF is rather weak, whereas it is quite clear that respiratory viral infections are important in the pathogenesis of obstructive lung diseases, such as COPD and asthma.", [["lung", "ANATOMY", 351, 355], ["IPF", "DISEASE", 15, 18], ["herpesviruses", "DISEASE", 72, 85], ["respiratory viruses", "DISEASE", 197, 216], ["IPF", "DISEASE", 222, 225], ["respiratory viral infections", "DISEASE", 273, 301], ["obstructive lung diseases", "DISEASE", 339, 364], ["COPD", "DISEASE", 374, 378], ["asthma", "DISEASE", 383, 389], ["lung", "ORGAN", 351, 355], ["IPF acute exacerbation", "PROBLEM", 15, 37], ["latent herpesviruses", "PROBLEM", 65, 85], ["further explorations", "TEST", 115, 135], ["associating respiratory viruses", "PROBLEM", 185, 216], ["IPF", "PROBLEM", 222, 225], ["respiratory viral infections", "PROBLEM", 273, 301], ["obstructive lung diseases", "PROBLEM", 339, 364], ["COPD", "PROBLEM", 374, 378], ["asthma", "PROBLEM", 383, 389], ["not", "UNCERTAINTY", 11, 14], ["IPF", "OBSERVATION_MODIFIER", 15, 18], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["exacerbation", "OBSERVATION", 25, 37], ["latent", "OBSERVATION_MODIFIER", 65, 71], ["herpesviruses", "OBSERVATION", 72, 85], ["FIBROSISIt", "OBSERVATION", 146, 156], ["respiratory viruses", "OBSERVATION", 197, 216], ["IPF", "OBSERVATION", 222, 225], ["weak", "OBSERVATION_MODIFIER", 236, 240], ["viral infections", "OBSERVATION", 285, 301], ["obstructive", "OBSERVATION_MODIFIER", 339, 350], ["lung", "ANATOMY", 351, 355], ["diseases", "OBSERVATION", 356, 364], ["COPD", "OBSERVATION", 374, 378], ["asthma", "OBSERVATION", 383, 389]]], ["Is this difference in association of respiratory virus and chronic lung disease due to the involvement of different cell types in the lung, such as airway epithelium versus alveolar epithelium?", [["lung", "ANATOMY", 67, 71], ["cell", "ANATOMY", 116, 120], ["lung", "ANATOMY", 134, 138], ["airway epithelium", "ANATOMY", 148, 165], ["alveolar epithelium", "ANATOMY", 173, 192], ["respiratory virus", "DISEASE", 37, 54], ["chronic lung disease", "DISEASE", 59, 79], ["respiratory virus", "ORGANISM", 37, 54], ["lung", "ORGAN", 67, 71], ["cell", "CELL", 116, 120], ["lung", "ORGAN", 134, 138], ["airway epithelium", "TISSUE", 148, 165], ["alveolar epithelium", "TISSUE", 173, 192], ["respiratory virus", "PROBLEM", 37, 54], ["chronic lung disease", "PROBLEM", 59, 79], ["different cell types in the lung", "PROBLEM", 106, 138], ["airway epithelium", "PROBLEM", 148, 165], ["alveolar epithelium", "PROBLEM", 173, 192], ["respiratory virus", "OBSERVATION", 37, 54], ["chronic", "OBSERVATION_MODIFIER", 59, 66], ["lung", "ANATOMY", 67, 71], ["disease", "OBSERVATION", 72, 79], ["different cell types", "OBSERVATION", 106, 126], ["lung", "ANATOMY", 134, 138], ["airway", "ANATOMY", 148, 154], ["epithelium", "ANATOMY_MODIFIER", 155, 165], ["alveolar epithelium", "OBSERVATION", 173, 192]]], ["Understanding the mechanism behind these differences will be important to determine.SARCOIDOSISSarcoidosis is a systemic inflammatory disease characterized by noncaseating epithelioid granulomatous inflammation in affected sites, including the lung.", [["epithelioid granulomatous", "ANATOMY", 172, 197], ["sites", "ANATOMY", 223, 228], ["lung", "ANATOMY", 244, 248], ["SARCOIDOSISSarcoidosis", "DISEASE", 84, 106], ["inflammation", "DISEASE", 198, 210], ["epithelioid granulomatous", "PATHOLOGICAL_FORMATION", 172, 197], ["lung", "ORGAN", 244, 248], ["SARCOIDOSISSarcoidosis", "PROBLEM", 84, 106], ["a systemic inflammatory disease", "PROBLEM", 110, 141], ["noncaseating epithelioid granulomatous inflammation in affected sites", "PROBLEM", 159, 228], ["systemic", "OBSERVATION_MODIFIER", 112, 120], ["inflammatory", "OBSERVATION_MODIFIER", 121, 133], ["noncaseating", "OBSERVATION_MODIFIER", 159, 171], ["epithelioid", "OBSERVATION_MODIFIER", 172, 183], ["granulomatous", "OBSERVATION_MODIFIER", 184, 197], ["inflammation", "OBSERVATION", 198, 210], ["lung", "ANATOMY", 244, 248]]], ["96 Although many patients experience disease remission within the first few years, more than 30% to 50% of patients develop chronic disease requiring treatment to prevent progression of organ dysfunction and fibrotic changes.", [["organ", "ANATOMY", 186, 191], ["organ dysfunction", "DISEASE", 186, 203], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 107, 115], ["organ", "ORGAN", 186, 191], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 107, 115], ["disease remission", "PROBLEM", 37, 54], ["chronic disease", "PROBLEM", 124, 139], ["treatment", "TREATMENT", 150, 159], ["organ dysfunction", "PROBLEM", 186, 203], ["fibrotic changes", "PROBLEM", 208, 224], ["chronic", "OBSERVATION_MODIFIER", 124, 131], ["disease", "OBSERVATION", 132, 139], ["organ", "ANATOMY", 186, 191], ["dysfunction", "OBSERVATION", 192, 203], ["fibrotic", "OBSERVATION", 208, 216]]], ["Epidemiologic studies and basic research suggest that sarcoidosis represents an immune response to an exogenous agent in a genetically susceptible individual.", [["sarcoidosis", "DISEASE", 54, 65], ["Epidemiologic studies", "TEST", 0, 21], ["sarcoidosis", "PROBLEM", 54, 65], ["an immune response", "PROBLEM", 77, 95], ["an exogenous agent", "TREATMENT", 99, 117], ["sarcoidosis", "OBSERVATION", 54, 65], ["immune response", "OBSERVATION", 80, 95]]], ["A definitive exogenous agent responsible for sarcoidosis remains elusive.", [["sarcoidosis", "DISEASE", 45, 56], ["A definitive exogenous agent", "TREATMENT", 0, 28], ["sarcoidosis", "PROBLEM", 45, 56], ["responsible for", "UNCERTAINTY", 29, 44], ["sarcoidosis", "OBSERVATION", 45, 56]]], ["Some investigators have speculated that a transmissible or infectious agent may cause sarcoidosis.", [["sarcoidosis", "DISEASE", 86, 97], ["a transmissible or infectious agent", "PROBLEM", 40, 75], ["sarcoidosis", "PROBLEM", 86, 97], ["infectious", "OBSERVATION", 59, 69], ["sarcoidosis", "OBSERVATION", 86, 97]]], ["97 There has been an increasing body of evidence to suggest a link between infection and sarcoidosis, especially with regard to Mycobacteria and Propionibacteria.", [["infection", "DISEASE", 75, 84], ["sarcoidosis", "DISEASE", 89, 100], ["Propionibacteria", "CHEMICAL", 145, 161], ["Propionibacteria", "SIMPLE_CHEMICAL", 145, 161], ["a link between infection", "PROBLEM", 60, 84], ["sarcoidosis", "PROBLEM", 89, 100], ["Mycobacteria", "PROBLEM", 128, 140], ["Propionibacteria", "PROBLEM", 145, 161], ["increasing", "OBSERVATION_MODIFIER", 21, 31], ["infection", "OBSERVATION", 75, 84], ["sarcoidosis", "OBSERVATION", 89, 100], ["Mycobacteria", "OBSERVATION", 128, 140], ["Propionibacteria", "OBSERVATION", 145, 161]]], ["The thought is that maybe persistent antigenic stimulation from microbial agents at sites of inflammation results in sarcoidosis.", [["inflammation", "DISEASE", 93, 105], ["sarcoidosis", "DISEASE", 117, 128], ["persistent antigenic stimulation", "PROBLEM", 26, 58], ["microbial agents", "TREATMENT", 64, 80], ["inflammation", "PROBLEM", 93, 105], ["sarcoidosis", "PROBLEM", 117, 128], ["persistent", "OBSERVATION_MODIFIER", 26, 36], ["antigenic stimulation", "OBSERVATION", 37, 58], ["inflammation", "OBSERVATION", 93, 105], ["sarcoidosis", "OBSERVATION", 117, 128]]], ["However, to date, identifying the etiology of sarcoidosis has remained elusive.", [["sarcoidosis", "DISEASE", 46, 57], ["sarcoidosis", "PROBLEM", 46, 57], ["sarcoidosis", "OBSERVATION", 46, 57]]], ["A variety of viruses have been proposed as etiologic agents or triggers for sarcoidosis; yet, this association has been difficult to define.", [["sarcoidosis", "DISEASE", 76, 87], ["A variety of viruses", "PROBLEM", 0, 20], ["sarcoidosis", "PROBLEM", 76, 87], ["viruses", "OBSERVATION", 13, 20], ["sarcoidosis", "OBSERVATION", 76, 87]]], ["The viruses associated with sarcoidosis based on serology include EBV, cytomegalovirus, herpes simplex, HHV-6 and HHV-8, and coxsackie virus.", [["sarcoidosis", "DISEASE", 28, 39], ["herpes simplex", "DISEASE", 88, 102], ["EBV", "ORGANISM", 66, 69], ["cytomegalovirus", "ORGANISM", 71, 86], ["herpes simplex", "ORGANISM", 88, 102], ["HHV-6", "ORGANISM", 104, 109], ["HHV-8", "ORGANISM", 114, 119], ["coxsackie virus", "ORGANISM", 125, 140], ["herpes simplex", "SPECIES", 88, 102], ["HHV-6", "SPECIES", 104, 109], ["coxsackie virus", "SPECIES", 125, 140], ["EBV", "SPECIES", 66, 69], ["HHV-6", "SPECIES", 104, 109], ["HHV-8", "SPECIES", 114, 119], ["coxsackie virus", "SPECIES", 125, 140], ["The viruses", "PROBLEM", 0, 11], ["sarcoidosis", "PROBLEM", 28, 39], ["serology", "TEST", 49, 57], ["EBV", "TEST", 66, 69], ["cytomegalovirus", "PROBLEM", 71, 86], ["herpes simplex", "TEST", 88, 102], ["HHV", "TEST", 104, 107], ["HHV", "TEST", 114, 117], ["coxsackie virus", "PROBLEM", 125, 140], ["viruses", "OBSERVATION", 4, 11], ["sarcoidosis", "OBSERVATION", 28, 39], ["cytomegalovirus", "OBSERVATION", 71, 86], ["coxsackie virus", "OBSERVATION", 125, 140]]], ["96, 98 Data supporting an increased frequency of these viral respiratory infections in sarcoidosis have been lacking.SUMMARYRespiratory viruses remain to be important in the pathogenesis of chronic lung diseases.", [["respiratory", "ANATOMY", 61, 72], ["lung", "ANATOMY", 198, 202], ["respiratory infections", "DISEASE", 61, 83], ["sarcoidosis", "DISEASE", 87, 98], ["chronic lung diseases", "DISEASE", 190, 211], ["lung", "ORGAN", 198, 202], ["these viral respiratory infections", "PROBLEM", 49, 83], ["sarcoidosis", "PROBLEM", 87, 98], ["SUMMARYRespiratory viruses", "PROBLEM", 117, 143], ["chronic lung diseases", "PROBLEM", 190, 211], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["respiratory infections", "OBSERVATION", 61, 83], ["sarcoidosis", "OBSERVATION", 87, 98], ["viruses", "OBSERVATION", 136, 143], ["chronic", "OBSERVATION_MODIFIER", 190, 197], ["lung", "ANATOMY", 198, 202], ["diseases", "OBSERVATION", 203, 211]]], ["Recent data with the use of more sensitive nucleic acid-based viral diagnostics highlight the underappreciation of prevalence of respiratory viruses and their role in lung diseases.", [["lung", "ANATOMY", 167, 171], ["nucleic acid", "CHEMICAL", 43, 55], ["respiratory viruses", "DISEASE", 129, 148], ["lung diseases", "DISEASE", 167, 180], ["lung", "ORGAN", 167, 171], ["nucleic acid", "TEST", 43, 55], ["viral diagnostics", "TEST", 62, 79], ["respiratory viruses", "PROBLEM", 129, 148], ["lung diseases", "PROBLEM", 167, 180], ["respiratory viruses", "OBSERVATION", 129, 148], ["lung", "ANATOMY", 167, 171], ["diseases", "OBSERVATION", 172, 180]]], ["Evidence for their contribution in disease pathogenesis and exacerbation is more compelling in chronic lung diseases, such as COPD, asthma, and CF, in which viruses are commonly found and associated with disease ex-acerbations.", [["lung", "ANATOMY", 103, 107], ["chronic lung diseases", "DISEASE", 95, 116], ["COPD", "DISEASE", 126, 130], ["asthma", "DISEASE", 132, 138], ["CF", "DISEASE", 144, 146], ["ex-acerbations", "DISEASE", 212, 226], ["lung", "ORGAN", 103, 107], ["disease pathogenesis", "PROBLEM", 35, 55], ["exacerbation", "PROBLEM", 60, 72], ["chronic lung diseases", "PROBLEM", 95, 116], ["COPD", "PROBLEM", 126, 130], ["asthma", "PROBLEM", 132, 138], ["CF", "PROBLEM", 144, 146], ["disease ex-acerbations", "PROBLEM", 204, 226], ["disease", "OBSERVATION", 35, 42], ["chronic", "OBSERVATION_MODIFIER", 95, 102], ["lung", "ANATOMY", 103, 107], ["diseases", "OBSERVATION", 108, 116], ["COPD", "OBSERVATION", 126, 130], ["asthma", "OBSERVATION", 132, 138], ["viruses", "OBSERVATION", 157, 164]]], ["There is much less compelling evidence for the association of viruses with IPF or sarcoidosis.", [["IPF", "DISEASE", 75, 78], ["sarcoidosis", "DISEASE", 82, 93], ["viruses", "PROBLEM", 62, 69], ["IPF", "PROBLEM", 75, 78], ["sarcoidosis", "PROBLEM", 82, 93], ["viruses", "OBSERVATION", 62, 69], ["IPF", "OBSERVATION", 75, 78], ["sarcoidosis", "OBSERVATION", 82, 93]]], ["Measures to better understand how respiratory viral infections contribute to disease pathogenesis of many of the chronic lung diseases are needed.", [["lung", "ANATOMY", 121, 125], ["respiratory viral infections", "DISEASE", 34, 62], ["chronic lung diseases", "DISEASE", 113, 134], ["lung", "ORGAN", 121, 125], ["respiratory viral infections", "PROBLEM", 34, 62], ["disease pathogenesis", "PROBLEM", 77, 97], ["the chronic lung diseases", "PROBLEM", 109, 134], ["chronic", "OBSERVATION_MODIFIER", 113, 120], ["lung", "ANATOMY", 121, 125], ["diseases", "OBSERVATION", 126, 134]]], ["Preventive measures to limit such viral infections with good hand hygiene, avoidance of sick contacts, and viral vaccinations are recommended for patients suffering from chronic lung diseases.\u2022Respiratory viruses remain to be important in the pathogenesis of chronic lung diseases.\u2022\u2022 Respiratory viruses play an important role in chronic lung diseases, such as chronic obstructive pulmonary disease, asthma, and cystic fibrosis, especially in disease exacerbations.\u2022There is not much evidence for the association of respiratory viruses with idiopathic pulmonary fibrosis or sarcoidosis.\u2022\u2022 Preventive measures are needed to limit such viral infections, with good hand hygiene, avoidance of sick contacts, and viral vaccinations recommended for patients suffering from chronic lung diseases.", [["hand", "ANATOMY", 61, 65], ["lung", "ANATOMY", 178, 182], ["lung", "ANATOMY", 267, 271], ["lung", "ANATOMY", 338, 342], ["pulmonary", "ANATOMY", 381, 390], ["cystic", "ANATOMY", 412, 418], ["pulmonary", "ANATOMY", 552, 561], ["hand", "ANATOMY", 662, 666], ["lung", "ANATOMY", 775, 779], ["viral infections", "DISEASE", 34, 50], ["chronic lung diseases", "DISEASE", 170, 191], ["Respiratory viruses", "DISEASE", 193, 212], ["chronic lung diseases", "DISEASE", 259, 280], ["Respiratory viruses", "DISEASE", 284, 303], ["chronic lung diseases", "DISEASE", 330, 351], ["chronic obstructive pulmonary disease", "DISEASE", 361, 398], ["asthma", "DISEASE", 400, 406], ["cystic fibrosis", "DISEASE", 412, 427], ["respiratory viruses", "DISEASE", 516, 535], ["idiopathic pulmonary fibrosis", "DISEASE", 541, 570], ["sarcoidosis", "DISEASE", 574, 585], ["viral infections", "DISEASE", 634, 650], ["chronic lung diseases", "DISEASE", 767, 788], ["hand", "ORGANISM_SUBDIVISION", 61, 65], ["patients", "ORGANISM", 146, 154], ["lung", "ORGAN", 178, 182], ["lung", "ORGAN", 267, 271], ["lung", "ORGAN", 338, 342], ["pulmonary", "ORGAN", 381, 390], ["pulmonary", "ORGAN", 552, 561], ["hand", "ORGANISM_SUBDIVISION", 662, 666], ["patients", "ORGANISM", 743, 751], ["lung", "ORGAN", 775, 779], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 743, 751], ["Preventive measures", "TREATMENT", 0, 19], ["such viral infections", "PROBLEM", 29, 50], ["sick contacts", "PROBLEM", 88, 101], ["viral vaccinations", "TREATMENT", 107, 125], ["chronic lung diseases", "PROBLEM", 170, 191], ["Respiratory viruses", "PROBLEM", 193, 212], ["chronic lung diseases", "PROBLEM", 259, 280], ["Respiratory viruses", "PROBLEM", 284, 303], ["chronic lung diseases", "PROBLEM", 330, 351], ["chronic obstructive pulmonary disease", "PROBLEM", 361, 398], ["asthma", "PROBLEM", 400, 406], ["cystic fibrosis", "PROBLEM", 412, 427], ["disease exacerbations", "PROBLEM", 443, 464], ["respiratory viruses", "PROBLEM", 516, 535], ["idiopathic pulmonary fibrosis", "PROBLEM", 541, 570], ["sarcoidosis", "PROBLEM", 574, 585], ["Preventive measures", "TREATMENT", 589, 608], ["such viral infections", "PROBLEM", 629, 650], ["sick contacts", "PROBLEM", 689, 702], ["viral vaccinations", "TREATMENT", 708, 726], ["chronic lung diseases", "PROBLEM", 767, 788], ["chronic", "OBSERVATION_MODIFIER", 170, 177], ["lung", "ANATOMY", 178, 182], ["diseases", "OBSERVATION", 183, 191], ["viruses", "OBSERVATION", 205, 212], ["chronic", "OBSERVATION_MODIFIER", 259, 266], ["lung", "ANATOMY", 267, 271], ["diseases", "OBSERVATION", 272, 280], ["viruses", "OBSERVATION", 296, 303], ["chronic", "OBSERVATION_MODIFIER", 330, 337], ["lung", "ANATOMY", 338, 342], ["diseases", "OBSERVATION", 343, 351], ["chronic", "OBSERVATION_MODIFIER", 361, 368], ["obstructive", "OBSERVATION_MODIFIER", 369, 380], ["pulmonary", "ANATOMY", 381, 390], ["disease", "OBSERVATION", 391, 398], ["asthma", "OBSERVATION", 400, 406], ["cystic", "OBSERVATION_MODIFIER", 412, 418], ["fibrosis", "OBSERVATION", 419, 427], ["not much evidence for", "UNCERTAINTY", 475, 496], ["respiratory viruses", "OBSERVATION", 516, 535], ["idiopathic", "OBSERVATION_MODIFIER", 541, 551], ["pulmonary", "ANATOMY", 552, 561], ["fibrosis", "OBSERVATION", 562, 570], ["sarcoidosis", "OBSERVATION", 574, 585], ["chronic", "OBSERVATION_MODIFIER", 767, 774], ["lung", "ANATOMY", 775, 779], ["diseases", "OBSERVATION", 780, 788]]]], "15eb8e7b11af583b246f91cc4b72d26f471bc640": [["SARS-CoV-2 (inversely related to the cycle threshold [Ct] value) peaks soon after symptom onset, with higher viral loads in the nose than in the throat (Pan et al. 2020; Wu et al. 2020; Yip et al. 2020) .", [["nose", "ANATOMY", 128, 132], ["throat", "ANATOMY", 145, 151], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["nose", "ORGAN", 128, 132], ["throat", "ORGANISM_SUBDIVISION", 145, 151], ["the cycle threshold", "TEST", 33, 52], ["Ct] value", "TEST", 54, 63], ["symptom onset", "PROBLEM", 82, 95], ["higher viral loads in the nose", "PROBLEM", 102, 132], ["viral loads", "OBSERVATION", 109, 120], ["nose", "ANATOMY", 128, 132], ["throat", "ANATOMY", 145, 151]]], ["But sputum samples are more commonly collected, and the relationship between the viral load of the nasopharyngeal samples and the sputum samples is still unclear.", [["sputum samples", "ANATOMY", 4, 18], ["nasopharyngeal samples", "ANATOMY", 99, 121], ["sputum samples", "ANATOMY", 130, 144], ["sputum samples", "CANCER", 4, 18], ["nasopharyngeal samples", "CANCER", 99, 121], ["sputum samples", "TEST", 4, 18], ["the viral load", "TEST", 77, 91], ["the nasopharyngeal samples", "TEST", 95, 121], ["the sputum samples", "TEST", 126, 144], ["viral load", "OBSERVATION", 81, 91], ["nasopharyngeal", "ANATOMY", 99, 113]]], ["With the control of the disease and the intervention of antiviral drugs, the viral load can be reduced, but the time required for the nasopharyngeal swab and sputum to turn negative varies.", [["nasopharyngeal swab", "ANATOMY", 134, 153], ["sputum", "ANATOMY", 158, 164], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 134, 153], ["sputum", "ORGANISM_SUBSTANCE", 158, 164], ["the disease", "PROBLEM", 20, 31], ["antiviral drugs", "TREATMENT", 56, 71], ["the viral load", "TEST", 73, 87], ["the nasopharyngeal swab", "TEST", 130, 153], ["disease", "OBSERVATION", 24, 31], ["nasopharyngeal", "ANATOMY", 134, 148]]], ["However, the viral load dynamics and characteristics in nasopharyngeal secretions and sputum samples during course of the COVID-19 disease remain unclear.", [["nasopharyngeal secretions", "ANATOMY", 56, 81], ["sputum samples", "ANATOMY", 86, 100], ["nasopharyngeal secretions", "MULTI-TISSUE_STRUCTURE", 56, 81], ["sputum samples", "MULTI-TISSUE_STRUCTURE", 86, 100], ["the viral load dynamics", "TEST", 9, 32], ["nasopharyngeal secretions", "PROBLEM", 56, 81], ["sputum samples", "TEST", 86, 100], ["the COVID-19 disease", "PROBLEM", 118, 138], ["viral load", "OBSERVATION", 13, 23], ["nasopharyngeal", "ANATOMY", 56, 70], ["secretions", "OBSERVATION", 71, 81]]]], "1176f711d45fd829ed65244584b5f632a301f0c9": [["IntroductionAnakinra is a recombinant IL-1 receptor antagonist originally marketed for use in rheumatoid arthritis.", [["Anakinra", "CHEMICAL", 12, 20], ["rheumatoid arthritis", "DISEASE", 94, 114], ["Anakinra", "CHEMICAL", 12, 20], ["Anakinra", "SIMPLE_CHEMICAL", 12, 20], ["IL-1 receptor antagonist", "GENE_OR_GENE_PRODUCT", 38, 62], ["IntroductionAnakinra", "TREATMENT", 0, 20], ["a recombinant IL-1 receptor antagonist", "TREATMENT", 24, 62], ["rheumatoid arthritis", "PROBLEM", 94, 114], ["rheumatoid arthritis", "OBSERVATION", 94, 114]]], ["It has increasingly found off-label use in patients with haemophagocytic lymphohistiocytosis (HLH).", [["haemophagocytic lymphohistiocytosis", "DISEASE", 57, 92], ["HLH", "DISEASE", 94, 97], ["patients", "ORGANISM", 43, 51], ["haemophagocytic lymphohistiocytosis", "CANCER", 57, 92], ["patients", "SPECIES", 43, 51], ["haemophagocytic lymphohistiocytosis", "PROBLEM", 57, 92], ["HLH", "PROBLEM", 94, 97], ["haemophagocytic lymphohistiocytosis", "OBSERVATION", 57, 92]]], ["Efficacy data predominantly comes from case series (1, 2) , where it achieves disease remission, normalization of laboratory abnormalities, and resolution of pyrexia from cytokine storm (3, 4) , even in the context of sepsis.", [["pyrexia", "DISEASE", 158, 165], ["sepsis", "DISEASE", 218, 224], ["cytokine", "PROTEIN", 171, 179], ["Efficacy data", "TEST", 0, 13], ["disease remission", "PROBLEM", 78, 95], ["laboratory abnormalities", "PROBLEM", 114, 138], ["pyrexia", "PROBLEM", 158, 165], ["cytokine storm", "PROBLEM", 171, 185], ["sepsis", "PROBLEM", 218, 224], ["pyrexia", "OBSERVATION", 158, 165], ["sepsis", "OBSERVATION", 218, 224]]], ["Traditionally given subcutaneously, the intravenous form is safe at doses up to 10mg/kg (5) .", [["subcutaneously", "ANATOMY", 20, 34], ["intravenous", "ANATOMY", 40, 51], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 40, 51]]], ["Despite the limited evidence, consensus guidelines support its use in the treatment algorithm of cytokine storm (6) .IntroductionCOVID-19 typically presents with fever, dry cough and dyspnea, although the array of symptoms is wide.", [["fever", "DISEASE", 162, 167], ["dry cough", "DISEASE", 169, 178], ["dyspnea", "DISEASE", 183, 190], ["cytokine", "PROTEIN", 97, 105], ["the treatment algorithm of cytokine storm", "TREATMENT", 70, 111], ["IntroductionCOVID", "TEST", 117, 134], ["fever", "PROBLEM", 162, 167], ["dry cough", "PROBLEM", 169, 178], ["dyspnea", "PROBLEM", 183, 190], ["symptoms", "PROBLEM", 214, 222], ["cough", "OBSERVATION", 173, 178], ["dyspnea", "OBSERVATION", 183, 190], ["wide", "OBSERVATION_MODIFIER", 226, 230]]], ["Mean time-lag from symptom onset to dyspnea is 5-8 days, and to acute respiratory distress syndrome (ARDS) is 8-14 days (7, 8) .", [["respiratory", "ANATOMY", 70, 81], ["dyspnea", "DISEASE", 36, 43], ["acute respiratory distress syndrome", "DISEASE", 64, 99], ["ARDS", "DISEASE", 101, 105], ["Mean time", "TEST", 0, 9], ["symptom", "PROBLEM", 19, 26], ["dyspnea", "PROBLEM", 36, 43], ["acute respiratory distress syndrome", "PROBLEM", 64, 99], ["ARDS", "PROBLEM", 101, 105], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["respiratory distress", "OBSERVATION", 70, 90], ["ARDS", "OBSERVATION", 101, 105]]], ["ARDS affects 8-19% of patients (3) , and these patients have increased risk of cytokine storm and progressive multi-organ damage.", [["multi-organ", "ANATOMY", 110, 121], ["ARDS", "DISEASE", 0, 4], ["multi-organ damage", "DISEASE", 110, 128], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 47, 55], ["multi-organ", "ORGAN", 110, 121], ["cytokine", "PROTEIN", 79, 87], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 47, 55], ["ARDS affects", "PROBLEM", 0, 12], ["cytokine storm", "PROBLEM", 79, 93], ["progressive multi-organ damage", "PROBLEM", 98, 128], ["cytokine storm", "OBSERVATION", 79, 93], ["progressive", "OBSERVATION_MODIFIER", 98, 109], ["multi-organ damage", "OBSERVATION", 110, 128]]], ["Severe COVID-19 is more common in older patients, and those with certain comorbidities including obesity, diabetes and cardiovascular disease (9) .IntroductionSevere COVID-19 is characterised by prominent alveolar damage, with focal reactive hyperplasia of pneumocytes, patchy inflammatory cellular infiltration as well as intravascular thrombosis.", [["cardiovascular", "ANATOMY", 119, 133], ["alveolar", "ANATOMY", 205, 213], ["pneumocytes", "ANATOMY", 257, 268], ["cellular", "ANATOMY", 290, 298], ["intravascular", "ANATOMY", 323, 336], ["obesity", "DISEASE", 97, 104], ["diabetes", "DISEASE", 106, 114], ["cardiovascular disease", "DISEASE", 119, 141], ["alveolar damage", "DISEASE", 205, 220], ["intravascular thrombosis", "DISEASE", 323, 347], ["patients", "ORGANISM", 40, 48], ["alveolar", "TISSUE", 205, 213], ["pneumocytes", "CELL", 257, 268], ["cellular", "CELL", 290, 298], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 323, 336], ["patients", "SPECIES", 40, 48], ["Severe COVID", "PROBLEM", 0, 12], ["certain comorbidities", "PROBLEM", 65, 86], ["obesity", "PROBLEM", 97, 104], ["diabetes", "PROBLEM", 106, 114], ["cardiovascular disease", "PROBLEM", 119, 141], ["IntroductionSevere COVID", "TEST", 147, 171], ["prominent alveolar damage", "PROBLEM", 195, 220], ["focal reactive hyperplasia of pneumocytes", "PROBLEM", 227, 268], ["patchy inflammatory cellular infiltration", "PROBLEM", 270, 311], ["intravascular thrombosis", "PROBLEM", 323, 347], ["more common", "OBSERVATION_MODIFIER", 19, 30], ["obesity", "OBSERVATION", 97, 104], ["diabetes", "OBSERVATION", 106, 114], ["cardiovascular disease", "OBSERVATION", 119, 141], ["prominent", "OBSERVATION_MODIFIER", 195, 204], ["alveolar damage", "OBSERVATION", 205, 220], ["focal", "OBSERVATION_MODIFIER", 227, 232], ["reactive", "OBSERVATION_MODIFIER", 233, 241], ["hyperplasia", "OBSERVATION", 242, 253], ["pneumocytes", "OBSERVATION", 257, 268], ["patchy", "OBSERVATION_MODIFIER", 270, 276], ["inflammatory", "OBSERVATION_MODIFIER", 277, 289], ["cellular infiltration", "OBSERVATION", 290, 311], ["intravascular", "OBSERVATION_MODIFIER", 323, 336], ["thrombosis", "OBSERVATION", 337, 347]]], ["Key pathological cells include CD4+ and CD8+ T cells and macrophages.", [["cells", "ANATOMY", 17, 22], ["CD4+", "ANATOMY", 31, 35], ["CD8+ T cells", "ANATOMY", 40, 52], ["macrophages", "ANATOMY", 57, 68], ["cells", "CELL", 17, 22], ["CD4", "GENE_OR_GENE_PRODUCT", 31, 34], ["CD8", "GENE_OR_GENE_PRODUCT", 40, 43], ["macrophages", "CELL", 57, 68], ["CD4", "PROTEIN", 31, 34], ["CD8+ T cells", "CELL_TYPE", 40, 52], ["macrophages", "CELL_TYPE", 57, 68], ["Key pathological cells", "TEST", 0, 22], ["CD4", "TEST", 31, 34], ["CD8", "TEST", 40, 43], ["macrophages", "PROBLEM", 57, 68], ["macrophages", "ANATOMY", 57, 68]]], ["The cytokine profile is similar to HLH, with increased interleukin (IL)-6, IL-1\u03b2, IL-10, granulocyte macrophage -colony stimulating factor (GM-CSF), interferon-\u03b3 (IFN-\u03b3) macrophage inflammatory protein 1-\u03b1, monocyte chemoattractant protein-1 (MCP-1), and tumour necrosis factor-\u03b1 (3, 10, 11).IntroductionSARS-CoV2 evades a number of immune system recognition points which usually initiate viralmediated immunity.", [["immune system", "ANATOMY", 333, 346], ["HLH", "DISEASE", 35, 38], ["necrosis", "DISEASE", 262, 270], ["interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 55, 73], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 75, 80], ["IL-10", "GENE_OR_GENE_PRODUCT", 82, 87], ["granulocyte macrophage -colony stimulating factor", "GENE_OR_GENE_PRODUCT", 89, 138], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 140, 146], ["interferon-\u03b3", "GENE_OR_GENE_PRODUCT", 149, 161], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 163, 168], ["macrophage inflammatory protein 1-\u03b1", "GENE_OR_GENE_PRODUCT", 170, 205], ["monocyte chemoattractant protein-1", "GENE_OR_GENE_PRODUCT", 207, 241], ["MCP-1", "GENE_OR_GENE_PRODUCT", 243, 248], ["tumour necrosis factor-\u03b1", "GENE_OR_GENE_PRODUCT", 255, 279], ["IntroductionSARS-CoV2", "GENE_OR_GENE_PRODUCT", 292, 313], ["cytokine", "PROTEIN", 4, 12], ["interleukin (IL)-6", "PROTEIN", 55, 73], ["IL-10", "PROTEIN", 82, 87], ["granulocyte macrophage -colony stimulating factor", "PROTEIN", 89, 138], ["CSF", "PROTEIN", 143, 146], ["interferon-\u03b3 (IFN-\u03b3) macrophage inflammatory protein 1-\u03b1", "PROTEIN", 149, 205], ["monocyte chemoattractant protein-1", "PROTEIN", 207, 241], ["MCP", "PROTEIN", 243, 246], ["tumour necrosis factor", "PROTEIN", 255, 277], ["CoV2", "PROTEIN", 309, 313], ["The cytokine profile", "TEST", 0, 20], ["HLH", "PROBLEM", 35, 38], ["increased interleukin (IL)", "TEST", 45, 71], ["IL", "TEST", 75, 77], ["IL", "TEST", 82, 84], ["granulocyte macrophage", "TEST", 89, 111], ["colony stimulating factor", "TEST", 113, 138], ["GM", "TEST", 140, 142], ["CSF", "TEST", 143, 146], ["interferon", "TEST", 149, 159], ["IFN", "TEST", 163, 166], ["macrophage inflammatory protein", "TEST", 170, 201], ["monocyte chemoattractant protein", "TEST", 207, 239], ["MCP", "TEST", 243, 246], ["tumour necrosis factor", "PROBLEM", 255, 277], ["IntroductionSARS", "TEST", 292, 308], ["HLH", "OBSERVATION", 35, 38], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["granulocyte", "ANATOMY", 89, 100], ["tumour necrosis", "OBSERVATION", 255, 270]]], ["The activation of innate immune cells by infected macrophages results in the expression of pro-inflammatory IL-1, IL-6 and TNF-\u03b1 production through the NF-\u03baB pathway.", [["immune cells", "ANATOMY", 25, 37], ["macrophages", "ANATOMY", 50, 61], ["innate immune cells", "CELL", 18, 37], ["macrophages", "CELL", 50, 61], ["IL-1", "GENE_OR_GENE_PRODUCT", 108, 112], ["IL-6", "GENE_OR_GENE_PRODUCT", 114, 118], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 123, 128], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 152, 157], ["innate immune cells", "CELL_TYPE", 18, 37], ["infected macrophages", "CELL_TYPE", 41, 61], ["TNF", "PROTEIN", 123, 126], ["NF-\u03baB", "PROTEIN", 152, 157], ["innate immune cells", "TREATMENT", 18, 37], ["infected macrophages", "PROBLEM", 41, 61], ["pro-inflammatory IL", "TEST", 91, 110], ["IL", "TEST", 114, 116], ["TNF", "TEST", 123, 126], ["innate immune cells", "OBSERVATION", 18, 37], ["infected macrophages", "OBSERVATION", 41, 61], ["pro-inflammatory", "OBSERVATION_MODIFIER", 91, 107]]], ["The concentrations of these cytokines continue to increase via a process of auto-amplification, and recruit adaptive immune cells (12) .IntroductionAberrant CD4+ T cell activation releases IFN-\u03b3 and GM-CSF.", [["immune cells", "ANATOMY", 117, 129], ["CD4+ T cell", "ANATOMY", 157, 168], ["immune cells", "CELL", 117, 129], ["CD4", "GENE_OR_GENE_PRODUCT", 157, 160], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 189, 194], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 199, 205], ["cytokines", "PROTEIN", 28, 37], ["adaptive immune cells", "CELL_TYPE", 108, 129], ["CD4", "PROTEIN", 157, 160], ["IFN", "PROTEIN", 189, 192], ["\u03b3", "PROTEIN", 193, 194], ["GM", "PROTEIN", 199, 201], ["CSF", "PROTEIN", 202, 205], ["these cytokines", "TREATMENT", 22, 37], ["auto-amplification", "TREATMENT", 76, 94], ["IntroductionAberrant", "TEST", 136, 156], ["IFN", "TEST", 189, 192], ["GM", "TEST", 199, 201], ["CSF", "ANATOMY", 202, 205]]], ["The GM-CSF results in increased CD14+ CD16+ inflammatory monocyte subsets, a subset rarely seen at significant levels in health (13) .", [["CD14+ CD16+ inflammatory monocyte", "ANATOMY", 32, 65], ["GM", "CHEMICAL", 4, 6], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 4, 10], ["CD14", "GENE_OR_GENE_PRODUCT", 32, 36], ["CD16", "GENE_OR_GENE_PRODUCT", 38, 42], ["CSF", "PROTEIN", 7, 10], ["CD14", "PROTEIN", 32, 36], ["CD16", "PROTEIN", 38, 42], ["inflammatory monocyte subsets", "CELL_TYPE", 44, 73], ["The GM", "TEST", 0, 6], ["CSF results", "TEST", 7, 18], ["increased CD14", "TEST", 22, 36], ["CD16", "TEST", 38, 42], ["inflammatory monocyte subsets", "PROBLEM", 44, 73], ["increased", "OBSERVATION_MODIFIER", 22, 31], ["inflammatory monocyte subsets", "OBSERVATION", 44, 73]]], ["This subset of monocytes express increased levels of IL-6 which are likely to be responsible for the acceleration and progression of a systemic ihinflammatory response.IntroductionIL-1 and related pro-inflammatory pathways intertwined with aberrant T-cell responses play a crucial role in disease severity (14) .", [["monocytes", "ANATOMY", 15, 24], ["T-cell", "ANATOMY", 249, 255], ["monocytes", "CELL", 15, 24], ["IL-6", "GENE_OR_GENE_PRODUCT", 53, 57], ["IntroductionIL-1", "GENE_OR_GENE_PRODUCT", 168, 184], ["T-cell", "CELL", 249, 255], ["monocytes", "CELL_TYPE", 15, 24], ["IL-6", "PROTEIN", 53, 57], ["increased levels of IL", "PROBLEM", 33, 55], ["the acceleration", "PROBLEM", 97, 113], ["a systemic ihinflammatory response", "PROBLEM", 133, 167], ["IntroductionIL", "TREATMENT", 168, 182], ["disease severity", "PROBLEM", 289, 305], ["monocytes", "OBSERVATION", 15, 24], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["levels", "OBSERVATION_MODIFIER", 43, 49], ["likely to be responsible for", "UNCERTAINTY", 68, 96], ["systemic", "OBSERVATION_MODIFIER", 135, 143], ["ihinflammatory response", "OBSERVATION", 144, 167]]], ["Elevated ferritin and IL-6 concentrations correlate with mortality (15) .IntroductionWe define hyperinflammation by this systemic inflammatory response, which has strong similarities to that seen in cytokine release syndrome.", [["hyperinflammation", "DISEASE", 95, 112], ["ferritin", "GENE_OR_GENE_PRODUCT", 9, 17], ["IL-6", "GENE_OR_GENE_PRODUCT", 22, 26], ["ferritin", "PROTEIN", 9, 17], ["cytokine", "PROTEIN", 199, 207], ["Elevated ferritin", "PROBLEM", 0, 17], ["IL", "TEST", 22, 24], ["hyperinflammation", "PROBLEM", 95, 112], ["this systemic inflammatory response", "PROBLEM", 116, 151], ["cytokine release syndrome", "PROBLEM", 199, 224], ["ferritin", "OBSERVATION", 9, 17], ["hyperinflammation", "OBSERVATION", 95, 112], ["systemic", "OBSERVATION_MODIFIER", 121, 129], ["inflammatory", "OBSERVATION", 130, 142], ["cytokine release syndrome", "OBSERVATION", 199, 224]]], ["One current treatment strategy is controlling hyperinflammation with targeted immunosuppression.IntroductionWe describe a cohort of patients with severe SARS-CoV-2 infection admitted to the intensive care unit during the pandemic, with elevated ferritins between 4,000 -30,000 \uf06dg/L. All four patients were diagnosed with COVID-19 and required ventilatory support.", [["hyperinflammation", "DISEASE", 46, 63], ["SARS-CoV-2 infection", "DISEASE", 153, 173], ["patients", "ORGANISM", 132, 140], ["ferritins", "GENE_OR_GENE_PRODUCT", 245, 254], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 292, 300], ["One current treatment strategy", "TREATMENT", 0, 30], ["hyperinflammation", "PROBLEM", 46, 63], ["targeted immunosuppression", "TREATMENT", 69, 95], ["severe SARS", "PROBLEM", 146, 157], ["CoV-2 infection", "PROBLEM", 158, 173], ["the pandemic", "PROBLEM", 217, 229], ["elevated ferritins", "PROBLEM", 236, 254], ["COVID", "TEST", 321, 326], ["ventilatory support", "TREATMENT", 343, 362], ["immunosuppression", "OBSERVATION", 78, 95], ["severe", "OBSERVATION_MODIFIER", 146, 152], ["SARS", "OBSERVATION", 153, 157], ["ventilatory support", "OBSERVATION", 343, 362]]], ["These patients all showed evidence of hyperinflammation with raised inflammatory markers, and CRP, and were given intravenous anakinra, with safe and successful use, suggesting the potential benefit from IL-1 blockade in this subgroup of patients with confirmed COVID-19.Case 1:30-year-old gentleman with a background of end stage renal failure (ESRF) secondary to birth asphyxia, and a DBD (donation after brainstem death) renal transplant (baseline creatinine 290 \uf06dmol/L), maintained on sirolimus and tacrolimus.", [["intravenous", "ANATOMY", 114, 125], ["renal", "ANATOMY", 331, 336], ["brainstem", "ANATOMY", 407, 416], ["renal", "ANATOMY", 424, 429], ["hyperinflammation", "DISEASE", 38, 55], ["anakinra", "CHEMICAL", 126, 134], ["end stage renal failure", "DISEASE", 321, 344], ["ESRF", "DISEASE", 346, 350], ["birth asphyxia", "DISEASE", 365, 379], ["death", "DISEASE", 417, 422], ["creatinine", "CHEMICAL", 451, 461], ["sirolimus", "CHEMICAL", 489, 498], ["tacrolimus", "CHEMICAL", 503, 513], ["COVID-19", "CHEMICAL", 262, 270], ["creatinine", "CHEMICAL", 451, 461], ["sirolimus", "CHEMICAL", 489, 498], ["tacrolimus", "CHEMICAL", 503, 513], ["patients", "ORGANISM", 6, 14], ["CRP", "GENE_OR_GENE_PRODUCT", 94, 97], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 125], ["anakinra", "SIMPLE_CHEMICAL", 126, 134], ["IL-1", "GENE_OR_GENE_PRODUCT", 204, 208], ["patients", "ORGANISM", 238, 246], ["gentleman", "ORGANISM", 290, 299], ["renal", "ORGAN", 331, 336], ["brainstem", "ORGANISM_SUBDIVISION", 407, 416], ["renal", "ORGAN", 424, 429], ["sirolimus", "SIMPLE_CHEMICAL", 489, 498], ["tacrolimus", "SIMPLE_CHEMICAL", 503, 513], ["inflammatory markers", "PROTEIN", 68, 88], ["CRP", "PROTEIN", 94, 97], ["IL", "PROTEIN", 204, 206], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 238, 246], ["hyperinflammation", "PROBLEM", 38, 55], ["raised inflammatory markers", "PROBLEM", 61, 88], ["CRP", "TEST", 94, 97], ["intravenous anakinra", "TREATMENT", 114, 134], ["IL-1 blockade", "TREATMENT", 204, 217], ["COVID", "TEST", 262, 267], ["end stage renal failure", "PROBLEM", 321, 344], ["ESRF)", "PROBLEM", 346, 351], ["birth asphyxia", "PROBLEM", 365, 379], ["a DBD (donation", "TREATMENT", 385, 400], ["brainstem death", "PROBLEM", 407, 422], ["renal transplant", "TREATMENT", 424, 440], ["baseline creatinine", "TEST", 442, 461], ["sirolimus", "TREATMENT", 489, 498], ["tacrolimus", "TREATMENT", 503, 513], ["evidence of", "UNCERTAINTY", 26, 37], ["hyperinflammation", "OBSERVATION", 38, 55], ["inflammatory", "OBSERVATION_MODIFIER", 68, 80], ["end stage", "OBSERVATION_MODIFIER", 321, 330], ["renal", "ANATOMY", 331, 336], ["failure", "OBSERVATION", 337, 344], ["asphyxia", "OBSERVATION", 371, 379], ["renal", "ANATOMY", 424, 429], ["transplant", "OBSERVATION", 430, 440]]], ["This was the patients' second transplant, the first being complicated by graft rejection, MAHA and requiring graft nephrectomy in 2013.", [["graft", "ANATOMY", 73, 78], ["graft", "ANATOMY", 109, 114], ["MAHA", "DISEASE", 90, 94], ["patients", "ORGANISM", 13, 21], ["graft", "TISSUE", 73, 78], ["graft", "TISSUE", 109, 114], ["patients", "SPECIES", 13, 21], ["the patients' second transplant", "TREATMENT", 9, 40], ["graft rejection", "PROBLEM", 73, 88], ["MAHA", "PROBLEM", 90, 94], ["graft nephrectomy", "TREATMENT", 109, 126], ["graft rejection", "OBSERVATION", 73, 88], ["graft nephrectomy", "OBSERVATION", 109, 126]]], ["The current transplant had taken place over a year prior to the current presentation, of which he had had one episode of BL nephropathy treated with steroids.", [["nephropathy", "DISEASE", 124, 135], ["steroids", "CHEMICAL", 149, 157], ["steroids", "CHEMICAL", 149, 157], ["The current transplant", "TREATMENT", 0, 22], ["BL nephropathy", "PROBLEM", 121, 135], ["steroids", "TREATMENT", 149, 157], ["transplant", "OBSERVATION", 12, 22], ["BL nephropathy", "OBSERVATION", 121, 135]]], ["He had been stable following this, with no significant infections.", [["infections", "DISEASE", 55, 65], ["He", "ORGANISM", 0, 2], ["significant infections", "PROBLEM", 43, 65], ["stable", "OBSERVATION_MODIFIER", 12, 18], ["no", "UNCERTAINTY", 40, 42], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["infections", "OBSERVATION", 55, 65]]], ["He presented with a 14-day history of feeling unwell with fevers, and a 5-day history of a cough, sore throat and difficulty breathing.Case 1:Initial saturations were 80% on room air, which improved to 100% on 35% oxygen via a venturi face mask.", [["fevers", "DISEASE", 58, 64], ["cough", "DISEASE", 91, 96], ["sore throat", "DISEASE", 98, 109], ["difficulty breathing", "DISEASE", 114, 134], ["oxygen", "CHEMICAL", 214, 220], ["oxygen", "CHEMICAL", 214, 220], ["oxygen", "SIMPLE_CHEMICAL", 214, 220], ["feeling unwell", "PROBLEM", 38, 52], ["fevers", "PROBLEM", 58, 64], ["a cough", "PROBLEM", 89, 96], ["sore throat", "PROBLEM", 98, 109], ["difficulty breathing", "PROBLEM", 114, 134], ["Initial saturations", "TEST", 142, 161], ["35% oxygen", "TREATMENT", 210, 220], ["a venturi face mask", "TREATMENT", 225, 244], ["fevers", "OBSERVATION", 58, 64], ["cough", "OBSERVATION", 91, 96], ["throat", "ANATOMY", 103, 109]]], ["His blood pressure (BP) was 127/73 mmHg, heart rate 95/min, temperature 38 o C, respiratory rate (RR) 21/min.", [["blood", "ANATOMY", 4, 9], ["heart", "ANATOMY", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["heart", "ORGAN", 41, 46], ["His blood pressure", "TEST", 0, 18], ["BP", "TEST", 20, 22], ["heart rate", "TEST", 41, 51], ["temperature", "TEST", 60, 71], ["respiratory rate", "TEST", 80, 96], ["RR", "TEST", 98, 100], ["heart", "ANATOMY", 41, 46]]], ["Chest X-ray (CXR) showed bilateral patchy consolidation and nasopharyngeal swab (NPS) confirmed SARS-CoV-2.", [["nasopharyngeal swab", "ANATOMY", 60, 79], ["SARS", "DISEASE", 96, 100], ["nasopharyngeal swab", "CANCER", 60, 79], ["Chest X-ray", "TEST", 0, 11], ["CXR", "TEST", 13, 16], ["bilateral patchy consolidation", "PROBLEM", 25, 55], ["nasopharyngeal swab (NPS", "TEST", 60, 84], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["bilateral", "ANATOMY_MODIFIER", 25, 34], ["patchy", "OBSERVATION_MODIFIER", 35, 41], ["consolidation", "OBSERVATION", 42, 55], ["nasopharyngeal swab", "ANATOMY", 60, 79]]], ["Blood tests revealed ferritin of 24617 \uf06dg/L, creatinine 519 \u00b5mol/L, CRP 92mg/l.Case 1:Oxygen was titrated to keep his saturations above 94%, and he was initiated on co-amoxiclav.", [["Blood", "ANATOMY", 0, 5], ["creatinine", "CHEMICAL", 45, 55], ["Oxygen", "CHEMICAL", 86, 92], ["co-amoxiclav", "CHEMICAL", 165, 177], ["creatinine", "CHEMICAL", 45, 55], ["Oxygen", "CHEMICAL", 86, 92], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["ferritin", "GENE_OR_GENE_PRODUCT", 21, 29], ["creatinine", "SIMPLE_CHEMICAL", 45, 55], ["Oxygen", "SIMPLE_CHEMICAL", 86, 92], ["co-amoxiclav", "SIMPLE_CHEMICAL", 165, 177], ["ferritin", "PROTEIN", 21, 29], ["CRP", "PROTEIN", 68, 71], ["Blood tests", "TEST", 0, 11], ["ferritin", "TEST", 21, 29], ["\uf06dg", "TEST", 39, 41], ["creatinine", "TEST", 45, 55], ["\u00b5mol", "TEST", 60, 64], ["CRP", "TEST", 68, 71], ["Oxygen", "TREATMENT", 86, 92], ["his saturations", "TEST", 114, 129], ["co-amoxiclav", "TREATMENT", 165, 177]]], ["After two days, with increasing oxygen requirements and progressive CXR consolidation, he was transferred to the ICU where he was commenced on CPAP (continuous positive airway pressure).Case 1:The sirolimus was stopped but he remained on tacrolimus.", [["airway", "ANATOMY", 169, 175], ["oxygen", "CHEMICAL", 32, 38], ["sirolimus", "CHEMICAL", 197, 206], ["tacrolimus", "CHEMICAL", 238, 248], ["oxygen", "CHEMICAL", 32, 38], ["CPAP", "CHEMICAL", 143, 147], ["sirolimus", "CHEMICAL", 197, 206], ["tacrolimus", "CHEMICAL", 238, 248], ["oxygen", "SIMPLE_CHEMICAL", 32, 38], ["airway", "MULTI-TISSUE_STRUCTURE", 169, 175], ["sirolimus", "SIMPLE_CHEMICAL", 197, 206], ["tacrolimus", "SIMPLE_CHEMICAL", 238, 248], ["increasing oxygen requirements", "PROBLEM", 21, 51], ["progressive CXR consolidation", "PROBLEM", 56, 85], ["CPAP", "TREATMENT", 143, 147], ["continuous positive airway pressure", "TREATMENT", 149, 184], ["The sirolimus", "TREATMENT", 193, 206], ["tacrolimus", "TREATMENT", 238, 248], ["increasing", "OBSERVATION_MODIFIER", 21, 31], ["oxygen requirements", "OBSERVATION", 32, 51], ["progressive", "OBSERVATION_MODIFIER", 56, 67], ["CXR", "OBSERVATION_MODIFIER", 68, 71], ["consolidation", "OBSERVATION", 72, 85]]], ["Ferritin at the time was 23788 \uf06dg/L, CRP 73mg/l, and procalcitonin 17.27 mcg/L (normal range <0.5mcg/L).", [["Ferritin", "GENE_OR_GENE_PRODUCT", 0, 8], ["CRP", "GENE_OR_GENE_PRODUCT", 37, 40], ["CRP", "PROTEIN", 37, 40], ["Ferritin", "TEST", 0, 8], ["CRP", "TEST", 37, 40], ["procalcitonin", "TEST", 53, 66]]], ["Microscopy from blood cultures and urine cultures were all negative, and CMV and EBV viraemias remained very low level.", [["blood cultures", "ANATOMY", 16, 30], ["urine cultures", "ANATOMY", 35, 49], ["blood cultures", "ORGANISM_SUBSTANCE", 16, 30], ["urine cultures", "ORGANISM_SUBSTANCE", 35, 49], ["CMV", "ORGANISM", 73, 76], ["EBV", "ORGANISM", 81, 84], ["CMV", "SPECIES", 73, 76], ["EBV", "SPECIES", 81, 84], ["Microscopy", "TEST", 0, 10], ["blood cultures", "TEST", 16, 30], ["urine cultures", "TEST", 35, 49], ["CMV", "TEST", 73, 76], ["EBV viraemias", "TEST", 81, 94]]], ["Given the increasing oxygen requirement, and persistent inflammatory state, intravenous anakinra 200mg was initiated (Table 1) .", [["intravenous", "ANATOMY", 76, 87], ["oxygen", "CHEMICAL", 21, 27], ["anakinra", "CHEMICAL", 88, 96], ["oxygen", "CHEMICAL", 21, 27], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 76, 87], ["anakinra", "SIMPLE_CHEMICAL", 88, 96], ["the increasing oxygen requirement", "PROBLEM", 6, 39], ["persistent inflammatory state", "PROBLEM", 45, 74], ["intravenous anakinra", "TREATMENT", 76, 96], ["increasing", "OBSERVATION_MODIFIER", 10, 20], ["oxygen requirement", "OBSERVATION", 21, 39], ["persistent", "OBSERVATION_MODIFIER", 45, 55], ["inflammatory", "OBSERVATION_MODIFIER", 56, 68]]], ["A marked improvement in ferritin was seen within two days, CRP steadily decreased ( Figure 1 ), creatinine improved, and his respiratory effort stabilised.", [["respiratory", "ANATOMY", 125, 136], ["creatinine", "CHEMICAL", 96, 106], ["creatinine", "CHEMICAL", 96, 106], ["ferritin", "GENE_OR_GENE_PRODUCT", 24, 32], ["CRP", "GENE_OR_GENE_PRODUCT", 59, 62], ["creatinine", "SIMPLE_CHEMICAL", 96, 106], ["ferritin", "PROTEIN", 24, 32], ["CRP", "PROTEIN", 59, 62], ["A marked improvement in ferritin", "PROBLEM", 0, 32], ["CRP", "TEST", 59, 62], ["creatinine", "TEST", 96, 106], ["his respiratory effort", "TEST", 121, 143], ["marked", "OBSERVATION_MODIFIER", 2, 8], ["improvement", "OBSERVATION_MODIFIER", 9, 20], ["ferritin", "OBSERVATION", 24, 32], ["respiratory effort", "OBSERVATION", 125, 143]]], ["After 3 days of CPAP, he was weaned off, and stepped down to the ward.", [["CPAP", "TREATMENT", 16, 20]]], ["Intravenous anakinra was stopped on day 10, where the ferritin was 4969 \uf06dg/l.", [["anakinra", "CHEMICAL", 12, 20], ["anakinra", "SIMPLE_CHEMICAL", 12, 20], ["ferritin", "GENE_OR_GENE_PRODUCT", 54, 62], ["ferritin", "PROTEIN", 54, 62], ["Intravenous anakinra", "TREATMENT", 0, 20], ["the ferritin", "TEST", 50, 62]]], ["He was discharged on day 12 with a creatinine of 371 \u00b5mol/L, and CRP 7mg/l and remained on tacrolimus.Case 2:48-year-old gentleman was admitted 11 days after having a DBD renal transplant for ESRF secondary to IgA nephropathy.", [["renal", "ANATOMY", 171, 176], ["creatinine", "CHEMICAL", 35, 45], ["tacrolimus", "CHEMICAL", 91, 101], ["ESRF", "DISEASE", 192, 196], ["IgA nephropathy", "DISEASE", 210, 225], ["creatinine", "CHEMICAL", 35, 45], ["tacrolimus", "CHEMICAL", 91, 101], ["creatinine", "SIMPLE_CHEMICAL", 35, 45], ["CRP", "GENE_OR_GENE_PRODUCT", 65, 68], ["tacrolimus", "SIMPLE_CHEMICAL", 91, 101], ["gentleman", "ORGANISM", 121, 130], ["renal", "ORGAN", 171, 176], ["IgA", "GENE_OR_GENE_PRODUCT", 210, 213], ["CRP", "PROTEIN", 65, 68], ["a creatinine", "TEST", 33, 45], ["CRP", "TEST", 65, 68], ["tacrolimus", "TREATMENT", 91, 101], ["a DBD renal transplant", "TREATMENT", 165, 187], ["ESRF", "PROBLEM", 192, 196], ["IgA nephropathy", "PROBLEM", 210, 225], ["renal", "ANATOMY", 171, 176], ["transplant", "OBSERVATION", 177, 187], ["IgA nephropathy", "OBSERVATION", 210, 225]]], ["The transplant itself was uneventful.", [["The transplant", "TREATMENT", 0, 14], ["transplant", "OBSERVATION", 4, 14]]], ["His other past medical history comprised of transfusion dependent beta-thalassaemia intermedia (baseline ferritin was 2236 \u03bcg/L), and splenectomy.", [["beta-thalassaemia intermedia", "DISEASE", 66, 94], ["beta-thalassaemia intermedia", "GENE_OR_GENE_PRODUCT", 66, 94], ["ferritin", "GENE_OR_GENE_PRODUCT", 105, 113], ["transfusion dependent", "PROBLEM", 44, 65], ["thalassaemia intermedia", "PROBLEM", 71, 94], ["baseline ferritin", "TEST", 96, 113], ["splenectomy", "TREATMENT", 134, 145], ["splenectomy", "OBSERVATION", 134, 145]]], ["He was discharged on tacrolimus, mycophenolate mofetil and prednisolone.Case 2:He was readmitted 6 days later with a 2-day history of dry cough, dyspnoea, and self-recorded pyrexia of 38\u00b0C. Examination revealed coarse crepitations predominantly on the right, saturations of 97% of room air, RR 18/min, BP 161/84 mmHg.", [["tacrolimus", "CHEMICAL", 21, 31], ["mycophenolate mofetil", "CHEMICAL", 33, 54], ["prednisolone", "CHEMICAL", 59, 71], ["dry cough", "DISEASE", 134, 143], ["dyspnoea", "DISEASE", 145, 153], ["pyrexia", "DISEASE", 173, 180], ["tacrolimus", "CHEMICAL", 21, 31], ["mycophenolate mofetil", "CHEMICAL", 33, 54], ["prednisolone", "CHEMICAL", 59, 71], ["tacrolimus", "SIMPLE_CHEMICAL", 21, 31], ["mycophenolate mofetil", "SIMPLE_CHEMICAL", 33, 54], ["prednisolone", "SIMPLE_CHEMICAL", 59, 71], ["He", "ORGANISM", 79, 81], ["tacrolimus", "TREATMENT", 21, 31], ["mycophenolate mofetil", "TREATMENT", 33, 54], ["prednisolone", "TREATMENT", 59, 71], ["dry cough", "PROBLEM", 134, 143], ["dyspnoea", "PROBLEM", 145, 153], ["self-recorded pyrexia", "PROBLEM", 159, 180], ["Examination", "TEST", 190, 201], ["coarse crepitations", "PROBLEM", 211, 230], ["saturations", "TEST", 259, 270], ["RR", "TEST", 291, 293], ["BP", "TEST", 302, 304], ["cough", "OBSERVATION", 138, 143], ["dyspnoea", "OBSERVATION", 145, 153], ["coarse", "OBSERVATION_MODIFIER", 211, 217], ["crepitations", "OBSERVATION_MODIFIER", 218, 230], ["predominantly", "OBSERVATION_MODIFIER", 231, 244], ["right", "ANATOMY_MODIFIER", 252, 257]]], ["Blood tests showed a ferritin 4054\u03bcg/l, CRP 84mg/l, and procalcitonin of 1.71mcg/L. CXR showed consolidation in the right mid and lower zones, and NPS confirmed SARS-CoV-2.", [["Blood", "ANATOMY", 0, 5], ["right mid", "ANATOMY", 116, 125], ["lower zones", "ANATOMY", 130, 141], ["SARS", "DISEASE", 161, 165], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["ferritin", "GENE_OR_GENE_PRODUCT", 21, 29], ["CRP", "GENE_OR_GENE_PRODUCT", 40, 43], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 56, 69], ["ferritin", "PROTEIN", 21, 29], ["CRP", "PROTEIN", 40, 43], ["CXR", "PROTEIN", 84, 87], ["Blood tests", "TEST", 0, 11], ["a ferritin", "TEST", 19, 29], ["CRP", "TEST", 40, 43], ["procalcitonin", "TEST", 56, 69], ["CXR", "TEST", 84, 87], ["consolidation in the right mid and lower zones", "PROBLEM", 95, 141], ["NPS", "TEST", 147, 150], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169], ["consolidation", "OBSERVATION", 95, 108], ["right", "ANATOMY_MODIFIER", 116, 121], ["mid", "ANATOMY_MODIFIER", 122, 125], ["lower", "ANATOMY_MODIFIER", 130, 135], ["zones", "ANATOMY_MODIFIER", 136, 141], ["SARS", "OBSERVATION", 161, 165]]], ["Ceftriaxone was initiated.Case 2:On day 2, his oxygen requirement increased with worsening bilateral mid zone air space shadowing.Case 2:He was commenced on CPAP 5 days after admission and underwent endotracheal intubation on day 7.", [["endotracheal", "ANATOMY", 199, 211], ["Ceftriaxone", "CHEMICAL", 0, 11], ["oxygen", "CHEMICAL", 47, 53], ["Ceftriaxone", "CHEMICAL", 0, 11], ["oxygen", "CHEMICAL", 47, 53], ["Ceftriaxone", "SIMPLE_CHEMICAL", 0, 11], ["oxygen", "SIMPLE_CHEMICAL", 47, 53], ["He", "ORGANISM", 137, 139], ["Ceftriaxone", "TREATMENT", 0, 11], ["his oxygen requirement", "PROBLEM", 43, 65], ["worsening bilateral mid zone air space shadowing", "PROBLEM", 81, 129], ["CPAP", "TREATMENT", 157, 161], ["endotracheal intubation", "TREATMENT", 199, 222], ["oxygen requirement", "OBSERVATION", 47, 65], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["worsening", "OBSERVATION_MODIFIER", 81, 90], ["bilateral", "ANATOMY_MODIFIER", 91, 100], ["mid", "ANATOMY_MODIFIER", 101, 104], ["zone", "ANATOMY_MODIFIER", 105, 109], ["air space shadowing", "OBSERVATION", 110, 129], ["endotracheal", "ANATOMY", 199, 211], ["intubation", "OBSERVATION", 212, 222]]], ["Given the clinical deterioration, and rising CRP (170 mg/l) he was commenced on anakinra 200mgCase 2:intravenously once a day (Table 1) .", [["intravenously", "ANATOMY", 101, 114], ["anakinra", "CHEMICAL", 80, 88], ["CRP", "GENE_OR_GENE_PRODUCT", 45, 48], ["anakinra", "SIMPLE_CHEMICAL", 80, 88], ["CRP", "PROTEIN", 45, 48], ["the clinical deterioration", "PROBLEM", 6, 32], ["rising CRP", "PROBLEM", 38, 48], ["anakinra", "TREATMENT", 80, 88]]], ["Following initiation of anakinra, inotropes were weaned within 24 hours, and significant improvement in his blood parameters was noted (ferritin 2687 \uf06dg/l, CRP 26 mg/l).Case 2:His ICU admission was complicated by an Enterococcus faecium bacteraemia on day 9 of admission, for which he completed 7 days of teicoplanin.", [["blood", "ANATOMY", 108, 113], ["anakinra", "CHEMICAL", 24, 32], ["Enterococcus faecium bacteraemia", "DISEASE", 216, 248], ["teicoplanin", "CHEMICAL", 305, 316], ["teicoplanin", "CHEMICAL", 305, 316], ["anakinra", "SIMPLE_CHEMICAL", 24, 32], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["ferritin", "GENE_OR_GENE_PRODUCT", 136, 144], ["teicoplanin", "SIMPLE_CHEMICAL", 305, 316], ["ferritin", "PROTEIN", 136, 144], ["CRP", "PROTEIN", 156, 159], ["Enterococcus faecium", "SPECIES", 216, 236], ["Enterococcus faecium", "SPECIES", 216, 236], ["anakinra", "TREATMENT", 24, 32], ["inotropes", "TREATMENT", 34, 43], ["his blood parameters", "TEST", 104, 124], ["ferritin", "TEST", 136, 144], ["CRP", "TEST", 156, 159], ["an Enterococcus faecium bacteraemia", "PROBLEM", 213, 248], ["teicoplanin", "TREATMENT", 305, 316], ["significant", "OBSERVATION_MODIFIER", 77, 88], ["improvement", "OBSERVATION_MODIFIER", 89, 100], ["Enterococcus", "OBSERVATION", 216, 228], ["faecium bacteraemia", "OBSERVATION", 229, 248]]], ["Anakinra was reduced and stopped after 21 days.Case 2:Following a successful tracheostomy wean, he was discharged on day 45.Case 3:A 68 year old woman with a background of non-Hodgkin's lymphoma (NHL) was re-admitted 2 weeks after being discharged with COVID-19.", [["non-Hodgkin's lymphoma", "ANATOMY", 172, 194], ["NHL", "ANATOMY", 196, 199], ["Anakinra", "CHEMICAL", 0, 8], ["non-Hodgkin's lymphoma", "DISEASE", 172, 194], ["NHL", "DISEASE", 196, 199], ["Anakinra", "CHEMICAL", 0, 8], ["COVID-19", "CHEMICAL", 253, 261], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["woman", "ORGANISM", 145, 150], ["non-Hodgkin's lymphoma", "CANCER", 172, 194], ["NHL", "CANCER", 196, 199], ["woman", "SPECIES", 145, 150], ["Anakinra", "TREATMENT", 0, 8], ["a successful tracheostomy wean", "TREATMENT", 64, 94], ["non-Hodgkin's lymphoma", "PROBLEM", 172, 194], ["COVID", "TEST", 253, 258], ["non-Hodgkin's lymphoma", "OBSERVATION", 172, 194]]], ["She has known follicular lymphoma stage 4A diagnosed in May 2018.", [["follicular lymphoma", "ANATOMY", 14, 33], ["follicular lymphoma", "DISEASE", 14, 33], ["follicular lymphoma", "CANCER", 14, 33], ["known follicular lymphoma", "PROBLEM", 8, 33], ["follicular lymphoma", "OBSERVATION", 14, 33]]], ["She was treated with rituximab, last receiving a dose three months prior to her first admission.", [["rituximab", "CHEMICAL", 21, 30], ["rituximab", "SIMPLE_CHEMICAL", 21, 30], ["rituximab", "TREATMENT", 21, 30]]], ["At the time of her first admission, she presented with a few weeks history of fever, myalgia and a sore throat.", [["fever", "DISEASE", 78, 83], ["myalgia", "DISEASE", 85, 92], ["sore throat", "DISEASE", 99, 110], ["throat", "ORGANISM_SUBDIVISION", 104, 110], ["fever", "PROBLEM", 78, 83], ["myalgia", "PROBLEM", 85, 92], ["a sore throat", "PROBLEM", 97, 110], ["fever", "OBSERVATION", 78, 83], ["myalgia", "OBSERVATION", 85, 92], ["sore throat", "ANATOMY", 99, 110]]], ["She had been given co-amoxiclav and azithromycin in the community, one week prior to admission.", [["co-amoxiclav", "CHEMICAL", 19, 31], ["azithromycin", "CHEMICAL", 36, 48], ["co-amoxiclav", "CHEMICAL", 19, 31], ["azithromycin", "CHEMICAL", 36, 48], ["co-amoxiclav", "SIMPLE_CHEMICAL", 19, 31], ["azithromycin", "SIMPLE_CHEMICAL", 36, 48], ["co-amoxiclav", "TREATMENT", 19, 31], ["azithromycin", "TREATMENT", 36, 48]]], ["Her shortness of breath on exertion was deteriorating, and she was found to have saturations of 89%.", [["shortness of breath", "DISEASE", 4, 23], ["Her shortness of breath", "PROBLEM", 0, 23], ["saturations", "TEST", 81, 92]]], ["NPS confirmed SARS-CoV-2, and her CXR was consistent with the diagnosis.", [["CXR", "PROTEIN", 34, 37], ["SARS-CoV", "SPECIES", 14, 22], ["NPS", "TEST", 0, 3], ["SARS", "PROBLEM", 14, 18], ["CoV", "TEST", 19, 22], ["her CXR", "TEST", 30, 37], ["SARS", "OBSERVATION", 14, 18], ["consistent with", "UNCERTAINTY", 42, 57]]], ["She was managed on the ward with oxygen and intravenous antibiotics, and was discharged 3 weeks later, having had a CTPA confirming no pulmonary emboli, and a PET scan which showed no advancement of her NHL.Case 3:She was readmitted 21 days later, with profound hypoxia, requiring intubation on arrival in hospital.Case 3:A CTPA at the time showed extensive bilateral PEs with evidence of right heart strain.", [["intravenous", "ANATOMY", 44, 55], ["pulmonary", "ANATOMY", 135, 144], ["NHL", "ANATOMY", 203, 206], ["right heart", "ANATOMY", 389, 400], ["oxygen", "CHEMICAL", 33, 39], ["pulmonary emboli", "DISEASE", 135, 151], ["NHL", "DISEASE", 203, 206], ["hypoxia", "DISEASE", 262, 269], ["PEs", "DISEASE", 368, 371], ["oxygen", "CHEMICAL", 33, 39], ["oxygen", "SIMPLE_CHEMICAL", 33, 39], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 55], ["pulmonary", "ORGAN", 135, 144], ["NHL", "CANCER", 203, 206], ["She", "ORGANISM", 214, 217], ["heart", "ORGAN", 395, 400], ["oxygen", "TREATMENT", 33, 39], ["intravenous antibiotics", "TREATMENT", 44, 67], ["a CTPA", "TEST", 114, 120], ["pulmonary emboli", "PROBLEM", 135, 151], ["a PET scan", "TEST", 157, 167], ["her NHL", "PROBLEM", 199, 206], ["profound hypoxia", "PROBLEM", 253, 269], ["intubation", "TREATMENT", 281, 291], ["A CTPA", "TEST", 322, 328], ["extensive bilateral PEs", "PROBLEM", 348, 371], ["right heart strain", "PROBLEM", 389, 407], ["no", "UNCERTAINTY", 132, 134], ["pulmonary", "ANATOMY", 135, 144], ["emboli", "OBSERVATION", 145, 151], ["no", "UNCERTAINTY", 181, 183], ["NHL", "OBSERVATION", 203, 206], ["profound", "OBSERVATION_MODIFIER", 253, 261], ["hypoxia", "OBSERVATION", 262, 269], ["extensive", "OBSERVATION_MODIFIER", 348, 357], ["bilateral", "ANATOMY_MODIFIER", 358, 367], ["PEs", "OBSERVATION", 368, 371], ["right", "ANATOMY_MODIFIER", 389, 394], ["heart", "ANATOMY", 395, 400], ["strain", "OBSERVATION", 401, 407]]], ["There were severe COVID related changes with widespread ground glass opacification throughout both lung fields.", [["lung", "ANATOMY", 99, 103], ["COVID", "DISEASE", 18, 23], ["lung", "ORGAN", 99, 103], ["severe COVID related changes", "PROBLEM", 11, 39], ["widespread ground glass opacification throughout both lung fields", "PROBLEM", 45, 110], ["severe", "OBSERVATION_MODIFIER", 11, 17], ["COVID", "OBSERVATION", 18, 23], ["widespread", "OBSERVATION_MODIFIER", 45, 55], ["ground glass opacification", "OBSERVATION", 56, 82], ["both", "ANATOMY_MODIFIER", 94, 98], ["lung", "ANATOMY", 99, 103], ["fields", "ANATOMY_MODIFIER", 104, 110]]], ["On admission, ferritin was 29784\uf06dg/L, CRP 78 mg/l, and procalcitonin was 2.04 mcg/l.", [["ferritin", "GENE_OR_GENE_PRODUCT", 14, 22], ["CRP", "GENE_OR_GENE_PRODUCT", 38, 41], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 55, 68], ["ferritin", "PROTEIN", 14, 22], ["CRP", "PROTEIN", 38, 41], ["ferritin", "TEST", 14, 22], ["CRP", "TEST", 38, 41], ["procalcitonin", "TREATMENT", 55, 68]]], ["She was anaemic (Hb 100 g/l), but not cytopaenic, with platelets of 199 x10 9 /L, and a neurophilia of 15.9x10 9 /L. NPS and EDTA blood samples were positive for SARS-CoV-2.Case 3:She was admitted to the ICU, initiated on intravenous tazocin and underwent thrombolysis for her PEs.", [["platelets", "ANATOMY", 55, 64], ["blood samples", "ANATOMY", 130, 143], ["intravenous", "ANATOMY", 222, 233], ["anaemic", "DISEASE", 8, 15], ["neurophilia", "DISEASE", 88, 99], ["tazocin", "CHEMICAL", 234, 241], ["PEs", "DISEASE", 277, 280], ["EDTA", "CHEMICAL", 125, 129], ["tazocin", "CHEMICAL", 234, 241], ["She", "ORGANISM", 0, 3], ["platelets", "CELL", 55, 64], ["NPS", "GENE_OR_GENE_PRODUCT", 117, 120], ["EDTA blood samples", "ORGANISM_SUBSTANCE", 125, 143], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 162, 172], ["She", "ORGANISM", 180, 183], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 222, 233], ["tazocin", "SIMPLE_CHEMICAL", 234, 241], ["platelets", "CELL_TYPE", 55, 64], ["anaemic", "PROBLEM", 8, 15], ["Hb", "TEST", 17, 19], ["cytopaenic", "PROBLEM", 38, 48], ["platelets", "TEST", 55, 64], ["a neurophilia", "TEST", 86, 99], ["L. NPS", "TEST", 114, 120], ["EDTA blood samples", "TEST", 125, 143], ["SARS-CoV", "PROBLEM", 162, 170], ["intravenous tazocin", "TREATMENT", 222, 241], ["thrombolysis", "TREATMENT", 256, 268], ["her PEs", "PROBLEM", 273, 280], ["anaemic", "OBSERVATION", 8, 15], ["PEs", "OBSERVATION", 277, 280]]], ["The following day, ferritin rose to 40069 \uf06dg/L, CRP was 109 mg/l, and procalcitonin increased to 9.85 mcg/l.", [["ferritin", "GENE_OR_GENE_PRODUCT", 19, 27], ["CRP", "GENE_OR_GENE_PRODUCT", 48, 51], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 70, 83], ["ferritin", "PROTEIN", 19, 27], ["CRP", "PROTEIN", 48, 51], ["ferritin", "TEST", 19, 27], ["CRP", "TEST", 48, 51], ["procalcitonin", "TREATMENT", 70, 83]]], ["Anakinra was initiated (Table 1) .", [["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["Anakinra", "TREATMENT", 0, 8]]], ["She was initially started on 100mg four times a day, but due to pressures on the nursing staff this was changed to 200mg twice a day.", [["pressures", "PROBLEM", 64, 73]]], ["Within 24 hours of intravenous anakinra, the ferritin improved to 20479 mcg/l (figure 1), and three days later continued to fall to 5118.", [["intravenous", "ANATOMY", 19, 30], ["anakinra", "CHEMICAL", 31, 39], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 30], ["anakinra", "SIMPLE_CHEMICAL", 31, 39], ["ferritin", "GENE_OR_GENE_PRODUCT", 45, 53], ["ferritin", "PROTEIN", 45, 53], ["intravenous anakinra", "TREATMENT", 19, 39], ["the ferritin", "TEST", 41, 53]]], ["A BioFire film was positive for Streptococcus pneumonia.", [["Streptococcus pneumonia", "DISEASE", 32, 55], ["A BioFire film", "TEST", 0, 14], ["Streptococcus pneumonia", "PROBLEM", 32, 55], ["positive for", "UNCERTAINTY", 19, 31], ["Streptococcus", "OBSERVATION_MODIFIER", 32, 45], ["pneumonia", "OBSERVATION", 46, 55]]], ["Her ICU stay was complicated by worsening consolidation on her CXRs, necessitating a prolonged course of meropenem.", [["meropenem", "CHEMICAL", 105, 114], ["meropenem", "CHEMICAL", 105, 114], ["meropenem", "SIMPLE_CHEMICAL", 105, 114], ["worsening consolidation", "PROBLEM", 32, 55], ["her CXRs", "TEST", 59, 67], ["meropenem", "TREATMENT", 105, 114], ["worsening", "OBSERVATION_MODIFIER", 32, 41], ["consolidation", "OBSERVATION", 42, 55]]], ["She commenced ambisome on day 2 of admission, which was continued after a positive galactomannan test on her sputum and strongly positive \u03b2D Glucan (341.5 pg/ml), 2 weeks into her admission.", [["sputum", "ANATOMY", 109, 115], ["\u03b2D Glucan", "CHEMICAL", 138, 147], ["\u03b2D Glucan", "SIMPLE_CHEMICAL", 138, 147], ["ambisome", "TREATMENT", 14, 22], ["a positive galactomannan test", "PROBLEM", 72, 101], ["her sputum", "TEST", 105, 115], ["Glucan", "TEST", 141, 147]]], ["It took 24 days from admission for the SARS-CoV-2 viraemia to disappear on both EDTA blood and NPS.", [["blood", "ANATOMY", 85, 90], ["SARS", "DISEASE", 39, 43], ["viraemia", "DISEASE", 50, 58], ["EDTA", "CHEMICAL", 80, 84], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["SARS-CoV", "SPECIES", 39, 47], ["the SARS", "PROBLEM", 35, 43], ["CoV", "TEST", 44, 47], ["viraemia", "PROBLEM", 50, 58], ["EDTA blood", "TEST", 80, 90]]], ["She remains on ICU, and is currently weaning off the ventilator, with a tracheostomy-in-situ, and on minimal inotropic support.Case 4:A 49-year-old lady presented with a 2-week history of non-productive cough and fever, with one week of diarrhoea.", [["cough", "DISEASE", 203, 208], ["fever", "DISEASE", 213, 218], ["diarrhoea", "DISEASE", 237, 246], ["the ventilator", "TREATMENT", 49, 63], ["a tracheostomy", "TREATMENT", 70, 84], ["minimal inotropic support", "TREATMENT", 101, 126], ["non-productive cough", "PROBLEM", 188, 208], ["fever", "PROBLEM", 213, 218], ["diarrhoea", "PROBLEM", 237, 246], ["tracheostomy", "OBSERVATION", 72, 84], ["inotropic support", "OBSERVATION", 109, 126], ["non-productive", "OBSERVATION_MODIFIER", 188, 202], ["cough", "OBSERVATION", 203, 208], ["fever", "OBSERVATION", 213, 218], ["diarrhoea", "OBSERVATION", 237, 246]]], ["She has ESRF secondary to lupus nephritis, requiring haemodialysis.", [["ESRF", "DISEASE", 8, 12], ["lupus nephritis", "DISEASE", 26, 41], ["ESRF", "PROBLEM", 8, 12], ["lupus nephritis", "PROBLEM", 26, 41], ["haemodialysis", "TREATMENT", 53, 66], ["ESRF", "OBSERVATION", 8, 12], ["lupus", "OBSERVATION_MODIFIER", 26, 31], ["nephritis", "OBSERVATION", 32, 41]]], ["Her past medical history includes antiphospholipid syndrome, with thromboses; and ischaemic heart disease.Case 4:Her medication included warfarin, and prednisolone.Case 4:Initial blood tests showed an elevated CRP (339 mg/L), and ferritin (2890 \u00b5g/L), with bilateral patchy consolidation on CXR.", [["heart", "ANATOMY", 92, 97], ["blood", "ANATOMY", 179, 184], ["antiphospholipid syndrome", "DISEASE", 34, 59], ["thromboses", "DISEASE", 66, 76], ["ischaemic heart disease", "DISEASE", 82, 105], ["warfarin", "CHEMICAL", 137, 145], ["prednisolone", "CHEMICAL", 151, 163], ["warfarin", "CHEMICAL", 137, 145], ["prednisolone", "CHEMICAL", 151, 163], ["heart", "ORGAN", 92, 97], ["Her", "ORGANISM", 113, 116], ["warfarin", "SIMPLE_CHEMICAL", 137, 145], ["prednisolone", "SIMPLE_CHEMICAL", 151, 163], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["CRP", "GENE_OR_GENE_PRODUCT", 210, 213], ["ferritin", "GENE_OR_GENE_PRODUCT", 230, 238], ["CRP", "PROTEIN", 210, 213], ["ferritin", "PROTEIN", 230, 238], ["CXR", "PROTEIN", 291, 294], ["antiphospholipid syndrome", "PROBLEM", 34, 59], ["thromboses", "PROBLEM", 66, 76], ["ischaemic heart disease", "PROBLEM", 82, 105], ["Her medication", "TREATMENT", 113, 127], ["warfarin", "TREATMENT", 137, 145], ["prednisolone", "TREATMENT", 151, 163], ["Initial blood tests", "TEST", 171, 190], ["an elevated CRP", "PROBLEM", 198, 213], ["ferritin", "TEST", 230, 238], ["bilateral patchy consolidation", "PROBLEM", 257, 287], ["CXR", "TEST", 291, 294], ["antiphospholipid syndrome", "OBSERVATION", 34, 59], ["thromboses", "OBSERVATION", 66, 76], ["ischaemic", "OBSERVATION_MODIFIER", 82, 91], ["heart", "ANATOMY", 92, 97], ["disease", "OBSERVATION", 98, 105], ["bilateral", "ANATOMY_MODIFIER", 257, 266], ["patchy", "OBSERVATION_MODIFIER", 267, 273], ["consolidation", "OBSERVATION", 274, 287]]], ["She was admitted on 2 l/min oxygen via nasal cannula.", [["nasal", "ANATOMY", 39, 44], ["oxygen", "CHEMICAL", 28, 34], ["oxygen", "CHEMICAL", 28, 34], ["oxygen", "SIMPLE_CHEMICAL", 28, 34], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 39, 52], ["oxygen", "TREATMENT", 28, 34], ["nasal cannula", "TREATMENT", 39, 52], ["nasal cannula", "ANATOMY", 39, 52]]], ["Ceftriaxone and gentamicin were initiated, and SARS-CoV-2 was confirmed via NPS.Case 4:On day 6, her oxygen requirements increased with worsening patchy consolidation bilaterally on CXR.", [["Ceftriaxone", "CHEMICAL", 0, 11], ["gentamicin", "CHEMICAL", 16, 26], ["SARS", "DISEASE", 47, 51], ["oxygen", "CHEMICAL", 101, 107], ["Ceftriaxone", "CHEMICAL", 0, 11], ["gentamicin", "CHEMICAL", 16, 26], ["oxygen", "CHEMICAL", 101, 107], ["Ceftriaxone", "SIMPLE_CHEMICAL", 0, 11], ["gentamicin", "SIMPLE_CHEMICAL", 16, 26], ["SARS-CoV-2", "ORGANISM", 47, 57], ["oxygen", "SIMPLE_CHEMICAL", 101, 107], ["CXR", "PROTEIN", 182, 185], ["SARS-CoV", "SPECIES", 47, 55], ["Ceftriaxone", "TREATMENT", 0, 11], ["gentamicin", "TREATMENT", 16, 26], ["her oxygen requirements", "PROBLEM", 97, 120], ["worsening patchy consolidation bilaterally", "PROBLEM", 136, 178], ["CXR", "TEST", 182, 185], ["worsening", "OBSERVATION_MODIFIER", 136, 145], ["patchy", "OBSERVATION_MODIFIER", 146, 152], ["consolidation", "OBSERVATION", 153, 166], ["bilaterally", "ANATOMY_MODIFIER", 167, 178]]], ["She underwent endotracheal intubation on ICU, and her antibiotics were changed to temocillin, teicoplanin and gentamicin.Case 4:On day 10, blood tests showed worsening thrombocytopenia and transaminitis with rising ferritin:Case 4:Plt 91x10 9 /L, ferritin 7636 mcg/L, with a peak in her procalcitonin of 198mcg/L. An assumed diagnosis of HLH was made, and she commenced anakinra 200mg intravenously (Table 1) .", [["endotracheal", "ANATOMY", 14, 26], ["blood", "ANATOMY", 139, 144], ["temocillin", "CHEMICAL", 82, 92], ["teicoplanin", "CHEMICAL", 94, 105], ["gentamicin", "CHEMICAL", 110, 120], ["thrombocytopenia", "DISEASE", 168, 184], ["transaminitis", "DISEASE", 189, 202], ["HLH", "DISEASE", 338, 341], ["anakinra", "CHEMICAL", 370, 378], ["temocillin", "CHEMICAL", 82, 92], ["teicoplanin", "CHEMICAL", 94, 105], ["gentamicin", "CHEMICAL", 110, 120], ["temocillin", "SIMPLE_CHEMICAL", 82, 92], ["teicoplanin", "SIMPLE_CHEMICAL", 94, 105], ["gentamicin", "SIMPLE_CHEMICAL", 110, 120], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["ferritin", "GENE_OR_GENE_PRODUCT", 215, 223], ["ferritin", "GENE_OR_GENE_PRODUCT", 247, 255], ["anakinra", "SIMPLE_CHEMICAL", 370, 378], ["ferritin", "PROTEIN", 215, 223], ["ferritin", "PROTEIN", 247, 255], ["endotracheal intubation", "TREATMENT", 14, 37], ["her antibiotics", "TREATMENT", 50, 65], ["temocillin", "TREATMENT", 82, 92], ["teicoplanin", "TREATMENT", 94, 105], ["gentamicin", "TREATMENT", 110, 120], ["blood tests", "TEST", 139, 150], ["worsening thrombocytopenia", "PROBLEM", 158, 184], ["transaminitis", "PROBLEM", 189, 202], ["rising ferritin", "PROBLEM", 208, 223], ["Plt", "TEST", 231, 234], ["ferritin", "TEST", 247, 255], ["her procalcitonin", "TEST", 283, 300], ["HLH", "PROBLEM", 338, 341], ["anakinra", "TREATMENT", 370, 378], ["endotracheal intubation", "OBSERVATION", 14, 37], ["worsening", "OBSERVATION_MODIFIER", 158, 167], ["thrombocytopenia", "OBSERVATION", 168, 184], ["transaminitis", "OBSERVATION", 189, 202], ["HLH", "OBSERVATION", 338, 341]]], ["She required increasing inotropic support and her thrombocytopaenia deteriorated with associated increasing ferritin over the following days.Case 4:On day 17, blood tests revealed ferritin 30,086 mcg/L. A CT chest revealed small bilateral lower lobe pulmonary emboli, and extensive consolidation throughout both lungs.", [["blood", "ANATOMY", 159, 164], ["chest", "ANATOMY", 208, 213], ["lower lobe pulmonary emboli", "ANATOMY", 239, 266], ["lungs", "ANATOMY", 312, 317], ["thrombocytopaenia", "DISEASE", 50, 67], ["lower lobe pulmonary emboli", "DISEASE", 239, 266], ["ferritin", "GENE_OR_GENE_PRODUCT", 108, 116], ["blood", "ORGANISM_SUBSTANCE", 159, 164], ["ferritin", "GENE_OR_GENE_PRODUCT", 180, 188], ["pulmonary", "ORGAN", 250, 259], ["lungs", "ORGAN", 312, 317], ["ferritin", "PROTEIN", 108, 116], ["ferritin", "PROTEIN", 180, 188], ["increasing inotropic support", "TREATMENT", 13, 41], ["her thrombocytopaenia", "PROBLEM", 46, 67], ["increasing ferritin", "PROBLEM", 97, 116], ["blood tests", "TEST", 159, 170], ["ferritin", "TEST", 180, 188], ["A CT chest", "TEST", 203, 213], ["small bilateral lower lobe pulmonary emboli", "PROBLEM", 223, 266], ["extensive consolidation throughout both lungs", "PROBLEM", 272, 317], ["inotropic support", "OBSERVATION", 24, 41], ["thrombocytopaenia", "OBSERVATION", 50, 67], ["increasing", "OBSERVATION_MODIFIER", 97, 107], ["ferritin", "OBSERVATION", 108, 116], ["chest", "ANATOMY", 208, 213], ["small", "OBSERVATION_MODIFIER", 223, 228], ["bilateral", "ANATOMY_MODIFIER", 229, 238], ["lower lobe", "ANATOMY", 239, 249], ["pulmonary", "ANATOMY", 250, 259], ["emboli", "OBSERVATION", 260, 266], ["extensive", "OBSERVATION_MODIFIER", 272, 281], ["consolidation", "OBSERVATION", 282, 295], ["both", "ANATOMY_MODIFIER", 307, 311], ["lungs", "ANATOMY", 312, 317]]], ["The clinical deterioration suggested worsening HLH, so anakinra was increased sequentially to 300mg twice a day, and antibiotics switched to meropenem and caspofungin.Case 4:2 days later, there was notable improvement in ferritin, CRP and the transaminases started to normalise.", [["HLH", "DISEASE", 47, 50], ["anakinra", "CHEMICAL", 55, 63], ["meropenem", "CHEMICAL", 141, 150], ["caspofungin", "CHEMICAL", 155, 166], ["meropenem", "CHEMICAL", 141, 150], ["caspofungin", "CHEMICAL", 155, 166], ["anakinra", "SIMPLE_CHEMICAL", 55, 63], ["meropenem", "SIMPLE_CHEMICAL", 141, 150], ["caspofungin", "SIMPLE_CHEMICAL", 155, 166], ["ferritin", "GENE_OR_GENE_PRODUCT", 221, 229], ["CRP", "GENE_OR_GENE_PRODUCT", 231, 234], ["transaminases", "SIMPLE_CHEMICAL", 243, 256], ["ferritin", "PROTEIN", 221, 229], ["CRP", "PROTEIN", 231, 234], ["transaminases", "PROTEIN", 243, 256], ["The clinical deterioration", "PROBLEM", 0, 26], ["worsening HLH", "PROBLEM", 37, 50], ["anakinra", "TREATMENT", 55, 63], ["antibiotics", "TREATMENT", 117, 128], ["meropenem", "TREATMENT", 141, 150], ["caspofungin", "TREATMENT", 155, 166], ["ferritin", "TEST", 221, 229], ["CRP", "TEST", 231, 234], ["the transaminases", "TEST", 239, 256], ["worsening", "OBSERVATION_MODIFIER", 37, 46], ["HLH", "OBSERVATION", 47, 50], ["notable", "OBSERVATION_MODIFIER", 198, 205], ["improvement", "OBSERVATION_MODIFIER", 206, 217], ["ferritin", "OBSERVATION", 221, 229]]], ["The patient remains intubated and ventilated, with reducing inotropic support.DiscussionWe present four cases of immunosuppressed patients, receiving beneficial effects from the use of intravenous anakinra to treat severe COVID-19 with hyperinflammation and concomitant bacterial infections.DiscussionCareful consideration of the immunosuppressive treatment needs to factor in the ability to clear the virus without allowing for hyperinflammation.", [["intravenous", "ANATOMY", 185, 196], ["anakinra", "CHEMICAL", 197, 205], ["COVID", "DISEASE", 222, 227], ["hyperinflammation", "DISEASE", 236, 253], ["bacterial infections", "DISEASE", 270, 290], ["hyperinflammation", "DISEASE", 429, 446], ["patient", "ORGANISM", 4, 11], ["patients", "ORGANISM", 130, 138], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 185, 196], ["anakinra", "SIMPLE_CHEMICAL", 197, 205], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 130, 138], ["intubated", "TREATMENT", 20, 29], ["ventilated", "TREATMENT", 34, 44], ["reducing inotropic support", "TREATMENT", 51, 77], ["immunosuppressed patients", "TREATMENT", 113, 138], ["beneficial effects", "TREATMENT", 150, 168], ["intravenous anakinra", "TREATMENT", 185, 205], ["severe COVID", "PROBLEM", 215, 227], ["hyperinflammation", "PROBLEM", 236, 253], ["concomitant bacterial infections", "PROBLEM", 258, 290], ["the immunosuppressive treatment", "TREATMENT", 326, 357], ["the virus", "PROBLEM", 398, 407], ["hyperinflammation", "PROBLEM", 429, 446], ["inotropic support", "OBSERVATION", 60, 77], ["concomitant", "OBSERVATION_MODIFIER", 258, 269], ["bacterial infections", "OBSERVATION", 270, 290], ["virus", "OBSERVATION", 402, 407]]], ["Anakinra has previously been used in the context of virally induced inflammatory conditions such as multicentric Castleman's disease; a reactive lymphoproliferative disorder typically described in HIV positive patients, with close association with HHV-8 (human herpes virus) (12).DiscussionCavalli et al (16) described the use of anakinra in patients with ARDS due to COVID-19, who also had hyperinflammation.", [["Anakinra", "CHEMICAL", 0, 8], ["Castleman's disease", "DISEASE", 113, 132], ["lymphoproliferative disorder", "DISEASE", 145, 173], ["HIV positive", "DISEASE", 197, 209], ["human herpes virus", "DISEASE", 255, 273], ["anakinra", "CHEMICAL", 330, 338], ["ARDS", "DISEASE", 356, 360], ["hyperinflammation", "DISEASE", 391, 408], ["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["HIV", "ORGANISM", 197, 200], ["patients", "ORGANISM", 210, 218], ["HHV-8", "ORGANISM", 248, 253], ["human herpes virus", "ORGANISM", 255, 273], ["anakinra", "SIMPLE_CHEMICAL", 330, 338], ["patients", "ORGANISM", 342, 350], ["HIV", "SPECIES", 197, 200], ["patients", "SPECIES", 210, 218], ["human", "SPECIES", 255, 260], ["herpes virus", "SPECIES", 261, 273], ["patients", "SPECIES", 342, 350], ["HIV", "SPECIES", 197, 200], ["HHV-8", "SPECIES", 248, 253], ["human herpes virus", "SPECIES", 255, 273], ["Anakinra", "TREATMENT", 0, 8], ["virally induced inflammatory conditions", "PROBLEM", 52, 91], ["multicentric Castleman's disease", "PROBLEM", 100, 132], ["a reactive lymphoproliferative disorder", "PROBLEM", 134, 173], ["HIV positive patients", "PROBLEM", 197, 218], ["HHV", "TEST", 248, 251], ["human herpes virus", "PROBLEM", 255, 273], ["anakinra", "TREATMENT", 330, 338], ["ARDS", "PROBLEM", 356, 360], ["COVID", "TEST", 368, 373], ["hyperinflammation", "PROBLEM", 391, 408], ["inflammatory", "OBSERVATION", 68, 80], ["multicentric", "OBSERVATION_MODIFIER", 100, 112], ["Castleman", "OBSERVATION", 113, 122], ["reactive", "OBSERVATION_MODIFIER", 136, 144], ["lymphoproliferative disorder", "OBSERVATION", 145, 173], ["anakinra", "OBSERVATION", 330, 338], ["hyperinflammation", "OBSERVATION", 391, 408]]], ["They used intravenous anakinra at 5mg/kg twice a day (high dose group) for 21 days.", [["intravenous", "ANATOMY", 10, 21], ["anakinra", "CHEMICAL", 22, 30], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 21], ["anakinra", "SIMPLE_CHEMICAL", 22, 30], ["intravenous anakinra", "TREATMENT", 10, 30]]], ["A subgroup of patients received 100 mg subcutaneously twice a day (low dose group) for 7 days.", [["subcutaneously", "ANATOMY", 39, 53], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["Standard care included 400mg hydroxychlorquine, along with lopinavir and ritonavir.", [["hydroxychlorquine", "CHEMICAL", 29, 46], ["lopinavir", "CHEMICAL", 59, 68], ["ritonavir", "CHEMICAL", 73, 82], ["hydroxychlorquine", "CHEMICAL", 29, 46], ["lopinavir", "CHEMICAL", 59, 68], ["ritonavir", "CHEMICAL", 73, 82], ["hydroxychlorquine", "SIMPLE_CHEMICAL", 29, 46], ["lopinavir", "SIMPLE_CHEMICAL", 59, 68], ["ritonavir", "SIMPLE_CHEMICAL", 73, 82], ["400mg hydroxychlorquine", "TREATMENT", 23, 46], ["lopinavir", "TREATMENT", 59, 68], ["ritonavir", "TREATMENT", 73, 82]]], ["At 21 days, survival was 90% in the high-dose group and 56% in the standard treatment group (P= 0.009).DiscussionTheir lower threshold for diagnosis of hyperinflammation ((CRP >100 mg/L or ferritin 900 ng/ml), and differing standard practice, reflects a cohort of patients not necessarily classified as severe in the UK.", [["hyperinflammation", "DISEASE", 152, 169], ["ferritin", "GENE_OR_GENE_PRODUCT", 189, 197], ["patients", "ORGANISM", 264, 272], ["CRP", "PROTEIN", 172, 175], ["ferritin", "PROTEIN", 189, 197], ["patients", "SPECIES", 264, 272], ["survival", "TEST", 12, 20], ["hyperinflammation", "PROBLEM", 152, 169], ["CRP", "TEST", 172, 175], ["ferritin", "TREATMENT", 189, 197], ["severe", "OBSERVATION", 303, 309]]], ["A ferritin <500 ng/ml have a high negative predictive value for HLH (6), whereas >10000 mg/l is diagnostic of HLH in children (17) .", [["HLH", "DISEASE", 64, 67], ["HLH", "DISEASE", 110, 113], ["ferritin", "GENE_OR_GENE_PRODUCT", 2, 10], ["children", "ORGANISM", 117, 125], ["ferritin", "PROTEIN", 2, 10], ["children", "SPECIES", 117, 125], ["A ferritin", "TEST", 0, 10], ["HLH", "PROBLEM", 64, 67], ["HLH", "PROBLEM", 110, 113], ["HLH", "OBSERVATION", 110, 113]]], ["The use of oral hydroxychloroquine may skew the mortality data, with a potential for increased cardiac complications (18) .", [["oral", "ANATOMY", 11, 15], ["cardiac", "ANATOMY", 95, 102], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["cardiac complications", "DISEASE", 95, 116], ["hydroxychloroquine", "CHEMICAL", 16, 34], ["oral", "ORGANISM_SUBDIVISION", 11, 15], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 16, 34], ["cardiac", "ORGAN", 95, 102], ["oral hydroxychloroquine", "TREATMENT", 11, 34], ["increased cardiac complications", "PROBLEM", 85, 116], ["cardiac", "ANATOMY", 95, 102], ["complications", "OBSERVATION", 103, 116]]], ["An observational study on the use of hydroxychloroquine in COVID-19 did not report any difference in mortality (19) , and is not included in UK treatment algorithms.", [["hydroxychloroquine", "CHEMICAL", 37, 55], ["hydroxychloroquine", "CHEMICAL", 37, 55], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 37, 55], ["An observational study", "TEST", 0, 22], ["hydroxychloroquine", "TREATMENT", 37, 55]]], ["Furthermore, concomitant bacterial infections were excluded.", [["bacterial infections", "DISEASE", 25, 45], ["concomitant bacterial infections", "PROBLEM", 13, 45], ["concomitant", "OBSERVATION_MODIFIER", 13, 24], ["bacterial", "OBSERVATION_MODIFIER", 25, 34], ["infections", "OBSERVATION", 35, 45]]], ["Anakinra has received increasing use in the context of cytokine storm syndromes/HLH (4) .", [["Anakinra", "CHEMICAL", 0, 8], ["HLH", "DISEASE", 80, 83], ["Anakinra", "CHEMICAL", 0, 8], ["Anakinra", "SIMPLE_CHEMICAL", 0, 8], ["cytokine", "PROTEIN", 55, 63], ["Anakinra", "TREATMENT", 0, 8], ["cytokine storm syndromes", "PROBLEM", 55, 79], ["HLH", "PROBLEM", 80, 83]]], ["Although licensed subcutaneously, concerns over unreliable absorption in the critically ill patient, and the requirement of multiple injections, along with the support of its safety at higher doses in the context of sepsis, have all favoured intravenous administration.", [["subcutaneously", "ANATOMY", 18, 32], ["intravenous", "ANATOMY", 242, 253], ["critically ill", "DISEASE", 77, 91], ["sepsis", "DISEASE", 216, 222], ["patient", "ORGANISM", 92, 99], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 242, 253], ["patient", "SPECIES", 92, 99], ["multiple injections", "TREATMENT", 124, 143], ["sepsis", "PROBLEM", 216, 222], ["intravenous administration", "TREATMENT", 242, 268], ["sepsis", "OBSERVATION", 216, 222]]], ["The support for our use of higher dose intravenous anakinra is further gained from the recent lack of benefit for the subcutaneous form in the context of COVID-19 (16) .DiscussionThe administration of anakinra intravenously leads to a maximum plasma concentration 24-29 times higher when compared to subcutaneous administration.", [["intravenous", "ANATOMY", 39, 50], ["subcutaneous", "ANATOMY", 118, 130], ["plasma", "ANATOMY", 243, 249], ["subcutaneous", "ANATOMY", 300, 312], ["anakinra", "CHEMICAL", 51, 59], ["anakinra", "CHEMICAL", 201, 209], ["COVID-19", "CHEMICAL", 154, 162], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 50], ["anakinra", "SIMPLE_CHEMICAL", 51, 59], ["anakinra", "SIMPLE_CHEMICAL", 201, 209], ["plasma", "ORGANISM_SUBSTANCE", 243, 249], ["higher dose intravenous anakinra", "TREATMENT", 27, 59], ["the subcutaneous form", "TREATMENT", 114, 135], ["COVID", "TEST", 154, 159], ["anakinra intravenously", "TREATMENT", 201, 223], ["a maximum plasma concentration", "TEST", 233, 263]]], ["It also has a shorter terminal half-life in the intravenous format as well (2.64 hrs compared to 5.24 hrs subcutaneously) (20, 21) , with the caveat that the subcutaneous half-life increases with greater adipose tissue.", [["intravenous", "ANATOMY", 48, 59], ["subcutaneously", "ANATOMY", 106, 120], ["subcutaneous", "ANATOMY", 158, 170], ["adipose tissue", "ANATOMY", 204, 218], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 59], ["adipose tissue", "TISSUE", 204, 218], ["greater adipose tissue", "PROBLEM", 196, 218], ["subcutaneous", "ANATOMY", 158, 170], ["greater adipose tissue", "OBSERVATION", 196, 218]]], ["The intravenous form therefore enables a higher and faster maximal plasma concentration of anakinra; a trait that is desirable during cytokine storm syndromes.DiscussionThere is not sufficient evidence currently to suggest that the majority of patients with severe COVID-19 develop HLH, as the other diagnostic parameters not including ferritin (hypertriglyceridaemia, low fibrinogen, cytopaenias) do not correlate with severe disease (22) .", [["intravenous", "ANATOMY", 4, 15], ["plasma", "ANATOMY", 67, 73], ["anakinra", "CHEMICAL", 91, 99], ["COVID", "DISEASE", 265, 270], ["HLH", "DISEASE", 282, 285], ["hypertriglyceridaemia", "DISEASE", 346, 367], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 15], ["plasma", "ORGANISM_SUBSTANCE", 67, 73], ["anakinra", "SIMPLE_CHEMICAL", 91, 99], ["patients", "ORGANISM", 244, 252], ["ferritin", "GENE_OR_GENE_PRODUCT", 336, 344], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 373, 383], ["cytokine", "PROTEIN", 134, 142], ["ferritin", "PROTEIN", 336, 344], ["fibrinogen", "PROTEIN", 373, 383], ["patients", "SPECIES", 244, 252], ["a higher and faster maximal plasma concentration of anakinra", "TREATMENT", 39, 99], ["a trait", "PROBLEM", 101, 108], ["cytokine storm syndromes", "PROBLEM", 134, 158], ["severe COVID", "PROBLEM", 258, 270], ["HLH", "PROBLEM", 282, 285], ["the other diagnostic parameters", "TEST", 290, 321], ["ferritin (hypertriglyceridaemia", "PROBLEM", 336, 367], ["low fibrinogen", "PROBLEM", 369, 383], ["cytopaenias", "PROBLEM", 385, 396], ["severe disease", "PROBLEM", 420, 434], ["anakinra", "OBSERVATION", 91, 99], ["low fibrinogen", "OBSERVATION_MODIFIER", 369, 383], ["severe", "OBSERVATION_MODIFIER", 420, 426], ["disease", "OBSERVATION", 427, 434]]], ["None of our cases developed organomegaly, and only case 4 showed evidence of thromcoytopaenia, however the other blood count lineages did not fall.", [["blood", "ANATOMY", 113, 118], ["organomegaly", "DISEASE", 28, 40], ["thromcoytopaenia", "DISEASE", 77, 93], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["blood count lineages", "CELL_TYPE", 113, 133], ["organomegaly", "PROBLEM", 28, 40], ["thromcoytopaenia", "PROBLEM", 77, 93], ["the other blood count", "TEST", 103, 124], ["organomegaly", "OBSERVATION", 28, 40], ["thromcoytopaenia", "OBSERVATION", 77, 93]]], ["Therefore we believe we are treating hyperinflammation, and not HLH in our 4 cases.DiscussionTiming of treatment with anakinra is one of the challenges in managing patients with COVID-19, and any clinical trial design.", [["hyperinflammation", "DISEASE", 37, 54], ["HLH", "DISEASE", 64, 67], ["anakinra", "CHEMICAL", 118, 126], ["anakinra", "SIMPLE_CHEMICAL", 118, 126], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["hyperinflammation", "PROBLEM", 37, 54], ["HLH", "PROBLEM", 64, 67], ["treatment", "TREATMENT", 103, 112], ["anakinra", "TREATMENT", 118, 126], ["COVID", "TREATMENT", 178, 183]]], ["Whereas antiviral therapy is likely to be beneficial in the early phase of the disease, cytokine modulation and immunosuppressive therapy are most likely to have an impact at later stages (11) .", [["cytokine", "PROTEIN", 88, 96], ["antiviral therapy", "TREATMENT", 8, 25], ["the disease", "PROBLEM", 75, 86], ["cytokine modulation", "TREATMENT", 88, 107], ["immunosuppressive therapy", "TREATMENT", 112, 137], ["antiviral therapy", "OBSERVATION", 8, 25], ["likely to be", "UNCERTAINTY", 29, 41], ["disease", "OBSERVATION", 79, 86]]], ["A recent large adaptiveplatform trial (Recovery trial) showed a significant mortality-benefit of low-dose dexamethasone, with the biggest risk-reduction in mortality observed in patients requiring invasive mechanical ventilation (23).", [["dexamethasone", "CHEMICAL", 106, 119], ["dexamethasone", "CHEMICAL", 106, 119], ["dexamethasone", "SIMPLE_CHEMICAL", 106, 119], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["A recent large adaptiveplatform trial", "TREATMENT", 0, 37], ["low-dose dexamethasone", "TREATMENT", 97, 119], ["invasive mechanical ventilation", "TREATMENT", 197, 228], ["large", "OBSERVATION_MODIFIER", 9, 14], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["mortality", "OBSERVATION", 76, 85], ["reduction", "OBSERVATION_MODIFIER", 143, 152]]], ["This affirms the concept of the need for immune modulation in critically unwell patients requiring ventilatory and organ support.", [["organ", "ANATOMY", 115, 120], ["patients", "ORGANISM", 80, 88], ["organ", "ORGAN", 115, 120], ["patients", "SPECIES", 80, 88], ["immune modulation", "TREATMENT", 41, 58], ["ventilatory", "TREATMENT", 99, 110], ["organ support", "TREATMENT", 115, 128]]], ["Further trials in the UK include REMAP-CAP (https://www.remapcap.org/); an adaptive-platform trial to assess the use of antibiotics, antivirals and immunomodulators in COVID-19.", [["an adaptive-platform trial", "TREATMENT", 72, 98], ["antibiotics", "TREATMENT", 120, 131], ["antivirals", "TREATMENT", 133, 143], ["immunomodulators", "TREATMENT", 148, 164], ["COVID", "TEST", 168, 173]]], ["It offers the opportunity to explore targeted immune modulation therapy which will include interferon-beta-1a, IL-1 receptor antagonists (anakinra), tocilizumab and sarilumab (both anti-IL-6), all against placebo.DiscussionCOVACTA (https://clinicaltrials.gov/ct2/show/NCT04320615) randomized severe SARS-Cov-2 pneumonitis to tocilizumab (a monoclonal antibody targeting the IL6 receptor).", [["interferon-beta-1a", "CHEMICAL", 91, 109], ["anakinra", "CHEMICAL", 138, 146], ["tocilizumab", "CHEMICAL", 149, 160], ["sarilumab", "CHEMICAL", 165, 174], ["SARS", "DISEASE", 299, 303], ["pneumonitis", "DISEASE", 310, 321], ["tocilizumab", "CHEMICAL", 325, 336], ["sarilumab", "CHEMICAL", 165, 174], ["interferon-beta-1a", "GENE_OR_GENE_PRODUCT", 91, 109], ["IL-1 receptor antagonists", "SIMPLE_CHEMICAL", 111, 136], ["anakinra", "SIMPLE_CHEMICAL", 138, 146], ["tocilizumab", "SIMPLE_CHEMICAL", 149, 160], ["sarilumab", "SIMPLE_CHEMICAL", 165, 174], ["anti-IL-6", "GENE_OR_GENE_PRODUCT", 181, 190], ["tocilizumab", "SIMPLE_CHEMICAL", 325, 336], ["IL6 receptor", "GENE_OR_GENE_PRODUCT", 374, 386], ["interferon", "PROTEIN", 91, 101], ["monoclonal antibody", "PROTEIN", 340, 359], ["IL6 receptor", "PROTEIN", 374, 386], ["targeted immune modulation therapy", "TREATMENT", 37, 71], ["interferon", "TREATMENT", 91, 101], ["beta", "TREATMENT", 102, 106], ["IL", "TREATMENT", 111, 113], ["receptor antagonists", "TREATMENT", 116, 136], ["anakinra", "TREATMENT", 138, 146], ["tocilizumab", "TREATMENT", 149, 160], ["sarilumab", "TREATMENT", 165, 174], ["randomized severe SARS", "PROBLEM", 281, 303], ["Cov", "PROBLEM", 304, 307], ["pneumonitis", "PROBLEM", 310, 321], ["tocilizumab", "TREATMENT", 325, 336], ["a monoclonal antibody targeting the IL6 receptor", "TREATMENT", 338, 386], ["severe", "OBSERVATION_MODIFIER", 292, 298], ["SARS", "OBSERVATION", 299, 303], ["pneumonitis", "OBSERVATION", 310, 321]]], ["CAN-COVID (https://clinicaltrials.gov/ct2/show/NCT04362813) randomises canikunimab (a monoclonal antibody https://mc.manuscriptcentral.com/rheumap which specifically targets the IL-1\u03b2 cytokine ) to severe COVID-19, not requiring mechanical ventilation.DiscussionThe results of these trials will be extremely informative to direct treatment strategy for COVID -19 infections in the future.", [["canikunimab", "CHEMICAL", 71, 82], ["infections", "DISEASE", 363, 373], ["canikunimab", "CHEMICAL", 71, 82], ["canikunimab", "SIMPLE_CHEMICAL", 71, 82], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 178, 183], ["COVID -19", "ORGANISM", 353, 362], ["canikunimab", "PROTEIN", 71, 82], ["monoclonal antibody", "PROTEIN", 86, 105], ["https://mc.manuscriptcentral.com/rheumap", "PROTEIN", 106, 146], ["IL-1\u03b2 cytokine", "PROTEIN", 178, 192], ["a monoclonal antibody https://mc.manuscriptcentral.com/rheumap", "TREATMENT", 84, 146], ["the IL", "TEST", 174, 180], ["severe COVID", "PROBLEM", 198, 210], ["mechanical ventilation", "TREATMENT", 229, 251], ["direct treatment strategy", "TREATMENT", 323, 348], ["COVID -19 infections", "PROBLEM", 353, 373], ["mechanical ventilation", "OBSERVATION", 229, 251]]], ["Whether single treatment, combination therapy, or early intervention are optimal remains to be elucidated.DiscussionOur case series supports the hypothesis of IL-1 blockade as an important disease modifying treatment in those patients with severe late stage COVID-19, with evidence of cytokine storm.", [["IL-1", "GENE_OR_GENE_PRODUCT", 159, 163], ["patients", "ORGANISM", 226, 234], ["IL", "PROTEIN", 159, 161], ["cytokine", "PROTEIN", 285, 293], ["patients", "SPECIES", 226, 234], ["single treatment", "TREATMENT", 8, 24], ["combination therapy", "TREATMENT", 26, 45], ["early intervention", "TREATMENT", 50, 68], ["IL-1 blockade", "TREATMENT", 159, 172], ["an important disease modifying treatment", "TREATMENT", 176, 216], ["severe late stage COVID", "PROBLEM", 240, 263], ["cytokine storm", "PROBLEM", 285, 299], ["cytokine storm", "OBSERVATION", 285, 299]]], ["We show that the intravenous form is safe at high doses, even in patients with concomitant bacterial infections.", [["intravenous", "ANATOMY", 17, 28], ["bacterial infections", "DISEASE", 91, 111], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 17, 28], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["concomitant bacterial infections", "PROBLEM", 79, 111], ["bacterial", "OBSERVATION_MODIFIER", 91, 100], ["infections", "OBSERVATION", 101, 111]]], ["We believe that administering intravenous anakinra at the height of the cytokine storm has profound beneficial effects, both clinically and biochemically on patients with severe COVID-19 infection.", [["intravenous", "ANATOMY", 30, 41], ["anakinra", "CHEMICAL", 42, 50], ["infection", "DISEASE", 187, 196], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 41], ["anakinra", "SIMPLE_CHEMICAL", 42, 50], ["patients", "ORGANISM", 157, 165], ["cytokine", "PROTEIN", 72, 80], ["patients", "SPECIES", 157, 165], ["intravenous anakinra", "TREATMENT", 30, 50], ["the cytokine storm", "TREATMENT", 68, 86], ["severe COVID-19 infection", "PROBLEM", 171, 196], ["infection", "OBSERVATION", 187, 196]]]], "PMC7118867": [["Sibilances associ\u00e9es aux\u00a0infections respiratoires du\u00a0nourrissonLa bronchite sifflante du nourrisson traduit l'obstruction bronchique secondaire \u00e0 l'agression virale des voies a\u00e9riennes.", [["infections", "DISEASE", 25, 35], ["aux\u00a0infections", "PROBLEM", 21, 35], ["infections", "OBSERVATION", 25, 35]]], ["Sa liaison est intime avec la survenue ult\u00e9rieure d'\u00e9pisodes de sibilance ou wheezing.", [["wheezing", "DISEASE", 77, 85], ["wheezing", "PROBLEM", 77, 85], ["wheezing", "OBSERVATION", 77, 85]]], ["Un suivi prospectif effectu\u00e9 \u00e0 Houston retrouve 70 % des enfants de moins de 1 an infect\u00e9s par le VRS, une affection des voies respiratoires basses se d\u00e9veloppe chez 20 % d'entre eux et seuls 10 % de ces derniers seront hospitalis\u00e9s [4].", [["an infect\u00e9s par le VRS", "PROBLEM", 79, 101], ["une affection des", "PROBLEM", 103, 120], ["respiratoires", "TEST", 127, 140], ["basses", "TEST", 141, 147], ["'entre eux et seuls", "TREATMENT", 172, 191]]], ["On estime que 0,5 \u00e0 2 % des nourrissons seraient hospitalis\u00e9s chaque ann\u00e9e lors de leur primo-infection \u00e0 VRS.", [["VRS", "PROBLEM", 106, 109]]], ["La cohorte de Tucson a permis de pr\u00e9ciser l'\u00e9pid\u00e9miologie virale en population g\u00e9n\u00e9rale des infections respiratoires basses.", [["infections respiratoires basses", "DISEASE", 92, 123], ["a permis de pr\u00e9ciser l'\u00e9pid\u00e9miologie virale", "TREATMENT", 21, 64]]], ["Sur 1246 enfants, 519 ont eu au moins une infection respiratoire basse avant l'\u00e2ge de 3 ans diagnostiqu\u00e9e et prise en charge par un m\u00e9decin [5].", [["infection", "DISEASE", 42, 51], ["ont eu au moins une infection", "TREATMENT", 22, 51], ["infection", "OBSERVATION", 42, 51]]], ["L'\u00e9pid\u00e9miologie pour les enfants ayant b\u00e9n\u00e9fici\u00e9 des investigations virologiques (472 enfants sur les 519) confirme la pr\u00e9dominance virale puisque 43,9 % des pr\u00e9l\u00e8vements retrouvaient le VRS, 14,4 % les VPI, 14,4 % un virus diff\u00e9rent des 2 1rs, chez 27,7 % des enfants aucun virus ne fut identifi\u00e9 lors de l'\u00e9pisode infectieux mais cette recherche virale ignorait les rhinovirus ou d'autres virus plus r\u00e9cemment mis en cause.", [["L'\u00e9pid\u00e9miologie pour les", "TREATMENT", 0, 24], ["virologiques", "TEST", 68, 80], ["la pr\u00e9dominance", "TEST", 116, 131], ["puisque", "TEST", 139, 146], ["le VRS", "TEST", 184, 190], ["VPI", "TEST", 203, 206], ["chez", "TEST", 245, 249], ["ignorait les rhinovirus", "PROBLEM", 355, 378]]], ["Notre \u00e9quipe a montr\u00e9 que cette identification variait selon l'\u00e2ge [1], le ph\u00e9notype clinique et la technique virologique mise en \u0153uvre (Tableau 1, Tableau 2).Virus initiateur de\u00a0l'asthme ou\u00a0de\u00a0l'atopieL'opinion pr\u00e9valente est que les infections virales de la prime enfance n'induisent pas l'asthme atopique, elles ne sont qu'un marqueur d'une population \u00e0 risque par le d\u00e9clenchement pr\u00e9coce d'une 1re exacerbation aigu\u00eb asthmatique [5], [6].", [["infections virales", "DISEASE", 235, 253], ["Virus", "ORGANISM", 159, 164], ["Virus initiateur de\u00a0l'asthme ou\u00a0de\u00a0l'atopieL'opinion pr\u00e9valente est que les infections virales de la prime enfance n'induisent pas l'asthme atopique, elles ne sont qu'un marqueur d'une population \u00e0 risque par le d\u00e9clenchement pr\u00e9coce d'une 1re exacerbation aigu\u00eb", "SPECIES", 159, 421], ["le ph\u00e9notype clinique et la technique", "TREATMENT", 72, 109], ["les infections", "PROBLEM", 231, 245], ["exacerbation aigu\u00eb asthmatique", "PROBLEM", 403, 433]]], ["L'\u00e9pid\u00e9miologie virale d\u00e9pend de la technique utilis\u00e9e (Tableau 3) mais elle diff\u00e8re de celle des bronchiolites aigu\u00ebs virales avec la pr\u00e9sence significativement plus importante des picornavirus (Tableau 2).", [["L'\u00e9pid\u00e9miologie virale", "TREATMENT", 0, 22], ["aigu\u00ebs", "TEST", 112, 118], ["virales", "TEST", 119, 126], ["importante des picornavirus", "PROBLEM", 167, 194]]], ["Cette relation retrouv\u00e9e avec le VRS (OR = 3,0) s'accentue avec le rhinovirus (OR = 6,6) : 63 % des nourrissons de moins de 1 an ayant siffl\u00e9 lors de la saison hivernale continueront \u00e0 le faire \u00e0 3 ans vs 20 % pour ceux qui resteront indemnes [7].", [["le VRS", "TEST", 30, 36], ["le rhinovirus", "PROBLEM", 64, 77], ["ans vs", "TEST", 198, 204], ["rhinovirus", "OBSERVATION", 67, 77]]], ["Une m\u00e9ta-analyse retenant des crit\u00e8res stricts de la bronchiolite \u00e0 VRS, excluant les \u00e9tudes portant sur les enfants \u00e2g\u00e9s de plus de 1 an et celles ne disposant pas de preuve virologique, souligne que les sifflements r\u00e9currents ne sont ni en rapport avec une \u00e9l\u00e9vation ult\u00e9rieure du risque atopique, ni li\u00e9s \u00e0 une fr\u00e9quence plus \u00e9lev\u00e9e des ant\u00e9c\u00e9dents familiaux d'atopie [6].", [["VRS", "TEST", 68, 71]]], ["Cependant une \u00e9tude su\u00e9doise, avec un recul de 13 ans, conclut par une analyse multivari\u00e9e qu'une bronchiolite \u00e0 VRS est le facteur de risque ind\u00e9pendant d'asthme et d'acquisition d'une sensibilisation allerg\u00e9nique [8].", [["multivari\u00e9e", "TEST", 79, 90], ["bronchiolite", "TEST", 98, 110]]], ["Une interpr\u00e9tation diff\u00e9rente peut \u00eatre oppos\u00e9e : les nourrissons non hospitalis\u00e9s lors d'une \u00e9pid\u00e9mie hivernale \u00e0 VRS ont de fait un facteur protecteur non identifi\u00e9 du risque de d\u00e9velopper ult\u00e9rieurement un asthme ou une allergie.Infections respiratoires chez\u00a0l'asthmatiqueLa reconnaissance du r\u00f4le pr\u00e9pond\u00e9rant des virus chez l'asthmatique lors de ces infections est r\u00e9cente.", [["ces infections", "DISEASE", 351, 365], ["Une interpr\u00e9tation", "TEST", 0, 18], ["Infections", "PROBLEM", 232, 242], ["du r\u00f4le", "TEST", 293, 300]]], ["La d\u00e9tection mol\u00e9culaire des virus a permis d'y souligner la 1re place du rhinovirus mais tous les virus capables de produire une infection aigu\u00eb des voies respiratoires peuvent \u00eatre responsables d'une exacerbation asthmatique.", [["infection aigu\u00eb", "DISEASE", 130, 145], ["asthmatique", "DISEASE", 215, 226], ["La d\u00e9tection", "TEST", 0, 12], ["souligner la", "TEST", 48, 60], ["d'une exacerbation asthmatique", "PROBLEM", 196, 226]]], ["Dans le 1er cas, il existe une chute brutale et pr\u00e9coce des d\u00e9bits de pointe puis une r\u00e9cup\u00e9ration lin\u00e9aire sur plusieurs jours, la r\u00e9ponse aux bronchodilatateurs est m\u00e9diocre.", [["Dans le 1er cas", "CHEMICAL", 0, 15]]], ["Nos \u00e9tudes \u00e9pid\u00e9miologiques dans cette pathologie l'ont r\u00e9guli\u00e8rement situ\u00e9e en 3e position avec une pr\u00e9valence oscillant entre 5 et 15 % (Tableau 2, Tableau 3), r\u00e9cemment une \u00e9tude sur les d\u00e9c\u00e8s p\u00e9diatriques li\u00e9s \u00e0 la grippe a retrouv\u00e9 que 20 % d'entre eux pr\u00e9sentaient une pathologie respiratoire chronique dont la moiti\u00e9 un asthme isol\u00e9 [10].ConclusionL'importance des virus respiratoires est maintenant bien \u00e9tablie dans la pathog\u00e9nie de l'asthme, l'int\u00e9r\u00eat demeure dans la poursuite des recherches portant sur l'inflammation g\u00e9n\u00e9r\u00e9e et les m\u00e9canismes pr\u00e9cis sous-jacents.", [["en 3e position avec une pr\u00e9valence oscillant entre", "TREATMENT", 77, 127], ["a retrouv\u00e9 que", "TREATMENT", 226, 240], ["entre eux", "TEST", 248, 257], ["des virus respiratoires", "TEST", 368, 391]]], ["Trois facteurs influencent significativement la survenue de l'asthme : une dysr\u00e9gulation de la s\u00e9cr\u00e9tion de cytokines, les infections virales des voies a\u00e9riennes sup\u00e9rieures et inf\u00e9rieures, les interactions entre g\u00e8nes et l'environnement durant une courte p\u00e9riode critique du d\u00e9veloppement immunitaire et pulmonaire.", [["infections", "DISEASE", 123, 133], ["Trois", "TEST", 0, 5], ["une dysr\u00e9gulation", "PROBLEM", 71, 88], ["les infections virales des", "PROBLEM", 119, 145], ["et inf\u00e9rieures", "PROBLEM", 174, 188]]]]}